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CHAPTER 1: INTRODUCTION 
Sterility has had a fundamental place in science and medicine since the introduction of 
the germ theory of disease, which posits that microscopic organisms cause contagious diseases 
[1-3]. The concept of sterility, as it applies to science and medicine, originated with the idea that 
an environment, whether it be a surface or a compartment of an organism or an inorganic object, 
is completely devoid of microorganisms; this includes protists, fungi, archaea, and bacteria [4, 
5]. The value of sterility in the medical community became clear through the practice of surgery 
and the treatment of wounds [3, 6-8]. The importance of sterility developed into the practice of 
aseptic technique, which refers to the prevention of introducing foreign microorganisms into 
tissues or organs that do not normally contain these microorganisms [9, 10]. Aseptic technique 
entails the removal and eradication of any microorganisms from instruments and surfaces, 
thorough handwashing, and barrier protection of medical personnel directly involved in a 
procedure [4, 6]. The purpose of aseptic technique is to ensure the sterility of medical procedures 
and the safety of patients by protecting patients from the unintentional introduction of foreign 
and potentially infectious materials. The practice of aseptic techniques in medicine has saved 
millions of lives by preventing and reducing cases of infection and concomitantly increasing the 
success rate of medical procedures and surgeries [3, 6-8]. Similarly, in science, aseptic technique 
serves as a fundamental practice in conducting accurate, controlled, and replicable experiments 
that are un-confounded by unknown variables and contamination related to microorganisms [4, 
9, 10]; this is necessary for the advancement and development of new technologies and practices. 
Microbial communities, their diversity, and advancements in their characterization 
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Although sterile workspaces shall continue to be essential in the medical and scientific 
fields, microbial populations will undeniably continue to occupy and persist in nearly every 
exposed environment on the planet [11-13]. A microbial community is an ecological community 
made up of microorganisms [14, 15]. In a specific environment, it is often referred to as a 
microbiome, defined as the collective microorganisms, and the genetic and genomic potential of 
these microorganisms, inhabiting a particular environmental niche [16]. As sequencing 
technologies have improved and become more accessible over the past decade, microbiome 
research is no longer restricted to culture-dependent investigations and has resulted in a 
considerable increase in the attention and research on microbial communities. Still, much is 
unknown, including a great deal regarding the symbiotic relationships between microbiota (the 
members of a microbial community constituting a microbiome) and hosts. It is also important to 
note that while a microbial community and microbiome encompasses all microbial cells 
(bacteria, archaea, and microscopic eukaryotes), for all intents and purposes of this document, 
usage of the terms microbes, microorganisms, microbiome, and microbiota will be exclusively 
referring to bacteria. 
Microorganisms are the most abundant life form on this planet and although their exact 
numbers are not possible to calculate, many estimates and formulations have made clear that we 
are living in a microbial world. For instance, our oceans alone contain more than 3 x 1028 
bacteria, which vastly exceeds the number of stars in the visible universe [11, 12]. Not only are 
their numbers great, but microorganisms are capable of inhabiting the most extreme 
environments on the planet. Bacteria, for instance, have been detected in deep sea thermal vents 
[17], in the deepest layers of the Earth’s crust [18], and in environments with extremely low [19] 
and high [20] pH environments – there is very little space on the planet that is unpopulated by 
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microorganisms. A recent estimate of the global diversity of bacteria and archaea suggests that 
there are more than a million species of bacteria on the planet [13]. The human body is no 
exception. Each human harbors more microorganisms in their gastrointestinal tract than there are 
people on the planet [21-23]. Indeed, all the external and mucosal surfaces of the human body 
are populated by diverse microbial communities. And yet, the historical presumption has been 
that the vast majority of internal organs of the human body are sterile. 
 Given that the human body consists of nearly equal numbers of human and bacterial cells 
(bacteria outnumber human cells if red blood cells are excluded), measuring around 1x1013 cells 
each [21, 24, 25], the importance of understanding the bacterial side of human health has been 
underappreciated and is gradually being rectified. Historically, microbial surveys in medical 
microbiology have been largely cultivation-based [26, 27], however, molecular surveys, 
especially those of phylogenetic marker genes (e.g. 16S rRNA gene) are becoming increasingly 
common [28-31]. Both methodological approaches have strengths and weaknesses, yet they can 
complement each other, thereby providing a more robust understanding of the microbial 
communities under investigation. Cultivating a microorganism from a clinical sample provides 
certainty of its viability [32, 33], and, once a microorganism is obtained in pure culture, its 
phenotype and genotype can be effectively characterized [34-36]. However, many 
microorganisms are recalcitrant to being cultivated in isolation within the laboratory [33, 36]. As 
such, cultivation-based surveys of microbial communities in clinical samples can preferentially 
select for community members that do grow well in the laboratory, thereby providing an 
incomplete or skewed representation of actual microbial community composition and structure 
[37-40]. With the development of next-generation sequencing (NGS) technologies, scientists can 
sequence millions of DNA molecules from clinical and research samples and describe the 
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genetic content in these samples to characterize their various biological features, including the 
compositions of microbial communities associated with these samples. More specifically, 
researchers now often utilize 16S rRNA gene sequencing to identify the compositions of 
microbial communities and metagenomic, or shotgun, sequencing to study the genomic and 
functional potential of these communities [41-53]. Culture-independent approaches like NGS 
surveys can provide more encompassing snapshots of microbial communities because they are 
not limited by the growth requirements of the bacteria [42, 43]. These new techniques facilitated 
the launch of the Human Microbiome Project, a large-scale NIH-funded collaborative project 
that utilized NGS in a major push towards understanding healthy human microbiota. 
Specifically, using 16S rRNA gene and metagenomic sequencing, the HMP characterized the 
bacterial communities of the human body including the mouth, skin, gut, and vagina [42]. The 
consortium of scientists and medical professionals involved in the HMP were tasked with 
investigating the microbiomes of various body sites of healthy individuals in order to establish a 
basic understanding of the diversity and function of the microorganisms in these environments. 
Understanding these communities in healthy individuals is a fundamental prerequisite to 
understanding their roles in disorders and diseases.  
The human microbiome in the context of disease and low microbial biomass tissues 
Since the inception of the HMP, thousands of studies have investigated various aspects of 
the human microbiome. Links to and associations with the human microbiome have been 
described in the context of multiple diseases and disorders, including Clostridium difficile 
infection (CDI) [54-56], obesity and Type II diabetes [57-59], dental caries [60-62], urinary tract 
disorders [48, 63-69], cystic fibrosis [70], inflammatory bowel disease [71-77], and asthma [78-
80]. While the HMP and a majority of subsequent studies primarily focused on body sites known 
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to be inhabited by microorganisms, there are other body sites that have a much lower microbial 
load or have even been historically considered sterile. Next-generation sequencing technologies 
have allowed these body sites to be interrogated for potential microbial communities. Most 
descriptions of human-associated microbial communities have been from body sites with high 
microbial biomass, especially the gut [58, 59, 71, 81-96]. These early uses of NGS technologies 
to characterize the human microbiome had a high signal-to-noise ratio, meaning the samples 
being described had a high microbial DNA signal that far exceeded the inherent noise introduced 
through background DNA contamination in laboratory reagents and environments [97-99]. This 
high ratio of signal to noise results in the characterization of legitimate microbial signals in 
samples. However, as the microbial load in samples decreases, the signal-to-noise ratio 
decreases, or even inverts, such that that the background noise becomes a predominate portion of 
the data generated and is ultimately included within the characterization of the putative microbial 
community in a sample [99]. In these cases, most, if not all, legitimate biological signals can be 
overwhelmed and no longer distinguishable from contamination [97-104]. This caveat is one that 
must be addressed as researchers continue to investigate lower microbial biomass environments, 
including human body sites historically presumed to be sterile. As exquisitely demonstrated by 
Salter et. al. [99], simply by performing serial dilutions on cells from a pure culture of bacteria is 
sufficient to obscure legitimate signal. After five serial dilutions (e.g. 108 cells diluted to 103 
cells), contaminating sequences from genera such as Pseudomonas and Propionibacterium 
comprised between 70-95% of the obtained microbial signal, with some variation depending 
upon the sequencing facility that was used to process the samples.  
Molecular surveys failing to address caveats associated with low microbial biomass 
samples, specifically background DNA contamination, have led some to conclude the existence 
6 
 
of microbial communities in body sites historically considered sterile, such as the brain [105], 
blood [106, 107], endometrium [108, 109], placenta [44, 45, 49, 84, 95, 110-113], and bladder 
[114-118]. One significant and ubiquitous caveat with these investigations is that microbial 
genes are pervasive in the environment, even in the absence of microbial cells. This issue has led 
to much debate and premature conclusions could potentially influence medical science and even 
clinical care, which runs the risk of negatively impacting patient care and clinical outcomes. One 
of the principal ways this caveat can be properly addressed is through the inclusion of 
background DNA contamination controls (i.e. samples that receive no biological input and are 
processed and extracted alongside the biological samples) in all studies of low microbial biomass 
samples. These technical controls serve to account for the microbial DNA sequences that are 
ubiquitous in both DNA extraction kits and PCR reagents [98-100, 102, 104, 119]. Many studies 
have specifically evaluated the microbial signals from such technical controls and have described 
many microbial taxa as potential contaminants [98-100, 119]. For instance Pseudomonas [99], 
Propionibacterium [98, 99, 119], Ralstonia [98-100], Corynebacterium [99, 119], Actinobacteria 
[99, 119], Burkholderia [99, 100], Escherichia [102, 119], Pelomonas [98, 99, 119], and 
Bradyrhizobium [99, 100] are some of the more commonly reported taxa identified as 
contaminants in these studies. These microbial signals, which most often originate from DNA 
extraction kit reagents, have been given their own name, the “kitome” [98].  
The kitome spreads uncertainty about the conclusions of microbiome work because it 
highlights the difficulty in knowing definitively if the presence of microbial DNA in a biological 
sample is legitimate or if it is a contaminant from the kitome. Several approaches and tools exist 
to help address this issue [120-122], however, there is no perfect way based solely on molecular 
surveys, which is why multiple methodologies are critical to validate DNA sequence-based 
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surveys. Various molecular techniques can be used to address the kitome such as targeted PCR, 
nested PCR, touchdown PCR, and metagenomic sequencing. While alternative PCR methods and 
metagenomics have their own biases (such as amplification biases that may exclude or 
underrepresent certain taxa [123-125] or limitations of taxonomic assignment based on reference 
databases) and can also be influenced by kitome contamination [98-100, 119], consistent trends 
in the data, such as one or two consistently detected and biologically relevant taxa across 
multiple investigatory approaches would help validate the potential microbiome data. For 
instance, conclusions from sequence-based surveys could be validated through Fluorescence in 
situ hybridization (FISH) [100], a molecular technique that allows for the visualization of 
bacterial cells within tissue samples; FISH is a critical tool for demonstrating the existence of a 
bacterial presence in vivo. While validating the presence of bacterial cells in tissue is important, 
cultivation persists as the most convincing evidence that bacterial cells are present in the 
biological samples and that they are alive. Again, both of these methodologies have their own 
caveats. In the case of FISH, fluorescent DNA probes can be cross-reactive or non-specific [126, 
127]. For cultivation to be successful, knowledge of the appropriate and required growth 
conditions are necessary and many bacteria have unknown or unattainable culture conditions at 
this time [36], especially when dealing with mixed bacterial communities. 
As previously mentioned, many studies investigating bacterial communities of these 
classically sterile sites have failed to employ multiple methodologies or failed to include 
appropriate kitome controls. This may lead to spurious conclusions, as these studies were 
missing critical information necessary for rejecting the null hypotheses that these sites are sterile. 
Bold claims suggesting a typical bacterial presence in tissues of the human body that are contrary 
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to historical views will certainly impact the practice of medicine and will, if incorrect, potentially 
result in improper patient care and treatment. 
While most microbiome studies investigate body sites in the context of disease and/or 
rely on comparisons of a diseased cohort to a healthy cohort, this can be precarious when the 
organs under investigation are typically considered sterile. In one example, researchers compared 
16S rRNA gene signals from post-mortem brains of Alzheimer’s disease (AD) patients to those 
from brains of control patients [105]. This study makes two problematic assumptions: 1) there 
are bacteria in the brains of both cohorts, and 2) these bacteria were present before death and 
post-mortem removal of the organs. While the authors concluded that there exists an increase in 
bacteria within Alzheimer brain tissue over normal brain tissue, they failed to address the 
inherent caveats associated with low microbial biomass studies. First, although a significantly 
greater 16S rRNA gene sequence read count was found in the brains of AD patients compared to 
those from normal controls, sequence read count is not a quantitative measure appropriate for 
assessing bacterial load. The appropriate approach would be quantitative real-time PCR. Second, 
the taxonomic profiles indicated a high relative abundance of Actinobacteria in the brains of AD 
patients compared to controls, primarily Propionibacterium acnes (recently reclassified as 
Cutibacterium acnes). P. acnes is a ubiquitous human skin bacterium that is frequently detected 
in culture and molecular surveys as both a legitimate biological signal and as a contaminant [98, 
99, 119, 128]. However, because this study was limited to a single methodology (i.e. 16S rRNA 
gene sequencing surveys), any conclusions about the existence of a brain microbiome should be 
considered premature. While 16S rRNA gene surveys alone may be appropriate for an 
exploratory study, to suggest paradigm-shifting conclusions like the brains of Alzheimer patients 
have more bacteria than normal patients is irresponsible and has the potential to cause harm.  
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Host-microbe interactions and consequences of premature shifts in sterility paradigms 
The importance of accurately evaluating the presence of a microbial community and fully 
understanding its relationship with the human body has been made clear through a variety of 
noninfectious diseases that have been associated with microorganisms [43, 60, 65, 70, 75-77, 80, 
108, 117, 129-133]. These associations reinforce the value of understanding where microbial 
communities begin and end in the human body. Should microbial communities be discovered in 
an anatomic environment that was previously believed to be sterile, it would open the door to 
new exploratory studies and research funding. However, if conclusions are drawn prematurely, it 
would put researchers on a fool’s errand with expensive molecular surveys revealing the 
taxonomic and functional profiles of exogenous and contaminant DNA. More importantly would 
be the consequences on the medical community of the declaration that a body site presumed to 
be sterile is not actually sterile. If practitioners begin believing mistakenly that bacteria are 
normally present in a body site of healthy individuals, even at low or hard to detect numbers, 
practitioners may become laxer with safety and hygiene procedures. This would put patients at a 
high risk for infections or at the very least disruption and alteration of these communities. These 
theoretical consequences illustrate the diligence we must employ as researchers before 
presenting and advocating for shifts in classical paradigms of sterility. 
Reevaluating paradigms of sterility in the context of pregnancy has been the focus of my 
dissertation research. Because infection is instrumental in pregnancy complications [134-146] 
and classically involves microorganisms reaching sterile tissues and causing inflammation, a 
thorough and complete understanding of the microbial signals in urogenital compartments is 
necessary for the best patient care and treatment. One important issue is that if there are actually 
resident microbiomes in the womb or bladder, it is likely that antibiotic use would affect these 
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microbial communities. While antibiotic therapy is generally only used when necessary, 
secondary consequences can result such as in the case of Clostridium difficile infection (CDI), 
which is a nosocomial infection that results from the use of antibiotics disturbing a patient’s 
intestinal microbiota and allowing for C. difficile spores to colonize and populate the intestinal 
lining of a patient, causing chronic diarrhea and severe intestinal discomfort. Although 
antibiotics are often used during pregnancy, there may be consequences previously overlooked 
under assumptions of sterility in the bladder and womb. Also, under the presumption that these 
sites harbor microbiomes, new therapeutic and diagnostic tools, such as probiotics [69, 147, 148] 
or biomarker assays [122], can be explored. I must reiterate, however, these data and must be 
vetted before concluding that there are resident microbial communities in the bladder or womb.  
CHAPTER 2: DOES THE HUMAN PLACENTA DELIVERED AT TERM HAVE A 
MICROBIOTA? 
In the second chapter, I will present our study that addressed the literature asserting the 
existence of a placental microbiome.  In 2014, Aagaard et al. published a pioneering study 
suggesting that a placental microbiome exists and that its primary member is Escherichia coli 
[44]. Since then, a wide range of studies from multiple groups have published reports either 
supporting Aagaard’s claim [45, 49] or refuting it [128, 149, 150]. Chapter 2 will provide an 
overview of our own study that addressed the issues and oversights from the previous studies by 
approaching the hypothesis that there is a placental microbiome in term pregnancies by 
surveying cesarean delivered placentas with multiple methodologies and including extensive 
background DNA contamination controls. I will further describe and discuss the metagenomic 
analysis portion of the study that I performed. Additionally, I will describe a secondary analysis 
of the amplicon 16S rRNA gene sequence data wherein I address the same questions concerning 
sterility of the placenta in the context of two sequence classification methods, operational 
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taxonomic units (OTUs) [151] and amplicon sequence variants (ASVs) [152]. Operational 
taxonomic units were developed as a method for grouping 16S rRNA gene sequences based on a 
defined level of sequence similarity (e.g. 97 or 99%). Grouping sequences at a defined similarity 
eliminates some of the error inherent in sequencing technologies and permits a small degree of 
sequence variation while treating those sequences as though they came from the same 
microorganism. A key limitation of the OTU approach is that it lacks taxonomic resolution; the 
16S rRNA gene sequences of multiple microorganisms, whether species or strains, can get 
grouped into the same OTU. This led to the proposal of ASVs as an alternative method for 
grouping and classifying sequences. This newer method increases the resolution of sequences to 
single nucleotide differences and this can be vital in differentiating different species and strains 
of bacteria. However, caveats exist with this method as well. By increasing the resolution to 
single nucleotide differences, researchers run the risk of characterizing sequences that are 
products of sequencing error and assuming that these sequences represent authentic and specific 
bacteria. Researchers are transitioning toward the use of ASVs as the dominant method for 
classifying 16S rRNA gene sequences, however, conclusions on which method is most 
appropriate need to be considered in various contexts, such as in investigations of low microbial 
biomass environments like the placenta.  
CHAPTER 3: DOES THE MOUSE PLACENTA HAVE A MICROBIOTA? CULTURE 
AND MOLECULAR SURVEYS OF THE MURINE MICROBIOTA 
The third chapter of my dissertation uses an animal model to more comprehensively 
address the sterility of the mammalian placental and fetal compartments. By transitioning from 
the human model to a mouse model we are able to address several questions that could not be 
answered using human participants. One benefit of using a mouse model is that sterile 
reproductive tissues and fetuses can be collected and investigated alongside other sterile and low 
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and high microbial biomass samples that can serve as controls for discriminating potential 
microbial signals. In this chapter, culture results from placental, fetal, and maternal tissues will 
be presented and analyzed extensively and compared to the microbial signals evident in murine 
tissues with high microbial load. Surprisingly few studies have assessed the broader mouse 
microbiome, outside of the intestine, and our data allow us to compare both molecular and 
culture-based surveys to determine if the murine placenta and fetus are sterile, compare the 
ability of culture to capture what is seen in 16S rRNA gene surveys, and to assess our results in 
the context of the established literature for culture and sequencing. 
CHAPTER 4: A URINARY MICROBIOTA IN PREGNANCY: CULTIVATION- AND 
MOLECULAR-BASED COMPARISON OF FOLEY CATHETERIZED URINE, CLEAN 
CATCH URINE, AND VAGINAL SWABS FROM THE SAME WOMEN 
The fourth chapter of my dissertation, while still investigating paradigms of sterility in 
perinatal medicine, shifts from the placenta to the female bladder in pregnancy. Like the 
placenta, the bladder has historically been considered a sterile organ. However, this is being 
reconsidered as recent molecular surveys of urine suggest the presence of a bladder microbiota 
[48, 63, 115-118, 153, 154]. Since urinary tract infections (UTIs) are the most frequent bacterial 
infection in women [155], and can lead to pregnancy complications such as spontaneous preterm 
birth [66, 134, 137, 138, 156-165], defining and characterizing bladder microbial communities 
could greatly alter how UTIs [69], and other urinary disorders [48, 63, 64, 67] are diagnosed and 
treated in pregnancy Additionally, urinary tract catheterization is standard practice for women 
delivering via cesarean section and such mechanical procedures can lead to UTIs [166] and 
potentially affect resident bladder microbial communities [65], Therefore, the objective of 
Chapter 4 is to evaluate the existence of a bladder microbiome in pregnant women, while also 
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assessing the effectiveness of different volume and collection methods for acquiring urine for 
microbiological investigations. 
CHAPTER 5: GENERAL CONCLUSIONS 
In closing, I provide a summary of the investigations I have completed, directions for 







CHAPTER 2: DOES THE HUMAN PLACENTA DELIVERED AT TERM HAVE A 
MICROBIOTA?   
The metagenomic data presented in this chapter were a fundamental component of the 
manuscript “Does the human placenta delivered at term have a microbiota? Results of 
cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics” 
published March 2019 in the American Journal of Obstetrics and Gynecology by Theis, K.R., 
Romero, R., Winters, A.D., Greenberg, J.M., et al.  [150]. Some of the text of this Chapter (i.e. 
Methods and Results) appears as it does in the published manuscript. I was an author on this 
manuscript and the data presented in this chapter include the portions of that manuscript with 
which I was most involved. 
I. Abstract 
Molecular surveys have allowed investigations of low microbial biomass tissues of the 
human body. The human placenta has been of particular interest, and its sterility has been the 
subject of recent debate. The majority of evidence suggesting there is a placental microbiota has 
relied on 16S rRNA gene sequencing and metagenomic sequencing without addressing the 
caveats inherent in low microbial biomass environments. The objective of this chapter was to 
determine whether human the placenta delivered at term has a microbiota using multiple modes 
of microbiologic inquiry and comparisons to background technical controls. Culture, quantitative 
real-time PCR (qPCR), and 16S rRNA gene sequencing were performed on 29 term cesarean 
placentas in addition to metagenomic sequencing on a subset of placentas. 28 out of 29 placentas 
were negative for culture and the one that was not had three unique bacterial colonies on a single 
plate that were not detected in 16S rRNA gene surveys of that placenta. Quantitative real-time 
PCR and 16S rRNA gene surveys indicated that the bacterial burden and profiles of placental 
samples were not distinct from technical controls. Metagenomic surveys of placental samples 
yielded limited bacterial signals and the predominant bacterial taxa included plant-associated and 
photosynthetic bacteria, which are ecologically implausible for internal tissues such as the 
placenta. Additional analyses of the 16S rRNA gene sequencing data, that utilized a new 
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classification method known as amplicon sequence variants (ASVs) and employed additional 
tools to control for background DNA contamination, supported the findings observed with the 
more traditional 16S rRNA gene classification method of operational taxonomic units (OTUs). 
Therefore, through multiple modes of microbiologic inquiry and computational approaches, we 
found a lack of evidence for a placental microbiota in the human placenta delivered at term. 
II. Introduction 
Most tissues within the human body are presumed to be sterile. In fact, nearly all internal 
sites, essentially anything not immediately adjacent to mucosal tissue, are viewed as being 
devoid of microbes. It is easier to list the mucosal or microbiota-containing sites of the body, i.e. 
nasal and oral cavities, lungs, gastrointestinal tract, vagina, and skin, than those considered 
sterile, i.e. most everything else. The presence of microbial communities in the urogenital and 
upper reproductive tracts, however, has been a source of much recent debate [44, 84, 108, 109, 
133, 150, 167-169]. While for both sexes, the distal urethra indisputably contains microbes, the 
literature is less clear regarding sterility of the more proximal sites, up to and including the 
bladder (further discussed in Chapter 4). Additionally, while the microbial communities of the 
vagina and the cervix have been widely described in the literature [170-174], the existence of 
microbial communities in the endometrium of the uterus are far less conclusive [108, 109, 168]. 
In the context of pregnancy, because the placenta implants in the decidualized endometrium of 
the uterus, and because the placenta serves as the interfacing organ between the mother and 
fetus, the placenta has also become a recent target of microbiome investigation [44, 84, 113, 
175]. 
 It is well established that symbiotic microbes can colonize the human placenta and that 
this can negatively impact pregnancy outcomes [141, 176-182]. However, a unique, low 
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abundance, resident microbiota in the placentas of normal, asymptomatic pregnancies is now 
being proposed [44, 183]. Following a landmark study in 2012 by Aagaard et al., the placenta 
became a focus of microbiome work; this study made the bold claim that the placenta was not a 
sterile organ. The potential for the placenta to harbor a resident microbiota has implications not 
only for pregnancy outcome but also for the initial inoculation and development of fetal and 
early neonatal microbiota [183-186]. For instance, fetal inoculation with maternal microbes in 
utero via the placenta could serve to bolster and shape the early immune system and set the stage 
for the colonization and growth of site-specific (e.g., oral cavity, large intestine) microbial 
communities upon delivery [186-188]. However, in a recent comprehensive review of the 
subject, Perez-Munoz et al. [149] explained that current evidence in support of the in utero 
colonization hypothesis is unconvincing. The three principal concerns they highlighted are that 
supporting studies 1) have not demonstrated that the microbes captured via molecular surveys of 
the placenta and in utero environments were viable, 2) have not given sufficient consideration to 
the potential influences of mode of delivery on study outcomes, and they 3) lacked sufficient 
technical controls to address potential background contamination. Specifically, when 
characterizing and comparing the microbial profiles of low biomass samples via highly sensitive 
next-generation sequencing technologies, there is a substantial risk of amplifying, sequencing, 
and consequently describing contaminating DNA that is unavoidably present in extraction kits, 
PCR and sequencing reagents, and broader laboratory environments [98, 99, 119, 128, 149, 189]. 
The high sensitivity afforded by the technology also provides susceptibility to false positives. 
Notably, one preliminary study that did incorporate sufficient technical controls for background 
DNA contamination found similar concentrations of bacterial DNA in placental tissue and 
control samples, and the bacterial profiles of the two were not distinguishable [128]. Lauder et al. 
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[128] concluded that, when working with low microbial biomass samples and capitalizing on 
next-generation sequencing technologies, begin with the null hypothesis that microbial signals 
obtained from the biological samples are contamination only. Perez-Munoz et al. [149] 
additionally proposed that there is a particular need for studies evaluating this null hypothesis in 
healthy term pregnancies, with delivery via caesarean section, in which corroborative evidence is 
evaluated across multiple modes of microbiologic inquiry. Therefore, the primary objective of 
the study featured in this chapter was to evaluate the existence of a unique resident microbiota in 
the placenta from normal term pregnancies using multiple modes of microbiologic inquiry and 
incorporating rigorous technical controls for DNA contamination. 
 As described in Theis et al. [150], the placentas of 29 women delivering via elective 
cesarean section at term were evaluated for evidence of a microbiota using bacterial culture, 16S 
rRNA gene quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics. Culture 
results were negative for all but one placenta, from which three unique colonies were recovered 
from a single agar growth plate. These microbes were common environmental bacteria and their 
16S rRNA genes were not detected in the 16S rRNA gene surveys of the placental sample from 
which they were “recovered,” suggesting that they were likely laboratory contaminants. Both 
16S rRNA gene quantitative real-time PCR and sequencing surveys demonstrated that the 
bacterial loads and bacterial profiles of placental tissues were indistinguishable from those of 
technical controls, thereby complementing the data obtained from the culture component of the 
study. Additionally, secondary qPCR and 16S rRNA gene sequencing analyses further 
corroborated the results from the primary analyses briefly described above and further addressed 
potential concerns over cross-contamination of bacteria from placental tissues to technical 
controls, and biases introduced through PCR methodology and primer design. Lastly, as the first 
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aim of this chapter, metagenomics was used to evaluate the existence of a placental 
microbiota in normal term pregnancy. Specifically, metagenomic sequencing was performed 
on a subset of samples to avoid any potential biases inherent in molecular methods that target 
specific genes (e.g. 16S rRNA gene) for amplification and/or sequencing. In metagenomics, all 
the DNA in a sample is sequenced with the absence or only minimal use of PCR. The results 
from the metagenomic survey reported in this chapter illustrate the importance of using multiple 
modes of microbiologic inquiry in reevaluating paradigms of sterility: the bacterial signals 
detected in the placenta were largely inconsistent with those obtained from the 16S rRNA gene 
surveys, and the bacteria identified were generally ecologically implausible because the placenta 
would not be a suitable environment in which for them to grow and reproduce.  
The second aim of this chapter is to determine if the manner in which 16S rRNA 
gene sequence data are processed influences the conclusions drawn from sequence-based 
studies evaluating the existence of a placental microbiota. Since the publication of Theis et 
al.[150], a review paper was published that included a reanalysis of the data in Theis et al., and in 
another placental microbiota study by Leiby et al. [167], that used a different sequence 
processing and classification method [103] than Theis et al. and Leiby et al. had used. Much of 
the early research on the microbiome using 16S rRNA gene sequencing was performed using 
operational taxonomic units (OTUs) as the predominant classification method for 16S rRNA 
gene sequences. Whether OTUs were generated and analyzed using the software programs 
Qiime2 [190] or mothur [41], the methodology relied on a user-defined sequence similarity 
identity threshold (97% was standard, although other thresholds such as 95% or 99% were 
occasionally used), which would group or cluster quality-filtered sequences with ≥ 97% 
sequence identity into a single OTU corresponding to a representative 16S rRNA gene sequence 
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that is then assigned a specific taxonomic identity/classification. This sequence clustering 
approach based on sequence identity can account for sequencing errors that are inevitable with 
existing sequencing technologies. However, it has been suggested that the resolution provided by 
this clustering method, while valuable for addressing sequencing errors, may obscure microbial 
biodiversity patterns in biological samples by disregarding potential species and strain level 
differences that can result from as little as a single nucleotide difference in the 16S rRNA gene 
[152, 191, 192]. While this issue can be partially ameliorated through OTU clustering at more 
stringent sequence identity thresholds, such as 99%, which only allows 1 or 2 nucleotide base 
differences across a 250 base amplicon, there are two additional concerns with the OTU 
classification method. First, with OTUs, the taxonomic units are constructed based upon the 
entire dataset, which can require substantial computational time and resources. Second, OTUs 
are typically generated de novo; OTUs from a dataset are specific to that dataset and can 
therefore not be directly compared across studies or generated based on a reference database, 
which can limit the taxa that are classified based on the thoroughness of the database [192].  
While the majority of microbiome studies have relied on the OTU classification method, 
an alternative method was recently proposed that identifies exact sequence variants, or amplicon 
sequence variants (ASVs), thereby providing resolution in the classification of sequences that 
differ by only a single nucleotide. This classification method, which is performed through the 
DADA2 [152] package in R [193], addresses the aforementioned caveats associated with OTU 
approaches and may allow for elucidating underlying patterns in microbial biodiversity that 
would otherwise be overlooked by OTU classification methods. The ASV approach has been 
proposed as a more accurate and biologically informative way to classify 16S rRNA gene 
sequences, specifically in regard to sensitivity and precision [97]. The strengths of this sequence 
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processing pipeline, in addition to the resolution of sequence variants at a single nucleotide 
difference, is that ASVs are inferred per sample, rather than per dataset, and are generated based 
on their relative abundance within a sample. By factoring in relative abundance, the ASV 
approach excludes extremely low abundance sequences based on the assumption that legitimate 
sequences are going to occur more frequently than sequences that were resultant from 
sequencing error. 
Proponents of the existence of a placental microbiota have capitalized on the ASV-
approach and argued that prior studies that used OTU-based approaches and determined that the 
bacterial profiles of placental tissues and background technical controls were indistinguishable 
lacked the resolution required to determine if the molecular signals of bacteria from tissues and 
controls were indeed from the same microorganisms [103, 175]. In the review by O’Callaghan 
[103], which re-classified publicly available 16S rRNA gene sequence datasets from the two 
aforementioned placental microbiota studies [150, 167] using the ASV pipeline, it was suggested 
that the results and conclusions of the re-analysis were inconsistent with what had been 
previously published using OTU classifications. Therefore, in this chapter, alongside the analysis 
of the metagenomic data of placental tissue and technical control samples, I will analyze, 
compare, and discuss the 16S rRNA gene sequence data from these samples processed using 
both sequence classification methods. Specifically, I will re-assess the publicly available dataset 
associated with Theis et al. [150], evaluating the data using ASV and OTU classification 
methods, compare the data from both methods to illustrate the differences and similarities 
between them in the context of the original publication, and address several points raised by 
O’Callaghan et al. [103] that are inconsistent with our analyses (such as their reporting of a high 
relative abundance of Ureaplasma sequences in our negative controls). While the published 
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manuscript [150] included several datasets generated using multiple PCR methodologies, the 
reanalysis presented in this chapter is focused on the primary nested PCR dataset and the 
secondary touchdown PCR dataset, as these were the two amplification methods that yielded 
large numbers of quality 16S rRNA gene sequences and were not entirely dominated by 
Escherichia sequences, a well-established background DNA contaminant in sequence-based 
studies [99, 119, 150]. The re-analysis of the data presented here counters the points raised by 
O’Callaghan et al. [103] and validates our initial findings and conclusions that there is a lack of 
evidence of a placental microbiota in normal term pregnancies. 
III. Methods and Materials 
Methods and Materials are further detailed in the published manuscript “Does the human 
placenta delivered at term have a microbiota? Results of cultivation, quantitative real-time PCR, 
16S rRNA gene sequencing, and metagenomics.” [150].  
Briefly, tissue samples were taken from the placentas of 29 women delivering by 
cesarean section without labor at term. Samples were collected and processed with aseptic 
techniques to avoid contamination. Following delivery, placentas were processed in a biological 
safety cabinet, wherein a core of tissue (i.e. from the amnion through to the basal plate) was 
collected halfway between the edge of the placental disc and the umbilical cord insertion site. 
The tissues were placed into sterile containers and frozen at -80° C until DNA extractions were 
performed.  
DNA extraction from placental tissues  
During the DNA extraction process, study personnel wore sterile surgical gowns, gloves, 
and masks, and used individually packaged, sterile, and disposable scalpels and forceps. For each 
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placental tissue specimen, the amnion and chorion (AC) were collectively cut away from the 
villous tree and basal plate (V); no tissue components were excluded and both tissue fractions 
likely contained subchorionic tissue. Genomic DNA was extracted from these two tissue 
fractions separately. Specifically, DNA was extracted from placental tissues (0.1 to 0.2 g) and 
background technical control samples using the MoBio PowerSoil DNA Isolation Kit (MoBio 
Laboratories, 12888), according to the manufacturer’s protocol. The DNA extraction kit used, 
and the mass of placental tissue from which DNA was extracted, were consistent with prior 
studies of potential placental microbiota [44, 128]. Background technical control samples 
included extractions performed on: 1) DNA extraction kits without any introduced placental 
tissue, processed exactly as the placental samples (N = 6); 2) extraction kits whose bead tubes 
had been exposed to a biological safety cabinet for 20 minutes during placental biopsy collection 
or processing (N = 16 samples from 3 biosafety cabinets); and 3) extraction kits whose bead 
tubes had been exposed for 20 minutes to an operating room or microbiology laboratory utilized 
in this study (N = 21 samples from three operating rooms and three laboratories). These control 
samples therefore represented five or six technical controls reflecting each potential source of 
background DNA contamination (i.e. extraction kits, 3 biosafety cabinets, 3 laboratories, and 
operating rooms), with the three contiguous operating room environments being treated as a 
single potential contamination source. DNA concentrations of placental tissue and background 
technical control samples were 42.0 ± 18.5 (standard deviation) ng/µl and ≤ 0.03 ng/µl, 
respectively. Purified DNA was stored at −20° C. 
To eliminate the possibility of any bacterial signal coming from the controls being due to 
cross-contamination from microbial-populated placental tissues, a secondary series of extractions 
and analyses were performed that included background technical control samples processed 
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alongside placental samples and independently of placental samples. Secondary DNA extractions 
were performed on the collective villous tree & basal plate portion of each of the 29 placental 
samples. The extraction protocol was the same as that described earlier, except that at least 4 
background technical controls were included in each of four rounds of extractions of the 
placental samples. Specifically, in the first three rounds of extractions, we processed eight 
placental and four technical control samples. In the fourth round, we processed five placental and 
five technical control samples. Additionally, we completed a fifth round of extractions composed 
entirely of 12 blank extraction kit controls, which were not exposed to the atmospheres of the 
biologic safety cabinets or the laboratories; they were processed exactly as the placental samples.   
DNA concentrations of placental tissue and background technical control samples were 56.0 ± 
24.3 ng/µl and ≤ 0.03 ng/µl, respectively. Purified DNA was stored at −20° C. 
Metagenomic sequencing of extracted DNA from placental tissue and background technical 
control samples 
In contrast to sequencing surveys targeting a specific bacterial gene (e.g. 16S rRNA 
gene), a metagenomic survey entails sequencing all the genes in a clinical sample and assigning 
the protein-coding genes of bacterial origin to particular bacterial taxa, even potentially at the 
species level. Nine placental and 11 technical control samples were submitted for metagenomic 
sequencing using the Illumina HiSeq 4000, 150 paired-end protocol at the University of 
Michigan’s DNA Sequencing Core (Ann Arbor, MI). The placental samples included amnion-
chorion and villous tissue and basal plate samples from each of four subjects (subjects 14, 15, 22, 
and 30), and a villous tissue and basal plate placental sample from one subject (subject 19). The 




Metagenomic sequence data processing using MG-RAST 
The twenty metagenomic sequence libraries were submitted to the MG-RAST 
metagenomes analysis server at the Argonne National Laboratory [194]. Forward and reverse 
reads were combined into joined paired-end reads, as applicable, yet those with non-overlapping 
paired-ends were retained as well. Default pipeline parameter options were used: assembled (no), 
dereplication (yes), and screening (H. sapiens, NCBI v36). Dynamic trimming was also set to 
default, except lowest quality base phred score was set to 10, and sequences were trimmed to 
contain at most seven bases with a phred score of 10 [195]. Reads more than two standard 
deviations from the mean read length were discarded, as were poor quality and artificial 
duplicate reads [194]. As the final processing step, sequences were screened for host DNA, in 
this case those that matched H. sapiens, via NCBI v36. SortMeRNA [196] was used to identify 
rRNA genes with a 70% identity cut-off and CD-HIT [197] was used to cluster those with a 97% 
nucleotide similarity. The longest representative from these clusters was run through a BLAST-
like alignment tool (BLAT) [198] similarity search against the M5rna database for rRNA 
identification [194]. Sequences of potential protein coding regions were identified via 
FragGeneScan [199], and predicted protein coding sequences were clustered at 90% identity 
with CD-HIT and run through a BLAT search against the M5NR protein database. Protein 
features were excluded if they overlapped with ribosomal RNA features. Identified rRNA and 
protein sequences were annotated and mapped back to the original sequences. Taxonomic 
assignments were made using the GenBank database and the default MG-RAST parameters: 
maximum e-value cutoff of 5, minimum percent identity cutoff of 60%, minimum alignment 
length cutoff of 15, minimum abundance of 1, and representative-hit classification [194]. For 
gene function characterization, sequences were mapped to the KEGG Orthology (KO) database 
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[200]. Metagenomic sequencing files are publicly available at MG-RAST (Project ID 
PRJNA397876). 
Reanalysis of published placental data after reclassification into ASVs 
ASV sequence data processing using DADA2 
Classification of ASVs was performed as described by Callahan et al. [152] using the 
DADA2 tutorial pipeline (benjjneb.github.io/dada2/tutorial.html). The tutorial was followed 
using the default parameters except in the following instances: multithreading was changed to 
FALSE throughout the pipeline; for the filter and trimming step the truncation length for forward 
reads was increased from 240 to 250  (“truncLen=c(250,160)”), and the maximum number of 
expected errors was increased from 2 to 7 for reverse reads (“maxEE=c(2,7)”); for the removal 
of chimeras, the method was changed to “pooled”; and to assign taxonomy, a minimum 
bootstrapping value was added (“minBoot=80”) and the reference database for assigning 
taxonomy was changed from the default Silva reference database to the RefSeq RDP 16S 




Following DADA2 processing, ASVs identified as chloroplasts were removed from the 
primary nested (n = 2 ASVs) and secondary touchdown (n = 6 ASVs) datasets. After removing 
the chloroplast ASVs, the primary nested dataset contained 5,239,414 reads and 714 ASVs, and 
the secondary touchdown dataset contained 2,050,376 reads and 704 ASVs. A preliminary 
analysis identified a significant proportion of human mitochondrial sequences in the secondary 
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touchdown dataset; after these sequences were removed, there were 1,642,769 sequences and 
492 ASVs in the secondary touchdown dataset. 
Subsampling of 16S rRNA gene sequence data for ASV vs OTU comparisons 
 Both primary nested and secondary touchdown datasets were subsampled to a sequence 
depth of 500, unless otherwise indicated, to mirror the analyses performed by O’Callaghan et al. 
[103]. In order to ensure that the bacterial profiles of samples remained sufficiently characterized 
after subsampling, samples were only included in analyses if they had a Good’s coverage ≥ 95%.  
Decontam program for the removal of likely background DNA contaminants 
Decontam is a program that classifies OTUs or ASVs in biological samples as either 
contaminants or non-contaminants based upon their distribution among complementary blank 
DNA extraction controls [120]. The decontam package was run in R Studio [201] and our ASV-
specific analyses were done using two methods. The isContaminant method was used for both 
primary nested and secondary touchdown datasets and parameters were kept in accordance with 
those used in O’Callaghan et al. [66]: the prevalence method was used with a threshold of 0.5 
(default is 0.1). The alternative isNotContaminant method was also used for both datasets, using 
the prevalence method and thresholds of 0.5 and 0.6 for the primary nested dataset and 0.2 and 
0.5 for the secondary touchdown dataset (default is 0.5). For each analysis, all background 
technical control sample types were grouped together as controls in the metadata file. 
Rationale for use of isNotContaminant method and thresholds 
The alternative method, isNotContaminant, in the decontam package is the most 
appropriate method for using in studies with low microbial biomass samples [120]. This method 
begins with the assumption that all sequences are contaminants and that the presence of an ASV 
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in a greater proportion of biological samples than controls identifies the sequence as a non-
contaminant. This method is valuable as it provides greater confidence in describing bacterial 
communities from sequence data when a large proportion of contaminant sequences are 
expected. It is not appropriate, however, to assume that taxa that remain after filtering are 
evidence of a legitimate bacterial community. It is critical that researchers using this tool further 
investigate whether the remaining taxa are ecologically plausible and are exceedingly and 
consistently present in biological samples more so than in controls. 
Additionally, when using decontam, as addressed in Davis et al. [120], it is critical to 
assess the distribution of decontam scores for each dataset in order to establish a cutoff or 
“threshold” of when sequences can be considered contaminants. This is important because a 
particular threshold for contaminant or non-contaminant classification may not be appropriate for 
every dataset and, in the case of the isNotContaminant function, the threshold classifies scores 
below the designated threshold as non-contaminants (e.g. a threshold of 1.0 would identify all 
sequences < 1.0 as non-contaminants). To identify appropriate thresholds for the primary nested 
and secondary touchdown datasets, a histogram was generated for each dataset illustrating the 
distribution of decontam scores, their presence in placental samples, and the number of ASVs at 
each score (Figure 2.1). The default threshold is 0.5 for this method and both datasets were 
analyzed at this threshold. Additionally, while the histogram for the primary nested dataset 
illustrated that there is a widespread distribution of scores, the large peak at 0.5 can be viewed as 
an inflection point for this dataset (Figure 2.1A). Because a large number of ASVs had a score 
between 0.5 and 0.6, we performed an additional analysis through decontam with a threshold of 




Figure 2.1. Histograms of decontam scores for identifying appropriate thresholds for 
filtering of the ASV datasets. Decontam scores indicating that A) thresholds of 0.5/0.6 for the 
primary nested PCR dataset should be appropriate for identifying non-contaminant sequences, 
and B) thresholds of 0.2/0.5 for the secondary touchdown PCR dataset appear appropriate owing 




secondary touchdown dataset showed several peaks with a much less clear distribution, however, 
an early cluster of low scores suggested a very conservative threshold of 0.2 could be appropriate 
for this dataset, in addition to the default 0.5 threshold (Figure 2.1B). 
Filtering of contaminant ASVs from the primary nested dataset using decontam 
Decontam analysis using isContaminant and a threshold of 0.5 
After running decontam on the primary nested dataset, 241 of 714 ASVs were identified 
as “TRUE” contaminants, leaving 66.2% (473/714) of the ASVs in the analysis. After removing 
the contaminant ASVs, the total sequence reads were reduced from 5,239,414 to 3,792,300 
(72.4% of the original dataset). Good’s coverage values remained > 98% after contaminant 
ASVs were removed, however, one placental sample (23V) and three technical controls 
(3Room1, 3Room4, 4Hood4) contained less than 500 sequences and were removed prior to 
subsampling. After subsampling, 283 ASVs remained and one placental sample (4V) and three 
controls (3Hood5, 4Hood2, 7Hood2) with Good’s coverage values < 95% were removed from 
analysis. 
Decontam analysis using isNotContaminant and a threshold of 0.5 
Applying the 0.5 threshold for the isNotContaminant function, the primary nested dataset 
contained 193 ASVs that were classified as non-contaminants. This represented 27.0% (193/714) 
of the total ASVs prior to running decontam. After removing the contaminant ASVs, coverage 
remained above 95% for all samples, however 16 samples no longer had ≥ 500 sequences. Of 
these 16 samples, two were placental samples (13AC, 23V), three were kit controls, four were 
hood controls, and seven were room controls (one of which was an operating room control). 
These samples were removed from analysis and the remaining samples were subsampled to 500 
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sequences. After subsampling, coverage for all samples remained above 95% and 156 ASVs 
were represented. 
Decontam analysis using isNotContaminant and a threshold of 0.6 
Using a less conservative threshold of 0.6, 348 ASVs were classified as non-
contaminants. This represented 48.1% (348/714) of the total ASVs prior to running decontam. 
After removing the contaminant ASVs, Good’s coverage values remained > 95% for all samples; 
however, three samples no longer had ≥ 500 sequences. Of these three samples, two were room 
controls and one was an extraction kit control. These samples were removed from analysis and 
the remaining samples were subsampled to 500 sequences. After subsampling, the Good’s 
coverage values for six samples were < 95% (3V, 6V, 18AC, and 3 Hood controls) and these 
samples were removed from analysis. The analysis proceeded with 235 ASVs represented in the 
dataset. 
Filtering of contaminant ASVs from the secondary touchdown dataset using decontam 
To maximize power in discriminating contaminating from non-contaminating ASVs, the 
secondary touchdown dataset was processed through decontam using all kit controls (n = 29, 
including DNA extraction kits processed alongside as well as independent of placental samples). 
There was no difference in the bacterial profiles of controls processed alongside placentas and 
those processed alone (NPMANOVA: F = 1.069, p = 0.278). Yet, to be conservative, following 
the execution of decontam, the kit controls not processed alongside placental samples were 
removed from analyses comparing and contrasting the bacterial profiles of control and biological 
samples. The removed kit controls accounted for 549,488 of the 1,642,769 total sequence reads, 
and 75 of the 492 total unique ASVs. Placental samples and the remaining controls were retained 
if they had ≥ 500 reads after the contaminant ASVs were removed (25/29 placental samples and 
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16/17 control samples). The total read count after removing samples with < 500 reads was 
1,091,208 and Good’s coverage values were ≥ 99% for all samples.  
Decontam analysis using isContaminant and a threshold of 0.5 
Of the 417 ASVs left in the dataset, 103 were identified as contaminants leaving 75.3% 
(314/417) of the ASVs in the analysis. The read count was reduced to 59.3% 
(647,016/1,091,208) and one control sample (TD_B3_3) was removed for having < 500 reads. 
All remaining samples had Good’s coverage values ≥ 99% and were subsampled to 500 
sequence reads. After subsampling, Good’s coverage values were> 98% and 277 ASVs 
remained. 
Decontam analysis using isNotContaminant and a threshold of 0.5 
For this analysis, 298 ASVs were identified as contaminants, leaving 28.5% (119/417) of 
the ASVs in the analysis. The read count was reduced to 45.1% (492,014/1,091,208). Only one 
sample was removed due to having < 500 reads (the same control as above: TD_B3_3). All 
remaining samples had Good’s coverage values ≥ 99% and were subsampled to 500 sequence 
reads. After subsampling, Good’s coverage values were > 98% and 103 ASVs remained. 
Statistical analyses 
16S rRNA gene profile structure comparisons of the primary nested PCR dataset 
Bray-Curtis similarity indices were calculated and differences in bacterial profiles 
between placental tissue samples and blank DNA extraction controls were statistically evaluated 
using one-way non-parametric multivariate ANOVA (NPMANOVA) with Bonferroni 




16S rRNA gene profile structure comparisons of the secondary touchdown PCR dataset 
Bray-Curtis similarity indices were calculated and differences in bacterial profiles 
between placental tissue samples and blank DNA extraction controls were statistically evaluated 
using NPMANOVA in the vegan [203] package in R (v. 3.61) [193] allowing for the analysis of 
multiple group variables and their interaction.  
Figure generation 
All Principal Coordinates Analysis (PCoA) plots were generated in PAST (v. 3.25) [202]. 
All heatmaps were generated using Morpheus [204] software. Prior to heatmap generation, 
unweighted pair group method with arithmetic mean clustering was performed based on Bray-
Curtis similarity values in PAST [202]. 
IV. Results 
The results from metagenomic sequencing presented below were published in the 
manuscript “Does the human placenta delivered at term have a microbiota? Results of 
cultivation, quantitative real-time PCR, 16S rRNA gene sequencing, and metagenomics” [150]. 
Metagenomic surveys of the bacterial profiles of placental tissues  
At least 43,000,000 sequence reads were obtained from each of nine placental tissue 
samples (61,027,678 ± 3,190,738 SEM; Table 2.1). On average, 0.05% of these sequences were 
classified as bacterial in origin. Good’s coverage values (99.61% ± 0.14 SEM) indicated that the 
bacterial profiles of these samples were thoroughly characterized from a taxonomic standpoint. 
The survey identified 267 bacterial genera, with 19 being considered prominent, defined as 
having an average relative abundance of ≥ 0.1% (Figure 2.2). Only five genera had an average 
relative abundance ≥ 1.0%: Cyanothece, Coprobacillus, Candidatus Phytoplasma, Chlorobium, 
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All 5 < 5 
14AC 77,603,776 95.63 350,330 40,188 11.47 126 99.8% 125 1 0 
14V 63,783,888 95.49 291,868 33,300 11.41 116 99.8% 116 0 0 
15AC 60,438,600 95.58 287,700 32,400 11.26 106 99.8% 106 0 0 
15V 62,928,591 95.63 278,408 34,638 12.44 112 99.8% 112 0 0 
19V 62,542,939 95.62 232,037 34,980 15.08 99 99.8% 99 0 0 
22AC 68,611,076 95.37 333,864 37,358 11.19 116 99.8% 116 0 0 
22V 52,974,105 95.65 236,102 28,788 12.19 97 99.8% 97 0 0 
30AC 56,771,638 95.43 266,375 8,353 3.14 124 98.5% 124 0 0 
30V 43,594,487 95.11 249,226 11,309 4.54 92 99.5% 92 0 0 
Average 61,027,678 96 280,657 29,035 10.30 110 99.6% 
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Figure 2.2. Bacterial profiles of placental samples as determined by metagenomic 
sequencing. Heatmap illustrating the relative abundances of prominent bacterial genera among 
placental samples. Prominent genera were here defined as those having an average relative 
abundance ≥ 0.1% among placental samples. AC indicates amnion and chorionic plate samples, 
and V indicates samples of the villous tree and basal plate.
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and Streptomyces. Escherichia was present in each placental sample, with an average relative 
abundance of 0.05%.  A small fraction (0.1%) of the bacterial reads were confidently assigned a 
gene function (Table 2.2). Broadly, these bacterial gene functions were metabolism (amino acid, 
carbohydrate, vitamin and energy metabolism), genetic machinery (DNA translation, replication, 
repair and degradation), and environmental processing (membrane transport and signal 
transduction), all of which were also heavily represented in the bacterial gene function profiles of 
the technical controls (Table 2.3).  
Given the necessary differences in metagenomic library preparation for the placental 
tissue and technical control samples, their broad bacterial profiles cannot be compared in a 
quantitative manner. However, it is reasonable to inquire if there are genera consistently 
identified in placental tissue samples that were not also widely present in the sequenced 
background technical controls. There were 36 genera present in all nine sequenced placental 
tissue samples, and 89 genera present in at least half of these samples. Each of these 125 genera 
was present in all 11 sequenced background technical controls. Of the 267 total genera, or 
approximate genus-level taxa, identified in placental tissue samples, only one was not found in 
every control sample (Table 2.1): an unclassified Myxococcales, present in one placental sample 
with a relative abundance < 0.01%.  
Of the prominent genera (≥ 1% average relative abundance) identified in the primary 16S 
rRNA gene sequencing analysis of this study (Figure 2.3), Clostridium and Propionibacterium 
were detected in each of the nine placental samples via metagenomic sampling. Staphylococcus 
was present in 8/9, Stenotrophomonas was present in 6/9, Achromobacter was present in 5/9, 




Table 2.2. Summary of metagenomic sequence reads from placentas assigned a bacterial 
gene function. 
KEGG Orthology 14AC 14V 15AC 15V 19V 22AC 22V 30AC 30V 
Amino Acid Metabolism 11 12 10 11 10 2 7 28 4 
Biosynthesis of Other 
Secondary Metabolites 
0 0 0 0 0 0 0 2 0 
Carbohydrate Metabolism 4 8 3 3 0 2 0 3 2 
Cell growth and death 0 0 2 0 1 0 0 0 
Cell motility 0 0 3 0 0 1 4 1 0 
Energy Metabolism 0 2 0 2 2 0 1 10 0 
Folding, sorting and 
degradation 
4 1 0 2 0 0 0 2 1 
Glycan biosynthesis and 
metabolism 
1 0 0 0 0 0 0 1 1 
Lipid metabolism 0 0 0 5 2 0 0 0 0 
Membrane Transport 4 11 8 1 7 9 3 7 3 
Metabolism of Cofactors 
and Vitamins 
6 2 0 2 5 0 1 1 2 
Metabolism of Other 
Amino Acids 
1 0 0 0 0 0 0 0 0 
Metabolism of Terpenoids 
and Polyketides 
0 0 0 1 0 0 0 0 0 
Nucleotide metabolism 0 1 0 2 0 0 0 3 0 
Replication and repair 0 0 1 0 1 2 2 15 4 
Signal transduction 2 2 2 1 0 3 0 3 1 
Transcription 0 0 0 0 0 0 0 2 0 
Translation 3 3 1 0 0 1 1 8 1 
Transport and catabolism 2 0 0 0 0 3 0 2 0 
Xenobiotics Biodegradation 
and Metabolism 


































4hood1 47,235,826 90.26 604,070 425,500 70.44 604 100.0% 128,294 
4hood2 55,527,650 92.52 1,291,131 1,189,969 92.16 630 100.0% 428,646 
4hood3 53,435,968 94.75 980,709 871,958 88.91 626 100.0% 308,573 
4hood4 55,516,701 95.06 988,718 885,749 89.59 623 100.0% 295,312 
7hood1 60,045,409 95.49 349,714 207,703 59.39 608 99.9% 70,931 
7hood2 71,332,222 95.09 622,774 463,449 74.42 636 99.9% 161,243 
7hood3 58,712,747 94.65 336,649 174,036 51.70 594 99.9% 56,894 
7hood5 62,886,028 94.52 1,069,227 916,346 85.70 636 100.0% 323,429 
Kit4 36,260,902 90.21 441,464 345,654 78.30 623 99.9% 118,668 
Kit5 38,429,367 93.72 744,139 657,313 88.33 629 100.0% 230,137 
Kit6 45,929,752 94.24 635,400 528,815 83.23 636 100.0% 192,513 





Figure 2.3. Bacterial profiles of placental samples based on 16S rRNA gene sequencing 
data. Heatmap illustrating similarity in percent relative abundances of prominent operational 
taxonomic units (OTUs) among placental samples and technical controls. Prominent OTUs were 
defined as those having an average relative abundance ≥ 1% among the placental samples. OTUs 
were generated using a 97% sequence similarity cutoff and the primary nested PCR data set. 
Asterisks indicate OTUs that were prominent in placental samples but not in technical controls.  
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Delftia and Ureaplasma were present in 1/9. Of these genera, only Clostridium was present in 
placental metagenomic bacterial profiles at an average relative abundance ≥ 0.1% (Figure 2.2).  
 Bacterial profiles of placental tissues and technical controls from the primary nested PCR 
dataset characterized using OTU and ASV approaches 
The results for the primary nested PCR analysis did not change after reanalyzing the 
sequence data using the ASV approach (Table 2.4, Figure 2.4). Both statistically and visually, 
the bacterial profiles of placental samples and technical controls were indistinguishable using 
either classification method (Figure 2.4, Figure 2.5A). 
Bacterial profiles of placental tissues from the primary nested PCR dataset after removing any 
ASVs that were identified in controls 
 The primary nested PCR dataset included 714 ASVs and had average read counts for 
amnion-chorion and villous tree & basal plate samples of 48,961 and 51,631, respectively 
(Figure 2.6). After removing any ASVs that were identified in technical controls, the average 
read counts for amnion-chorion and villous tree & basal plate samples dropped to 189 and 154, 
respectively (Figure 2.6). Only 118/714 (16.5%) ASVs from the full dataset remained, and these 
ASVs were represented by only 0.3% of the total reads from placental samples (Figure 2.7). 
After removing these 596 ASVs identified in controls, 9951 reads remained in the dataset 
leaving eight amnion-chorion and 10 villous tree & basal plate samples with no reads. After 
removing placental samples with no reads, the average read count for amnion-chorion samples (n 
= 21) was 261; the average read count for villous tree & basal plate samples (n = 19) was 236. Of 
the remaining 118 ASVs, no ASV was detected in more than four placental samples. The only 
two ASVs detected in four placental samples were classified within the bacterial families 
Alcaligenaceae and Caulobacteraceae. Notably, the three Ureaplasma ASVs in the original 
dataset were also removed due to occurrence in controls (4, 1, and 1 reads total for the 3  
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Table 2.4. Comparison of the bacterial profiles of placental samples and technical controls 
using OTU and ASV approaches for the primary nested PCR dataset. ASV and the original 
OTU sample datasets were subsampled to 500 sequences each and only samples with ≥ 95% 
Good’s coverage values were included.  Non-parametric multivariate analysis of variance 
(NPMANOVA) based on the Bray-Curtis index was used to assess variation among placental 
samples and technical controls.  Results of overall global effect analyses are presented along 
with the results of pairwise comparisons that involve placental samples. Probability values for 
these permutation tests were not adjusted for multiple pairwise comparisons, because this can be 
overly conservative. However, for pairwise tests that were statistically significant, we present the 
Bonferroni corrected probability value in parentheses. 
 
 
Figure 2.4. Principal Coordinates Analysis (PCoA) comparing the bacterial community 
structure of OTU and ASV approaches for the primary nested dataset. For both datasets, 
placental samples and controls overlap illustrating the lack of variation between sample types. 
 Structure (OTUs) Structure (ASVs) 
 F p-value F p-value 
Amnion-
chorion  
Global 1.153 .244 1.126 .275 
Rooms 2.275 .010 (.058) 2.018 .021 (.128) 
Hoods 1.228 .256 0.585 .391 
Kits 0.530 .885 1.353 .907 
Villous tree & 
basal plate 
Global 1.217 .188 1.289 .129 
Rooms 2.489 .008 (.045) 1.463 .005 (.028) 
Hoods 1.076 .359 0.670 .859 




Figure 2.5. Heatmaps of the bacterial profiles from ASV datasets. Heatmaps of placental 
datasets with ASVs ≥ 1% relative abundance illustrating that placental samples cluster 
indiscriminately with control samples. A) Primary nested dataset corresponding to the dataset 
indicated in Figure 2.3B. All Ureaplasma ASVs were included despite not having an average 
relative abundance ≥ 1% in placental samples. B) Secondary touchdown dataset with no ASV 
removal and from the same dataset illustrated in Figure 2.10B. Panel C) Secondary touchdown 
dataset with mitochondrial ASVs removed and from the same dataset illustrated in Figure 2.10C. 
Samples for all panels were clustered by hierarchical clustering using Bray-Curtis similarity 




Figure 2.6. Average sequence read count for placental samples from the primary nested 
PCR dataset.  Read counts include before and after removal of ASVs that occurred in controls. 
The Y-axis is graphed on a log10 scale. 
 
Figure 2.7. Unique ASV counts per placental sample type after removal of ASVs that were 

































Ureaplasma ASVs). Only 18 placental samples had > 100 reads and only 12 samples had > 250 
reads. Good’s coverage at either sequencing depth exceeded 97%, yet a subsequent taxonomic 
analysis was only performed on placental samples with ≥ 250 remaining reads. Principal 
Coordinates Analyses (PCoAs) could not be generated for this dataset because only one ASV 
was detected in more than one sample. This was the same Caulobacteraceae ASV reported 
above; it occurred in two villous tree & basal plate samples at 942 reads (942/942 total reads) 
and one read (1/651 total reads), respectively, in these two samples. The limited magnitude of a 
remaining bacterial signal in placental samples, combined with a lack of consistency in the ASVs 
detected across samples, suggests that the removal of all ASVs identified in technical controls 
from the dataset before the characterization of a potential placental microbiota is not an 
appropriate approach. Removing these data essentially removes any analyzable bacterial signal. 
Bacterial profiles of placental tissues from the primary nested PCR dataset after filtering out 
likely background DNA contaminants identified through the program decontam 
After filtering the primary nested PCR dataset through decontam and removing the ASVs 
identified as contaminants, statistical analysis of the structure of the bacterial profiles of 
placental samples and technical controls did not change compared to the unfiltered dataset 
(Table 2.5, Figure 2.8), regardless of the decontam approach used. In fact, in some cases, p-
values of statistical analyses actually increased when compared to the analyses without using 
decontam, further supporting the conclusion that the bacterial profiles of placental samples and 
technical controls are not distinct (Table 2.5, Figure 2.9). 
Bacterial profiles of placental tissues and technical controls from the secondary touchdown 
PCR dataset characterized using OTU and ASV approaches 
After the reclassification of 16S rRNA gene sequence data into ASVs, the secondary 
touchdown PCR analysis did initially appear to reveal an effect of sample type, round of 
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Table 2.5. Comparison of the structure of bacterial profiles of placental samples and 
technical controls before and after decontam filtering for the primary nested PCR dataset.  
The values on the left are identical to those in the right panel in Table 2.4. The other panels are 
evaluating variation between placental samples and controls after applying three different 
filtering methods through decontam. In the second panel, the isContaminant function in 
decontam was used. In the third and fourth panels, the conservative isNotContaminant function 
was used at two different thresholds. All sample datasets were subsampled to 500 sequences 
(samples were excluded if they had < 500 reads) and only samples ≥ 95% Good’s coverage 
values were included. Non-parametric multivariate analysis of variance (NPMANOVA) based 
on the Bray-Curtis index was used to assess variation among placental samples and technical 
controls. Results of overall global effect analyses are presented along with the results of pairwise 
comparisons that involve placental samples. Probability values for these permutation tests were 
not adjusted for multiple pairwise comparisons, because this can be overly conservative. 
However, for pairwise tests that were statistically significant, we present the Bonferroni 
corrected probability value in parentheses.  















value F p-value F p-value 
Amnion
-chorion  
Global 1.126 .275 1.033 .405 0.844 .655 1.318 .147 
Rooms 2.018 .021 
(.128) 
1.883 .070 0.847 .537 2.558 .012 
(.071) 
Hoods 0.585 .391 0.636 .736 0.968 .431 0.621 .790 





Global 1.289 .129 1.227 .208 0.782 .752 1.405 .087 




.649 .784 2.775 .005 
(.029) 
Hoods 0.670 .859 0.785 .593 .853 .512 0.623 .817 




Figure 2.8. Principal Coordinates Analyses (PCoAs) illustrating the structure of the 
bacterial profiles of placental samples and technical controls from the primary nested PCR 
dataset after various contaminant filtering methods. Panel A is the same as Figure 2.4B. In 
panel B, ASVs identified as contaminants by the isContaminant function in decontam were 
removed. In panels C and D, two different thresholds were applied to identify and subsequently 
remove contaminants using the alternative function isNotContaminant in the decontam package. 
For all panels, sample datasets were subsampled to 500 sequence reads (samples were excluded 




Figure 2.9. Heatmaps of the primary nested PCR dataset after decontam filtering.  Bacterial 
profiles of placental samples and technical controls cluster indiscriminately, regardless of 
filtering method. The Y-axis indicates ASVs with ≥ 1% average relative abundance across 
placental samples for each respective dataset; also included are Ureaplasma ASVs. Samples are 




extraction, and an interaction effect between the two, effects which were not evident in the OTU 
dataset (Table 2.6). However, 273 of the 704 ASVs could only be classified to the taxonomic 
level of Kingdom. A BLAST [205] query of these sequences against the 16S rRNA gene 
sequences of bacterial and archaeal type strains indicated that no sequences could be matched 
with ≥ 86% sequence identity and with a query coverage ≥ 50%. Widening the BLAST query to 
the entirety of organismal type strains in the Nucleotide collection database revealed that 
212/273 (77.7%) ASVs had ≥ 98% sequence match for the Homo sapiens neanderthalensis 
mitochondrial genome. We therefore suspected that these sequences were most likely obtained 
from human mitochondria, and a BLAST query aligning the 273 unclassified bacteria against the 
human mitochondrial 16S rRNA gene (GenBank accession # NC_012920) confirmed that these 
212 ASVs were ≥ 98.3% matches to human mitochondria. This was in contrast to the primary 
nested PCR dataset, which contained only 16 unclassified bacterial ASVs, of which two were ≥ 
98.9% matches to the human mitochondria 16S rRNA gene.  To address the potential influence 
of mitochondrial sequences on the secondary touchdown PCR dataset analyses, the analyses 
were repeated after removing the 212 mitochondrial ASVs; the other unclassified bacteria were 
conservatively left in the dataset. Before subsampling, four placental samples and two technical 
controls (one from the 5th extraction round) were removed due to sequence counts below 500. 
After subsampling, all samples had ≥ 97.2% Good’s coverage values and there were 430 ASVs 
retained from the 492 non-mitochondrial ASVs in the dataset. Statistical analyses of this dataset 
indicated that the mitochondrial ASVs had indeed been the primary drivers of the difference 
observed between the bacterial profiles of the placental samples, because removing these 




Table 2.6. Comparison of bacterial community structure of OTU and ASV approaches for 
the secondary touchdown dataset. ASV and the original OTU datasets were subsampled to 500 
(samples were excluded if they had < 500 reads) and only samples ≥ 95% coverage were 
included in subsequent analyses. 
 Bacterial community structure 
Classification method OTUs ASVs 
ASVs after removing 
human mitochondrial 
sequences 
 F p-value F p-value F p-value 
Source Sample type 0.767 0.841 2.081 0.001 1.040 0.371 
Round 0.902 0.614 2.377 0.002 1.023 0.405 
Interaction 0.743 0.872 1.901 0.005 0.816 0.855 
 
 
Figure 2.10. Principal Coordinates Analyses (PCoAs) illustrating the structure of the 
bacterial profiles of placental samples and technical controls from the secondary 
touchdown PCR dataset under different classification and contaminant removal 
approaches. Three variants of the secondary touchdown dataset are illustrated: Panel A with the 
OTU approach, Panel B with the ASV approach, Panel C with the ASV approach after removing 
ASVs identified as human mitochondria. No differences are seen between Panels A and C, 
suggesting that mitochondrial sequences are driving any potential variation seen in Panel B. 
Sample datasets were subsampled to 500 sequence reads (samples were excluded if they had < 




Bacterial profiles of placental tissues from the secondary touchdown PCR dataset after 
removing any ASVs identified in controls 
 For the secondary touchdown PCR dataset, following removal of any ASVs that were 
identified in controls, 121/492 (24.6%) of the non-mitochondrial ASVs were retained. The total 
read count dropped from 383,121 to 64,501. Average sequence read counts for the placental 
samples dropped from 13,211 to 2,224, with many losing over half of their reads. Despite losing 
83.2% of the total reads from the placental dataset, Good’s coverage values for all placental 
samples > 92%. While the secondary touchdown PCR dataset retained more reads (16.8%) than 
the primary nested PCR dataset (0.3%) after removing all the ASVs identified in technical 
controls the same trend of only a modest bacterial signal persisting in placental samples and a 
lack of consistency in observed bacterial taxonomies across placental samples was again evident.  
While 7/121 (5.8%) remaining ASVs in the dataset occurred in more than four placental samples 
(detected in anywhere from 5 to 23 different placental samples, Figure 2.11), six of these were 
subsequently matched to human genes. While any mitochondrial ASVs had been removed prior 
to this analysis, a BLAST query of these six ASVs against the 16S rRNA Bacteria and Archaea 
database revealed no matches. However, querying the entirety of the Nucleotide collection 
database revealed that all six of these ASVs had ≥ 99.4 % similarity to human genes. The other 
ASV (ASV 217) was identified as Anaerococcus, with an average relative abundance of 2.9%. 
This ASV occurred in seven placental samples, at a relative abundance < 3%, with the exception 
of one placental sample in which this ASV accounted for 76.0% of the bacterial profile. The 
majority (15/27) of prominent ASVs (ASVs with an average relative abundance ≥ 1% in 
placental samples) could each be attributed to an individual sample (Figure 2.11) further 





Figure 2.11. Heatmap of the bacterial profiles of placental samples from the secondary 
touchdown PCR dataset after the removal of all ASVs identified in technical controls. Each 
column represents a placental sample, and the round of extraction that the sample was processed 
in is indicated. Samples on the x-axis were clustered based on the Bray-Curtis similarity index. 






Bacterial profiles of placental tissues from the secondary touchdown PCR dataset after 
filtering out likely background DNA contaminants identified through the program decontam 
The secondary touchdown PCR dataset after decontam filtering also mirrored the analysis 
done without decontam filtering for both isContaminant and isNotContaminant approaches 
(Table 2.7, Figure 2.12). The exception to this was when using the conservative decontam 
threshold of 0.2. Analyses in which this threshold was used indicated that sample type (i.e. 
placental sample or technical control) contributed to bacterial profile structure (Table 2.7). This 
could partly be explained by the profiles of five blank extraction kits being almost entirely (≥ 
99.8% of their sequences) composed of a single ASV (ASV8 Pelomonas aquatica), and 6/10 kits 
having > 80.4% their profiles being comprised of this ASV (Figure 2.13). Because this ASV 
was, in essence, the entire bacterial profile for half of the blank extraction kits, overshadowing 
the variation in the other blank extraction kits, a subsequent analysis in which those 5 control 
samples were removed had no differences in bacterial profiles between placental samples and the 
remaining extraction kit controls (NPMANOVA: Bray-Curtis, sample type, F = 0.730, p = 
0.828). Additionally, this ASV was also the most relatively abundant ASV in placental samples, 
with an average relative abundance of 15.0%; it was identified in 16/19 (84.2%) placental 
samples. Only three ASVs occurred in at least nine (47%) placental samples. These ASVs were 
classified as Pelomonas aquatica, Ralstonia syzygii, and a Spartobacteria. In all three cases, 
these ASVs were also prominent (≥ 1% average relative abundance) in kit controls. The next 
three most frequently detected ASVs in placental samples were identified as human gene 
sequences upon BLAST query. Indeed, 6/23 prominent ASVs in placental samples were 
identified as human gene sequences, and 5/10 ASVs most frequently occurring (in ≥ 5 placental 
samples) were human-derived. Of the remaining 5 ASVs occurring in ≥ 5 placental samples, 
three were the previously discussed Pelomonas aquatica, Ralstonia syzygii, and Spartobacteria 
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Table 2.7. Comparison of the structure of the bacterial profiles of placental samples and 
technical controls for the secondary touchdown PCR dataset after decontam filtering of 
ASVs. All datasets had human mitochondrial ASVs removed before filtering and analysis. 
Sample datasets were subsampled to 500 sequences each (samples were excluded if they had < 
500 reads) and only samples with ≥ 95% Good’s coverage values were included.  Non-
parametric multivariate analysis of variance (NPMANOVA) based on the Bray-Curtis index was 
used to assess variation among placental samples and technical controls.   Sample type refers to 
placental sample versus technical control. Round refers to the four different rounds of DNA 
extractions that were performed; each round of extractions included placental samples and 
technical controls. 
  














F p-value F p value F p value F p value 
1.040 0.371 1.034 0.389 2.045 0.026 1.140 0.250 
1.023 0.405 1.108 0.262 1.218 0.220 1.007 0.411 




Figure 2.12. Principal Coordinates Analyses (PCoAs) of the structure of the bacterial 
profiles of placental samples and technical controls from the secondary touchdown PCR 
dataset after different filtering approaches with the program decontam. Panel A is the same 
as Figure 2.9C. In panel B, ASVs identified as contaminants by the isContaminant function in 
decontam were removed. For panels C and D, ASVs were removed if they were classified by the 
isNotContaminant function in decontam, using a threshold of 0.2 for panel C, and a threshold of 
0.5 for panel D. For all panels, sample datasets were subsampled to 500 sequence reads (samples 
were excluded if they had < 500 reads) and only samples with ≥ 95% Good’s coverage values 





Figure 2.13. Heatmaps of the bacterial profiles of placental samples and technical controls 
from the secondary touchdown PCR dataset after different filtering approaches with the 
program decontam. Bacterial profiles of villous tree & basal plate (V) samples and background 
DNA contamination controls cluster indiscriminately, except for panel B wherein several kits are 
composed almost entirely of a single ASV (Pelomonas aquatica). The Y-axis indicates ASVs 
with ≥ 1% average relative abundance in placental samples for each respective dataset. Samples 
on the x-axis were clustered based on the Bray-Curtis similarity index. 
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above and the two other ASVs were a Comamonadaceae and another Spartobacteria. The 
Comamonadaceae sequence (ASV 58) was 100% identical to that of Delftia. Delftia is a well-
documented contaminant of sequence-based studies and it was here only present in placental 
samples from a single round of extractions. The sequence associated with this ASV was also 
identical to that of ASV 634 in the primary nested PCR dataset. In that dataset, ASV 634 was 
relatively abundant in both placental samples and technical controls. The ASV classified as 
Spartobacteria (ASV 40) was detected in five placental samples among different extraction 
rounds, but it was also identified in a kit control. Interestingly, this Spartobacteria was detected 
in the same samples as the more prominent Spartobacteria ASV (ASV 17), suggesting ASV 40 
could be a result of sequencing error. Overall, however, no consistent pattern in bacterial signal 
is evident among placental samples that distinguishes these samples from technical controls 
(Figure 2.13A). 
V. Discussion 
Pregnancy involves an incredibly complex reorganization of physiological and 
anatomical processes. Not only does the mother have to sustain new life for 9 months, protection 
and tolerance are necessary to ensure a healthy pregnancy and term gestation. Considering the 
placenta serves as a critical component to this entire process, complications affecting the 
placenta are readily detrimental to the fetus and potentially the mother. Thus, comprehensive 
knowledge of the intrauterine and intra-amniotic environments is critical to prevent and treat 
these complications. Given that decades of medicine have operated under the understanding that 
the placenta and intra-amniotic environments are sterile under healthy conditions, concluding 
that this is not the case should require incontestable evidence. In this study, we found no 
evidence to support the claim that there is a placental microbiota. We approached the question 
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with due consideration for the inherent caveats and limitations associated with the various 
molecular microbiological methods that have been employed previously to conclude there is a 
placental microbiota [44, 45, 49, 111, 206]. By capitalizing on multiple methodologies, we were 
able to demonstrate that there is a lack of evidence of a placental microbiota, consistent with the 
recent research of others [128, 149, 167], and that any shift in paradigms of sterility with respect 
to the placenta and the fetus would be premature. 
Metagenomic surveys of a potential placental microbiota 
The metagenomic data presented in this chapter revealed that the bacterial profiles of 
placental samples as characterized through metagenomics were not consistent with the those 
from 16S rRNA gene surveys and, although limited in our ability to compare these profiles to 
those of background technical controls, out of the entire dataset there was only a single bacterial 
genus not identified in the controls, which was limited to very low relative abundance in a single 
placental sample. In general, the metagenomic data from placental samples were consistent with 
DNA contamination in that over one-half of the bacterial sequences were from plant-associated 
or photosynthetic bacteria. The importance of recognizing the effects of DNA contamination in 
microbiome studies was highlighted in a recent commentary [100], which emphasized that the 
data obtained from investigations of low microbial biomass environments should be evaluated 
through the lens of microbial ecology. In fact, the authors specifically suggest skepticism 
regarding sequence data that indicate photosynthetic bacteria inhabit internal organs in the 
human body (e.g. the placenta), which would prohibit photosynthesis. Furthermore, it is unlikely 
that microorganisms associated with non-human, non-mammalian environments, such as the 
plant pathogens “Candidatus Phytoplasma”, Xanthomonas, and Xyella , the aquatic bacteria 
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Beggiatoa, Roseobacter, Hahella, and Halangium, or the algal symbiont Dinoroseobacter, could 
readily grow and reproduce within the ecologic niche of the placenta. 
In thorough consideration of a placental microbiota, our metagenomic data did identify 
sequences from ecologically-plausible microorganisms warranting further discussion. 
Coprobacillus was detected in placental samples and constituted 30.5% of the bacterial 
sequences. This genus has been detected in two sequence-based studies of term and preterm 
placentas at low abundance [45, 207], however, it was not detected in any of our 16S rRNA gene 
surveys. Although the primers used to target the 16S rRNA gene in the first round of 
amplification in the primary and secondary nested PCRs (27F/1492R; 341F/1061R) were not an 
exact match for C. cateniformis, the only member of the genus Coprobacillus [208], the primers 
used for the secondary standard and touchdown PCRs (515F/806R) were a perfect match for this 
bacterium. Therefore, if Coprobacillus was present in placental tissues and if its 16S rRNA gene 
sequence was similar to that of the lone characterized representative of this genus, we should 
have identified it in the 16S rRNA gene analyses. 
Streptomyces is another microorganism to consider as it was, on average, 1% of the 
bacterial sequences in the metagenomic data obtained from placental tissues and has been 
previously detected in sequencing studies of placentas at term [44, 45, 84]. In the 16S rRNA 
gene surveys of our study only 2 sequences were assigned to Streptomyces, and for this genus, 
the V4 primers (515F/806R) were perfect matches for nearly all (98.6%) of the 588 type strains 
found in the Ribosomal Database Project [209]. This suggests that if Streptomyces were actually 
present in these placental samples, it should have exhibited a stronger signal than two sequences 
in the standard 16S rRNA gene PCR and touchdown PCR analyses. Although even less abundant 
than Streptomyces ( >0.1% average relative abundance), other bacterial genera identified in the 
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metagenomic data of our study and also in other sequence-based studies of placental tissues at 
term include Neisseria [44, 45], Rhodococcus [44, 111], Clostridium [210], Streptococcus [49, 
95], and Burkholderia [45]. Again however, in our study, sequences for these microorganisms 
were detected in all placental samples and background technical control samples and all five 
have been identified as contaminant sequences in prior sequence-based studies [99, 119, 211]. 
Therefore, both alone, and more importantly in consideration with the other methodologies, we 
did not find sufficient evidence to conclude that the bacterial signals identified through the 
metagenomic sequencing represent evidence of a placental microbiota and, given the diminutive 
fraction of reads attributed to functional genes, a functional bacterial ecosystem in this human 
organ. 
 Classifying 16S rRNA gene sequence data as operational taxonomic units (OTUs) versus as 
amplicon sequence variants (ASVs) 
The caveats and limitations associated with low microbial biomass studies, especially 
studies of the placenta, have spawned attention in the field [97-99, 119, 149], including the 
recent review by O’Callaghan et al. that contained a reanalysis of our study’s data [103]. While 
they did not reach a different conclusion than us regarding the existence of a placenta microbiota, 
they did suggest there were some noteworthy results that differed from our original OTU 
analysis presented in Theis et al. [150]. However, we identified specific issues with the review’s 
analysis. First, samples were grouped together for sequence read counts and heatmaps, which 
inflates the magnitude of the signals. Second, their visualization of β-diversity was limited to 
eight out of the total 58 placental samples included in our original study, without explanation. 
One potential explanation could be that subsampling led to the exclusion of the majority of 
samples, but this was not communicated by the authors. Third, they assert that the pooled 
placental samples had > 200,000 sequence reads, even after removing the ASVs identified in 
59 
 
technical controls, yet in our reanalysis, the result is quite different [maximum read count for any 
sample was 2206 (not shown), and the average read counts were much lower; Figure 2.6].  
Fourth, the review documented the presence of an ASV classified as Ureaplasma in the room 
control samples that is completely discordant with our own analyses. Specifically, the review 
pooled control sample types and indicated in the heatmap that Ureaplasma parvum had a read 
abundance ≥ 3,000 in room controls. However, in our original OTU analysis, individual room 
controls contained no more than two reads for Ureaplasma OTUs and no more than one read 
after reclassifying the sequences through the DADA2 ASV pipeline, prior to any subsampling. 
To help illustrate this in the Results section of this chapter, Ureaplasma ASVs were included in 
the heatmaps even if they did not meet the cutoff for inclusion as a prominent ASV in a given 
analysis (Figure 2.5A, Figure 2.9).  
 Although the review provided very limited details regarding how our data were re-
analyzed, restricting our ability to replicate the exact analyses done in the review, our reanalysis 
was conducted with the methods we have ascertained to be the most appropriate and 
comprehensive for this type of microbiome data. We performed the OTU/ASV reanalysis on the 
primary nested PCR dataset and the secondary touchdown PCR dataset from Theis et al. [150], 
as these were the two PCR amplification methods that yielded large numbers of quality 
sequences and yet were not dominated almost exclusively by Escherichia coli sequences, as was 
the case with the secondary nested PCR dataset (as discussed in Theis et. al. [150]). With each of 
these two datasets, we performed three different analyses to address differences between OTU 
and ASV classification approaches, as well as the implementation of the program decontam to 
identify and remove likely background DNA contaminants. First, we directly compared the 
original OTU dataset with a dataset in which the sequences were reclassified using ASVs. In 
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doing so, we subsampled both datasets to a sequence depth of 500 (a depth of 500 sequences was 
also used by O’Callaghan et al. [103]). Additionally, all our analyses were limited to samples 
with ≥ 95% Good’s coverage, because samples with lower Good’s coverage values are unlikely 
to provide thorough representations of the actual diversity in those samples; Good’s coverage 
was not addressed in the review. Second, we analyzed the ASV dataset after removing all ASVs 
detected in controls without any subsampling (an approach also featured in the review [103]). 
Third, we utilized the program decontam [120] to identify and remove any ASVs determined to 
be contaminants from the ASV dataset. This analysis was performed two ways: following 
methods described by O’Callaghan et al. [103] using the isContaminant function, and using the 
isNotContaminant function, which we believe to be the more appropriate way to use the 
decontam tool, in the context of low microbial biomass samples, as suggested by Davis et. al. 
[120]. Upon re-analysis of our own study after ASV classification and with detailed methods to 
account for our results and conclusions, despite some subtle differences to our original work, we 
validated our previous findings and conclusions; there is a lack of evidence of a human placental 
microbiota from placentas delivered at term. 
As technologies improve and new computational tools are explored, the sequencing and 
characterization of presumed sterile environments will remain a target of investigation for 
microbial signals. Because sequencing surveys produce enormous amounts of data, the way these 
data are processed and analyzed can have a significant influence over observed results and 
subsequent conclusions. Efforts have been made to create standardized and reproducible ways to 
analyze these data, however, preferences among researchers will always exist. In the case of 16S 
rRNA gene sequencing, OTUs have been the most common approach for classifying sequences. 
While the microbiome community is beginning to embrace ASVs as a valuable tool, suggesting 
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they should replace OTUs as the predominant method to classify 16S rRNA gene sequences may 
not be appropriate in all circumstances. The thorough reanalysis of the data from our placental 
study [150] demonstrates that for these two methods, we found very little difference. It is, 
however, critical to consider the context. In this case, the environment being investigated in our 
study is one classically considered sterile. The advantages that ASV classification have over 
OTU classification will likely be limited to environments with a substantive microbial 
community. In the context of low microbial biomass, sequencing technologies are producing a 
larger proportion of sequences from background DNA contaminants, which are more likely to be 
of lower quality and consequently more prone to sequencing errors. By analyzing 16S rRNA 
gene data of this sort as ASVs, the single nucleotide resolution is likely to detect an increased 
number of ASVs, an artifact of sequencing the poor quality background DNA that is likely in 
greater abundance in low microbial biomass than in high microbial biomass environments. 
Analysis of ASV data from a situation like this may lead to an observation of strain level 
variation of microbial communities that does not actually exist and thusly, multiple approaches 
to the data are warranted (e.g. analysis with multiple tools/methods). This example further 
illustrates the caveats associated with studies investigating environments with low microbial 





CHAPTER 3: DOES THE MOUSE PLACENTA HAVE A MICROBIOTA? CULTURE 
AND MOLECULAR SURVEYS OF THE MURINE MICROBIOTA 
The data presented in this chapter are part of the manuscript “No Consistent Evidence for 
Microbiota in Murine Placental and Fetal Tissues,” published January 2020 in mSphere by Theis, 
K.R., Romero, R., Greenberg, J.M., et al. [212], of which I am third author behind two senior 
authors. Some of the text of this Chapter (i.e. Methods and Results) appears as it does in the 
published manuscript. Dr. Andrew Winters generated the quantitative real-time PCR data for this 
study. Madison Ahmad, a Master’s student in our laboratory, contributed to the bacterial culture 
component of this study and was responsible for the plate wash PCR and 16S rRNA gene 
sequencing of plate washed samples. 
I. Abstract 
The existence of a placental microbiota and in utero colonization of the fetus have been 
the subjects of recent debate. While the bulk of this work has been focused on humans, the 
mouse model presents a unique opportunity for more in-depth investigation of mammalian 
pregnancy. In this chapter, my objective was to complement our previous work on the human 
placenta by evaluating whether the placental and fetal tissues of mice harbor bacterial 
communities using multiple methodologies with comparisons to maternal samples and 
background technical controls. Bacterial profiles of the placenta and fetal brain, lung, liver, and 
intestine samples were characterized through culture, quantitative real-time PCR (qPCR), and 
16S rRNA gene sequencing. Maternal samples included the mouth, lung, liver, uterus, cervix, 
vagina, and intestine. Positive bacterial cultures from placental and fetal tissues were rare; of the 
165 total bacterial cultures of placental tissues from the 11 mice included in this study, only nine 
yielded at least a single colony, and five of those nine positive cultures came from a single 
mouse. Cultures of fetal intestinal tissues yielded just a single bacterial isolate: Staphylococcus 
hominis, a common skin bacterium. Bacterial loads of placental and fetal brain, lung, liver, and 
intestinal tissues were not higher than those of DNA contamination controls and did not yield 
substantive 16S rRNA gene sequencing libraries. Overall, from all placental or fetal tissues, there 
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was only a single bacterial isolate that came from a fetal brain sample having a bacterial load 
higher than that of contamination controls and that was identified in sequence-based surveys of 
at least one of its corresponding maternal samples. Therefore, using multiple modes of 
microbiologic inquiry, there was not consistent evidence of bacterial communities in the 
placental and fetal tissues of mice. 
II. Introduction 
As previously discussed in the Introduction and Chapter 2 of this thesis, the existence of a 
placental microbiota has been the focus of debate for over half a decade. Utilization of molecular 
surveys has led some to the conclusion that a placental microbiota exists in healthy pregnancies; 
however, as shown in Chapter 2, the caveats associated with these surveys must be thoroughly 
complemented through alternative methodologies. Considering the well-documented 
relationships between hosts and their microbiota, a placental microbiota would likely have been 
conserved among mammals (i.e. if humans have a placental microbiota then other mammals 
likely do as well). Several studies have investigated the placenta for bacterial communities in 
mice and rats [83, 213, 214], and as with human placental studies [44, 45, 49, 111, 206, 215], 
they have concluded that there are bacterial communities in these tissues. Investigation of a 
placental microbiota in animal models has the advantage of being able to surgically remove the 
placenta and fetal tissues before the onset of labor, a process that can introduce microbes into the 
upper reproductive tract [216-218]. Additionally, if in utero colonization is occurring, the source 
of the colonizing bacteria must be the mother, and with animal models, researchers can collect an 
array of samples from the mother for investigation and contrast that are not obtainable from 
human subjects.  
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After our evaluation of a placental microbiota in humans and the subsequent lack of 
evidence for it [150] presented in Chapter 2, I transition from the human model to the mouse 
model for which we can validate our findings from the human placenta and further support these 
findings with additional fetal and maternal tissues. As established in Theis et al. [150], the 
evidence necessary in establishing that there exists bacterial communities in placental or fetal 
tissues requires: 1) the identification of bacterial DNA in placental or fetal tissues that is distinct 
from bacterial DNA detected in technical controls (e.g. DNA extraction kits, PCR reagents, 
laboratory environments), 2) confirmation that the bacterial load of placental or fetal tissues 
exceeds that of technical controls through quantitative real-time PCR (qPCR), 3) visualization of 
bacteria in placental or fetal tissues using microscopy, 4) demonstration of the viability of 
bacteria in these tissues through culture, and 5) ecological plausibility (i.e. the detected bacteria 
could survive and reproduce in these tissues) [100]. To date, these criteria have not been met in 
any one study. In the previous chapter, we evaluated the human placenta thoroughly addressing 
the first, second, fourth, and fifth criteria and were unable to find evidence supporting the 
existence of a placental microbiota. The objective of this chapter is to validate those findings by 
thorough evaluation of placental and fetal tissues from mice, similar to our human study, via 
bacterial culture, qPCR, and 16S rRNA gene sequencing, and by comparing them to background 
technical controls and maternal tissues for additional contrast. 
III. Methods and Materials 
Study subjects and sample collection 
Eleven pregnant C57BL/6 (B6) mice were anesthetized with isoflurane at 17.5 days 
gestation. The dam’s abdomen was shaved, and alcohol was liberally applied to the abdomen. 
Maternal blood was collected by cardiac puncture and death was assured by cervical dislocation. 
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The dam was then placed on a surgical platform within a biological safety cabinet. Study 
personnel (i.e. myself or Dr. Theis) donned sterile surgical gowns, masks, full hoods, and 
powder-free exam gloves during sample collection. The oral cavity and vagina were swabbed 
with Dacron and ESwabs for molecular microbiology and bacterial culture, respectively. For the 
abdomen, a Dacron swab was collected, iodine was applied and, after the iodine dried, an ESwab 
was collected. A midline incision was made along the full length of the abdomen. The 
peritoneum was sampled with a Dacron swab. The uterine horns were separated from the cervix 
and placed within a sterile petri dish, wherein they were immediately processed by a different 
investigator within the biological safety cabinet. Uterine horns were dissected and fetuses (the 
fetus inside the amniotic sac attached to the placenta) were placed in individual Petri dishes. 
Uterine tissues were collected for both molecular microbiology and bacterial culture. Two 
fetuses from each dam were selected for analysis; tissues from one were used for molecular 
microbiology and tissues from the other for bacterial culture. From each fetus, the placenta, lung, 
liver, intestine, and brain (molecular microbiology was performed on fetal brain samples from all 
11 mice; bacterial culture was completed on fetal brain samples from mice E-K) were collected. 
The fetal spleen and tail were also collected for molecular microbiology.  
Next, the maternal cervix, liver, and lung were sectioned and one sample of each was 
placed into a sterile 1.5 ml microcentrifuge tube and an anaerobic transport medium tube for 
molecular microbiology and bacterial culture, respectively. Lastly, after all placental and fetal 
tissues were sampled and stored, the maternal heart and the maternal proximal and distal 
intestine were collected for molecular microbiology, and the maternal middle intestine was 
collected for bacterial culture. Procedures were approved by the Institutional Animal Care and 
Use Committee at Wayne State University (Protocol 18-03-0584). 
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Mouse tissue processing  
Maternal and fetal mouse tissue samples within anaerobic transport containers or ESwabs 
were delivered to the lab immediately after surgery was completed on the final mouse of the day. 
Upon receipt into the lab, samples were brought into a hypoxic chamber under 5% CO2, 5% O2, 
90% N2 atmospheric conditions and processed in the following order processed in the following 
order: placenta, fetal liver, fetal lung, fetal brain, fetal intestine, maternal uterus, maternal liver, 
maternal lung, maternal cervix, maternal skin post-sterilization, maternal vagina, maternal oral 
cavity, and the maternal mid-intestine. While processing samples for bacterial culture within the 
chamber, study personnel wore sterile sleeve protectors, nitrile exam gloves, and sterile nitrile 
gloves over the top of the nitrile exam gloves. Tissues were removed from anaerobic transport 
medium tubes using a sterile disposable inoculating loop, placed into a dounce reservoir (2ml or 
5 ml) containing 1ml of sterile PBS, and carefully homogenized for one minute. The tissue 
homogenates were then transferred into a 5 ml tube containing 1.5 ml of sterile PBS. Maternal 
lung and maternal mid-intestine tissues for mice E-K were homogenized in sterile 5ml tubes 
using 0.5ml PBS and a sterile disposable scalpel. Each ESwab sample was vortexed thoroughly 
and the container’s medium was transferred into a 5ml tube containing 1.5ml of sterile PBS 
using sterile disposable transfer pipettes. After the last tissue was processed for a mouse, each 
tissue homogenate was split between 3 sterile tubes for culturing under three atmospheric 
conditions.  
During the processing of each mouse’s samples for culture, three chocolate agar plates 
were left in the hypoxic chamber to serve as negative controls; they were subsequently incubated 
for seven days under oxic, hypoxic, and anoxic conditions. Additionally, for each mouse the PBS 
stock used for tissue homogenization was plated on blood agar, chocolate agar, and MacConkey 
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agar, and was further added to SP4 broth containing urea and arginine. The PBS-control blood 
agar and chocolate agar plates were incubated under all three atmospheric conditions, and the 
MacConkey agar plates and SP4 brothers were incubated under oxic conditions only. These 
negative controls were incubated for seven days. 
Mouse tissue cultivation methods 
Tissue homogenates and swab solutions were cultured for 7 days under three atmospheric 
conditions: anoxic (5% CO2, 10% H2, 85% N2), hypoxic (5% CO2, 5% O2, 90% N2), and oxic 
(ambient). Every tissue was plated on tryptic soy agar with 5% sheep’s blood and chocolate agar 
plates in duplicate under each atmospheric condition; under oxic conditions all tissues were also 
plated on MacConkey’s agar, also in duplicate. For each plate, 100ul of tissue or swab 
homogenate was pipetted onto the center and thoroughly spread over the plate until dry using an 
L-shaped spreader. 100ul of each fetal tissue and maternal reproductive tissue were inoculated in 
SP4 broth with urea and SP4 broth with arginine. For each atmosphere and media type a PBS 
control was included following the same protocol as above by inoculating 100ul of sterile PBS.  
Agar plates and SP4 broth tubes were observed for days 1-4 and day 7 (each day 
represents ~24 hours after plating). Colonies were counted when appropriate (< ~25 colonies) 
and any colonies observed on placental tissues, fetal tissues, and negative control plates were 
restreaked for isolation and purity. Pure colonies from restreaked plates were saved in 2mL 
cryovial tubes containing PBS with 15% glycerol, in triplicate when possible, and stored at -80 
℃. An additional colony was saved in a 1.5ml tube containing ≤ 500ul of sterile PCR-grade H2O 
for downstream taxonomic identification via Sanger sequencing of the 16S rRNA gene 
(described below). Contiguous growth was observed on a single plate for one placental sample 
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(mouse J); the isolates all had the same morphotype, so only representative isolate was streaked 
for purity and downstream taxonomic identification.  
The negative-control plates yielded five total bacterial isolates over the course of the 
experiment. Four were successfully sequenced: two were identified as Cutibacterium acnes, and 
two were identified as Staphylococcus hominis. If a specific bacterium was cultured on a 
technical control plate on the day a mouse’s samples were processed as well as on a placental or 
fetal sample plate for that mouse (i.e., there was a 100% 16S rRNA gene sequence match 
between the bacterial isolates recovered on the two plates), that bacterium was not included in 
analyses. Overall, this included 11 bacterial isolates for three mice (D, J, and K). Of these 11 
isolates, four were C. acnes, and seven were S. hominis. If a specific bacterium was cultured on a 
mouse’s placental or fetal sample plate as well as on a technical control plate from another 
sample processing day, but not on a control plate from that mouse’s sampling day, the bacterium 
was included in analyses. 
For maternal cervix, uterus, and liver samples, the unique isolate morphotypes on each 
plate were streaked for purity and taxonomically identified through Sanger sequencing of the 
16S rRNA gene. Maternal samples from the intestine, vagina, mouth, and lung and any other 
plates with contiguous growth (either too many colonies to count or a lawn of growth) were 
saved for downstream plate wash PCR and 16S rRNA gene sequencing (detailed below). 
Taxonomic identification of individual bacterial isolates 
After the bacterial isolates were streaked for purity, the isolates from placental, fetal, and 
maternal uterine, cervical, and liver samples were stored in nuclease-free water and frozen at -20 
℃ until colony PCR targeting the 16S rRNA gene was performed. The 16S rRNA gene of each 
isolate was first amplified using the 27F/1492R primer set and then bi-directionally Sanger 
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sequenced through GeneWiz using the 515F/806R primer set, which targets the V4 
hypervariable region of the 16S rRNA gene. Forward and reverse reads were trimmed using 
DNA Baser software (http://www.dnabaser.com/) with default settings and assembled using the 
CAP (contig assembly program) of BioEdit software (v7.0.5.3), also with default settings. The 
taxonomic identities of individual bacterial isolates were determined using the Basic Local 
Alignment Search Tool (BLAST) [205]. 16S rRNA gene sequence similarities between isolates 
and their top match on BLAST were ≥ 99.5%, unless otherwise noted (Table 3.1, Table 3.2). 
DNA extraction from plate washes of cultured bacteria 
Plate wash was performed by pipetting 1-2 ml of PBS onto the agar plate and dislodging 
bacterial colonies with either sterile L-shaped spreaders or inoculating loops. The PBS wash was 
then transferred into cryovials and stored at -80°C until DNA was extracted. DNA was extracted 
from plate wash samples using Qiagen DNeasy PowerSoil extraction kits. Washes from maternal 
samples that yielded growth under multiple atmospheres for the same media type were pooled 
prior to the extraction process. Purified DNA was stored at -20 ℃. 
16S rRNA gene sequencing of plate wash extracts 
The 16S rRNA genes in plate wash extracts were sequenced at Wayne State University 
on an Illumina MiSeq system using a 2 X 250 cycle V2 kit, and following Illumina sequencing 
protocols [219]. The 515F/806R primer set was used to target the V4 region of the 16S rRNA 
gene. The 16S rRNA gene sequences from the paired fastq files for these samples were 
processed as previously described [150]. 
DNA extraction from swab and tissue samples 
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 All Dacron swab and tissue samples collected for molecular microbiology were stored at 
-80 ℃ until DNA extractions were performed. DNA extractions were performed in a biological 
safety cabinet by study personnel donning sterile surgical gowns, masks, full hoods, and powder-
free exam gloves. Extractions of tissues generally included 0.015 – 0.100 grams of tissue, except 
for the fetal tail and spleen, whose masses were very low.  
DNA was extracted from swabs, tissues, and background technical controls (i.e. sterile 
Dacron swabs (N = 11) and blank DNA extraction kits (N = 23)) using the DNeasy PowerLyzer 
PowerSoil Kit (Qiagen, Germantown, MD) with minor modifications to the manufacturer’s 
protocol. Specifically, 400 μl of bead solution, 200 μl of phenol:chloroform:isoamyl alcohol (pH 
7–8), and 60 μl of Solution C1 were added to the supplied bead tube. Cells within samples were 
lysed by mechanical disruption for 30 seconds using a bead beater. After centrifugation, the 
supernatants were transferred to new tubes, and 100 μl of solution C2, 100 μl of solution C3, and 
one μl of RNase A enzyme were added, and tubes were incubated at 4° C for five minutes. After 
centrifugation, the supernatants were transferred to new tubes that contained 650 μl of solution 
C4 and 650 μl of 100% ethanol. The lysates were loaded onto filter columns, centrifuged for one 
minute, and the flow-through was discarded. This step was repeated until all sample lysates were 
spun through the filter columns. Five hundred μl of solution C5 were added to the filter columns, 
centrifuged for one minute, the flow-through was discarded, and the tube was centrifuged for an 
additional three minutes as a dry-spin. Finally, 60 μl of solution C6 were placed on the filter 
column and incubated for five minutes before centrifuging for 30 seconds to elute the extracted 
DNA. Purified DNA was stored at -20° C.  
Purified DNA was quantified using a Qubit 3.0 fluorometer with a Qubit dsDNA BR 
Assay kit (Life Technologies, Carlsbad, CA), according to the manufacturer’s protocol. All 
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purified DNA samples were then normalized to 80 ng/µl (when possible) by diluting each 
sample with the Qiagen elution buffer (Solution C6).  
16S rRNA gene quantitative real-time PCR (qPCR) 
A preliminary test was performed to investigate whether DNA amplification inhibition 
existed among the different sample types. For this test, 4.7 μl of purified Escherichia coli ATCC 
25922 (GenBank accession: CP009072) genomic DNA (0.005 ng/µl) containing seven 16S 
rDNA copies per genome was spiked into 7.0 μl of purified DNA from mouse samples that were 
serially diluted with Solution C6 by a factor of 1:3 (i.e. 1:0, 1:3, 1:9). For tissue sample types 
with a mean DNA concentration above 250 ng/µl, DNA concentrations were normalized to 80 
ng/μl by dilution with Solution C6 before being serially diluted and spiked with E. coli genomic 
DNA. Genomic DNA was quantified using a Qubit 3.0 fluorometer with a Qubit dsDNA HS 
Assay kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Three μl 
of each spiked sample were then used as a template for qPCR. For all samples, spiked reactions 
contained approximately 1.0 x 103 E. coli 16S rDNA copies. There was no evidence of DNA 
amplification inhibition (data not shown).  
Total bacterial DNA abundance within samples was measured via amplification of the V1 
- V2 region of the 16S rRNA gene according to the protocol of Dickson et al [70] with minor 
modifications. These modifications included the use of a degenerative forward primer (27f-CM: 
5’-AGA GTT TGA TCM TGG CTC AG-3’) [123] and a degenerate probe containing locked 
nucleic acids (+) (BSR65/17: 5’-56FAM-TAA +YA+C ATG +CA+A GT+C GA-BHQ1-3’). 
Each 20 μl reaction contained 0.6 μM of 27f-CM primer, 0.6 μM of 357R primer (5’-CTG CTG 
CCT YCC GTA G-3’), 0.25 μM of BSR65/17 probe, 10.0 μl of 2X TaqMan Environmental 
Master Mix 2.0 (Life Technologies, Carlsbad, CA), and 3.0 μl of either purified DNA (diluted to 
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80 ng/µl when possible), elution buffer, or nuclease-free water. The total bacterial DNA qPCR 
was performed using the following conditions: 95° C for 10 min, followed by 45 cycles of 94° C 
for 30 sec, 50° C for 30 sec, and 72° C for 30 sec. Duplicate reactions were run for all samples. 
All samples were run across a total of five runs. 
Raw amplification data were normalized to the ROX passive reference dye and analyzed 
using the on-line platform Thermo Fisher Cloud: Standard Curve (SR) 3.3.0-SR2-build15 with 
automatic threshold and baseline settings. Cycle of quantification (Cq) values were calculated for 
samples based on the mean number of cycles required for normalized fluorescence to 
exponentially increase.  
After plotting a regression of log(E. coli 16S rRNA gene copy number) and Cq value for 
standard curves included in each qPCR run, 16S rRNA gene copy number in mouse samples was 
calculated according to Gallup [220] using the equation Xo = EAMP(b-Cq), where EAMP is the 
exponential amplification value for the qPCR assay, calculated as EAMP = 10(-1/m) and b and m are 
the intercept and slope of the regression. 
16S rRNA gene sequencing of swab and tissue sample extracts 
Amplification and sequencing of the V4 region of the 16S rRNA gene was performed at 
the University of Michigan’s Center for Microbial Systems as previously described [109], except 
that library builds were performed in triplicate and  pooled for each individual sample prior to 
the equimolar pooling of all sample libraries for multiplex sequencing. Sample-specific MiSeq 
run files have been deposited on the NCBI Sequence Read Archive (BioProject ID 
SUB6641162). 
Raw sequence reads were processed using mothur software (v1.39.5) [41] following the 
Standard Operating Procedure provided by Schloss et al. (www.mothur.org/wiki/MiSeq_SOP). 
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Paired-end reads were assembled into contiguous sequences, quality checked (maximum 
length = 275, maximum ambiguous base pairs = 0, and maximum number of homopolymers = 8), 
and aligned against the SILVA 16S rDNA reference database (release 102) [221, 222]; 
sequences falling outside the target alignment space were removed. Quality sequences were pre-
clustered (diffs = 2) and chimeric sequences were identified with VSEARCH [223] and removed. 
The remaining sequences were taxonomically classified using the SILVA reference database 
with a k-nearest neighbor approach and a confidence threshold of 80%. Sequences derived from 
an unknown domain, Eukaryota, Archaea, chloroplasts, or mitochondria were removed. 
Operational taxonomic units (OTUs) were defined by clustering sequences at a 97% sequence 
similarity cutoff using the average neighbor method. 
Statistical analysis 
The bacterial loads, as assessed through qPCR, of maternal, placental and fetal samples 
were compared to those of background technical controls (i.e. sterile Dacron swabs and blank 
DNA extraction kits) using t-tests or Mann-Whitney U tests with sequential Bonferroni 
corrections applied. The bacterial loads of placental and fetal tissues were compared to one 
another using Wilcoxon matched pairs tests, again corrected for multiple comparisons. 
The beta diversity of 16S rRNA gene profiles among maternal, placental, fetal and 
technical control samples were characterized using the Bray-Curtis similarity index. Bray-Curtis 
similarities in sample profiles were visualized using Principal Coordinates Analysis (PCoA) 
plots and statistically evaluated using non-parametric multivariate ANOVA (NPMANOVA). 
These analyses were limited to samples that yielded a 16S rRNA gene library with ≥ 250 quality-
filtered sequences and a Good’s coverage ≥ 95%. All data analysis was completed in PAST 
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software (v 3.25) [202]. Heat maps of sample bacterial profiles were generated using the open-





Bacterial culture from placental and fetal tissues 
 Growth of bacterial isolates from placental and fetal tissues was rare (Figure 
3.1A, Figure 3.2). Only 3/11 mice (F, H & J) yielded more than two total bacterial isolates 
across all their cultured placental and fetal samples under all growth conditions (Table 3.1). 
Most of the bacterial isolates from placental and fetal samples were Staphylococcus spp. (mostly 
S. hominis) (Figure 3.1A). Staphylococcus spp. were cultured from the mouth, intestine, and 
vagina of mouse dams (Figure 3.1B); however, two of the five bacterial isolates recovered from 
the 114 negative control plates included in this study were also Staphylococcus, specifically S. 
hominis. The non-staphylococci bacteria cultured from placental or fetal samples were Bacillus, 
Corynebacterium, Paenibacillus, Propionibacterium, and unclassified bacilli (Table 3.1). These 
bacteria were rarely, if ever, cultured from maternal samples (Figure 3.1A & B).  
In general, only one or two placental or fetal sites within a given fetus yielded a bacterial 
isolate, and there was little consistency among the fetuses in terms of which site yielded an 
isolate (Table 3.1, Figure 3.1A).  For example, of the 132 blood and chocolate agar plates on 
which placental tissue homogenates were spread, only nine (6.8%) yielded even a single 
bacterial isolate, and five of these plates came from a single placental sample (Mouse H) (Figure 
3.2). All of the bacterial isolates from Mouse H’s placental sample were Staphylococcus (either 
S. hominis or S. epidermidis / caprae / capitis). There were no exact matches of the 16S rRNA 
genes of these isolates within the 16S rRNA gene surveys of placental tissues from Mouse H, nor 




Figure 3.1. Bacterial cultivation results for A) placental and fetal tissues in relation to those 
for B) maternal intestinal, mouth, vaginal, and lung samples, and C) a comparison of the 
bacterial loads of individual placental samples and blank extraction kit controls in light of 
the cultivation results. Panel A indicates the recovery of any bacterial isolates from placenta 
and/or fetal tissues, by mouse and across different growth media and atmosphere conditions. The 
taxonomic assignments of these isolates were determined by comparing their 16S rRNA gene 
sequences to those of the operational taxonomic units (OTUs) of molecular surveys of the mixed 
bacterial communities cultured from maternal intestinal, oral, vaginal, and lung samples 
(sequence identity was ≥ 97.2%). Panel B provides the results of 16S rRNA gene molecular 
surveys of the plate washes of bacterial growth from maternal intestinal, oral, vaginal, and lung 
samples, as well as of blank extraction kit controls processed alongside the plate washes. OTUs 
were included in the heat map in Panel B if they had an average percent relative abundance ≥ 
0.5% across all plate washes or if they were the best 16S rRNA gene sequence match to bacterial 
isolates in Panel A (indicated by an asterisk). The bolded OTUs represent the best 16S rRNA 
gene sequence matches to placental and fetal isolates in Panel A. Panel C illustrates similarities 
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in bacterial load, as assessed by 16S rRNA gene quantitative real-time PCR (qPCR), between 
placental samples yielding at least one bacterial isolate and blank DNA extraction kit controls. 
 
Figure 3.2. Heat maps illustrating bacterial cultivation results for A) placenta and B) fetal 
intestinal tissues. Each column of the heat map represents a single agar plate. The x-axis 
indicates the mouse identity, atmospheric condition, growth medium, and paired replicate for 
each agar plate. The vast majority of blood and chocolate agar plates did not yield any bacterial 
growth over seven days for placental (93.2%) and fetal intestinal (99.2%) samples. The 
operational taxonomic units (OTUs) on the y-axis are those that represent the best 16S rRNA 
gene sequence matches to bacterial isolates recovered from any placental or fetal sample in this 




Table 3.1. Bacterial cultivation results for placental and fetal brain, lung, liver, and 
intestinal samples. 
  Bacterial culture 16S rRNA gene 
qPCR 
16S rRNA gene sequence match between the isolate and ≥ 1 sequence 
within a 16S rRNA gene library  
Mouse Placental or 
fetal body 
site 
Total # of 
isolates 
recovered 
Top NCBI BLAST 
taxonomic designation (≥ 
99.5% 16S rRNA gene 
sequence identity unless 
otherwise indicated) 
Was sample 
bacterial load > 
that of blank kit 
controls? 
Library for that specific tissue 
type in that Mouse  
Library for any maternal body site 
in that Mouse 
A Placenta 0  No n/a n/a 
Lung 0  No n/a n/a 
Liver 0  No n/a n/a 
Intestine 0  Yes n/a n/a 
B Placenta 1 Cutibacterium acnes  No No No 
Lung 0  No n/a n/a 
Liver 1 Cutibacterium acnes No No No 
Intestine 0  No n/a n/a 
C Placenta 0  No n/a n/a 
Lung 1 Bacillus simplex / 
frigoritolerans 
No No No 
Liver 0  No n/a n/a 
Intestine 0  No n/a n/a 
D Placenta 0  No n/a n/a 
Lung 0  No n/a n/a 
Liver 0  No n/a n/a 
Intestine 0  No n/a n/a 
E Placenta 1 Corynebacterium 
tuberculostearicum (98.5%) 
Yes No No 
Brain 1 Bacillus halosaccharovorans Yes No No 
Lung 0  No n/a n/a 
Liver 0  No n/a n/a 
Intestine 0  No n/a n/a 
F Placenta 1 Staphylococcus hominis No No Yes (blood, lung, skin) 
Brain 7 Bacillus circulans; Bacillus 
megaterium / flexus; Bacillus 
spp.; Ornithinibacillus sp. 
Marseille-P3601; 
Paenibacillus spp. 
Yes No Yes, for 1/7 isolates (skin) 
Lung 0  No n/a n/a 
Liver 1 Bacillus sonorensis No No No 
Intestine 1 Staphylococcus hominis 
(99.4%) 
No No Yes (blood, lung, skin) 
G Placenta 0  No n/a n/a 
Brain 1 Staphylococcus hominis No No Yes (peritoneum, skin) 
Lung 0  No n/a n/a 
Liver 1 Staphylococcus hominis No No Yes (peritoneum, skin) 
Intestine 0  No n/a n/a 
H Placenta 16 Staphylococcus hominis; 
Staphylococcus epidermidis / 
caprae / capitis 
No No No 
Brain 3 Staphylococcus hominis; 
Staphylococcus warneri; 
Staphylococcus epidermidis / 
caprae / capitis 
No No No 
Lung 0  No n/a n/a 
Liver 1 Paenibacillus timonensis 
(98.0%) 
No No No 
Intestine 0  Yes n/a n/a 
I Placenta 0  No n/a n/a 
Brain 0  No n/a n/a 
Lung 1 Cutibacterium acnes (99.0%) No No No 
Liver 0  No n/a n/a 
Intestine 0  No n/a n/a 
J Placenta TMTC* Staphylococcus caprae No Yes Yes (heart, mouth, intestine) 
Brain 0  No n/a n/a 
Lung 0  No n/a n/a 
Liver 0  No n/a n/a 
Intestine 0  No n/a n/a 
K Placenta 0  No n/a n/a 
Brain 0  No n/a n/a 
Lung 0  No n/a n/a 
Liver 0  No n/a n/a 






sites for Mouse H, which included the maternal skin, blood, heart, mouth, lung, liver, proximal 
intestine, distal intestine, peritoneum, cervix, and vagina (Table 3.1). The placental sample from 
Mouse J yielded many colonies of Staphylococcus caprae on one chocolate agar plate under 
hypoxic conditions; yet there were no bacterial colonies on the replicate chocolate agar plate 
incubated under hypoxic conditions or on any other plate for this sample (Table 3.1, Figure 3.2). 
An exact match of the 16S rRNA gene of this Staphylococcus caprae isolate was identified in the 
16S rRNA gene survey of placental tissues from Mouse J, as well as in the 16S rRNA gene 
surveys of the maternal heart, mouth, and proximal intestine samples for Mouse J. However, the 
bacterial load of the placental sample from Mouse J, as assessed by 16S rRNA gene qPCR, was 
not high – it was less than the bacterial load of 14/23 (60.9%) DNA extraction kit controls 
(Figure 3.1C). 
 Of the 132 blood and chocolate agar plates on which fetal intestinal tissue homogenates 
were spread, only one yielded growth – a single bacterial colony of Staphylococcus hominis 
(Figure 3.2). The 16S rRNA gene of this bacterial isolate was not detected in the molecular 
survey of fetal intestines from this mouse (Mouse F), but it was identified in the 16S rRNA gene 
surveys of maternal blood, lung, and skin from Mouse F (Table 3.1). This sample had the lowest 
bacterial load of any fetal intestinal sample in the study, and had a bacterial load less than that of 
14/23 (60.9%) DNA extraction kit controls (Figure 3.3). 
Bacterial culture from maternal compartments 
Bacterial cultures of the maternal intestine, mouth, vagina, and lung often yielded lawns 
of bacterial growth dominated by unclassified Pasteurellaceae, Lactobacillus, and 
Staphylococcus (Figure 3.1B). Body site-specific variation in the structure of cultured bacterial 




Figure 3.3. Quantitative real-time PCR (qPCR) analyses illustrating variation in bacterial 
load among A) maternal swab samples and Dacron swab controls, and B) maternal, 
placental, and fetal tissue samples and blank DNA extraction kit controls. Bars indicate the 
median and quartile log-16S rRNA gene copy values for each sample and control type. Points, 
color-coded by mouse identity, indicate the mean values of two replicate qPCR reactions. An 
asterisk indicates that bacterial loads of that sample type were greater than those of 




of bacteria cultured from the vagina were unclassified Pasteurellaceae, while Bacteroides and a 
distinct strain of Lactobacillus were consistently cultured from the maternal intestine in addition 
to the unclassified Pasteurellaceae, Lactobacillus, and Staphylococcus isolated from other body 
sites (Figure 3.1B). 
 Bacterial cultures of the maternal cervix yielded isolates in 6/11 (54.5%) mice (Table 
3.2). The most common bacterium cultured from the murine cervix was Pasteurella caecimuris; 
it was recovered in culture from 5/11 cervical samples. In each case, an exact match for the 16S 
rRNA gene of the Pasteurella caecimuris isolate was identified in the 16S rRNA gene survey of 
the corresponding cervical sample (Table 3.2). 
Bacteria were rarely cultured from the uterus (2/11 mice) and maternal liver (4/11 mice) 
(Table 3.2). The two bacteria cultured from the uterus were Bacillus niabensis and 
Staphylococcus aureus. An exact match of the 16S rRNA gene of these isolates was not 
identified in the 16S rRNA gene surveys of the respective uterine samples. The bacteria cultured 
from maternal liver samples were primarily Lactobacillus and Staphylococcus species. Of the 
nine distinct bacterial morphotypes cultured from maternal liver tissues, only 3 (33%) had an 
exact match of their 16S rRNA gene identified in the 16S rRNA gene surveys of their respective 
samples (Table 3.2).  
Quantitative real-time PCR (qPCR) of murine and control samples 
Bacterial load, as characterized by 16S rRNA gene copy abundance, varied greatly across 
maternal, placental, and fetal body sites (Figure 3.3). The bacterial loads of swabs of the 
maternal mouth, vagina, and skin exceeded those of sterile Dacron swabs (Figure 3.3A). 




Table 3.2. Bacterial cultivation results for maternal cervical, uterine, and liver samples. 
  Bacterial culture 16S rRNA 
gene qPCR 
16S rRNA gene sequence 
match between the isolate 
and ≥ 1 sequence within a 










Top NCBI BLAST taxonomic 
designation (≥ 99.5% 16S rRNA gene 




> that of blank 
kit controls? 
Library for that specific 
tissue type in that Mouse  
A Cervix 1 Rodentibacter pneumotropicus (98.0%) No Yes 
Uterus 1 Bacillus niabensis No No 
Liver 0  No n/a 
B Cervix 0  No n/a 
Uterus 0  No n/a 
Liver 2 Lactobacillus gasseri; L. murinus No Yes, for 1/2 morphotypes 
C Cervix 0  No n/a 
Uterus 0  No n/a 
Liver 5 Bacteroides sartorii (98.0%); Klebsiella 
variicola; L. gasseri / L. johnsonii; L. 
murinus; Staphylococcus hominis 
Yes Yes, for 2/5 morphotypes 
D Cervix 0  No n/a 
Uterus 0  No n/a 
Liver 0  No n/a 
E Cervix 1 Pasteurella caecimuris Yes Yes 
Uterus 0  No n/a 
Liver 0  No n/a 
F Cervix 0  Yes n/a 
Uterus 0  No n/a 
Liver 1 Staphylococcus epidermidis / S. caprae 
/ S. capitis 
No No 
G Cervix 5 Bacteroides sartorii; Faecalibaculum 
rodentium (97.9%); Lactobacillus 
murinus; L. reuteri (99.2%); 
Pasteurella caecimuris 
Yes Yes, for 5/5 morphotypes 
Uterus 0  No n/a 
Liver 0  No n/a 
H Cervix 0  Yes n/a 
Uterus 0  No n/a 
Liver 0  No n/a 
I Cervix 6 Bacillus circulans; Pasteurella 
caecimuris; Rodentibacter 
pneumotropicus (98.1%); 
Staphylococcus hominis; S. xylosus; 
Streptococcus thoraltensis (99.3%) 
No Yes, for 4/6 morphotypes 
Uterus 0  No n/a 
Liver 0  No n/a 
J Cervix 1 Pasteurella caecimuris No Yes 
Uterus 1 Staphylococcus aureus No No 
Liver 1 Staphylococcus epidermidis / S. caprae 
/ S. capitis 
No No 
K Cervix 1 Pasteurella caecimuris Yes Yes 
Uterus 0  Yes n/a 




heart, liver, and uterus exceeded those of blank DNA extraction kits (Figure 3.3B). In contrast, 
bacterial loads of the maternal peritoneum, the placenta, and the fetal lung, liver, brain, and 
intestine did not exceed those of their respective background technical controls (Figure 3.3A & 
B). The spleen and tail were the only fetal tissues with bacterial loads exceeding those of blank 
DNA  
extraction kits (Figure 3.3B). However, only 1/11 (9.1%) fetal tail and 2/11 (18.2%) fetal spleen 
samples had bacterial loads exceeding those of each of the blank DNA extraction kits. Corrected 
for multiple comparisons, no placental or fetal tissue, including the tail and spleen, had a 
bacterial load exceeding that of any other placental or fetal tissue (Wilcoxon matched pairs, p ≥ 
0.68). 
16S rRNA gene sequencing of murine and control samples 
Six of the 23 (26.1%) blank DNA extraction kits, and 8/11 (72.7%) sterile swab controls, 
yielded a 16S rRNA gene library with ≥ 250 quality-filtered sequences and a Good’s coverage ≥ 
95%. The prominent (i.e. ≥ 2.25% relative abundance) operational taxonomic units (OTUs) in 
the bacterial profiles of the DNA extraction kit controls were identified as Ralstonia, unclassified 
Bacillales, Flavobacterium, S24-7, Brevibacterium, Pelomonas, unclassified Bacteroidetes, and 
Acinetobacter (Figure 3.4). However, only two of these prominent OTUs, identified as Ralstonia 
and Pelomonas, were present in the bacterial profiles of more than half of the DNA extraction kit 
controls. A decontam analysis indicated that the OTUs identified as Ralstonia, Pelomonas, 
Pseudomonas, and Acinetobacter were likely background DNA contaminants (Figure 3.4). 
The bacterial profiles of placental and fetal samples could not be compared to those of 
background technical controls because only two of the 77 (2.6%) placental and fetal brain, lung, 




Figure 3.4 Heatmap illustrating the 16S rRNA gene profiles of maternal swab and tissue 
samples and background technical controls featuring the relative abundances of prominent 
(≥ 2.25% average relative abundance) operational taxonomic units (OTUs). The four OTUs 




with ≥ 250 sequences and a Good’s coverage ≥ 95%. These two samples were the placenta from 
Mouse I and the fetal spleen from Mouse B. The placenta from Mouse I had an average bacterial 
load in comparison to that of other placentas (Figure 3.3), and no bacteria were cultured from 
the placental tissues of this mouse (Table 3.1, Figure 3.1, Figure 3.2). The prominent OTUs in 
the bacterial profile of the placental sample from Mouse I were identified as Bacteroides, 
Akkermansia, S24-7, Lactobacillus, and Escherichia. The fetal spleen from Mouse B had the 
highest bacterial load of any fetal spleen sample; its bacterial load was 58% higher than any 
other spleen sample (Figure 3.3). The prominent OTUs in the bacterial profile of the fetal spleen 
from Mouse B were Lactobacillus, S24-7, and unclassified Lachnospiraceae.  
 All maternal skin, mouth, proximal and distal intestinal samples yielded a 16S rRNA 
gene library with ≥ 250 sequences and a Good’s coverage ≥ 95%. Six (54.5%), four (36.4%), and 
three (27.3%) maternal peritoneal, cervical, and lung samples, respectively, yielded a 16S rRNA 
gene library with ≥ 250 sequences and a Good’s coverage ≥ 95%. However, no maternal liver or 
uterine samples, and only one (9.1%) maternal heart sample, yielded a 16S rRNA gene library. 
The structure of the bacterial profiles of the maternal body sites with at least three 16S rRNA 
gene libraries were compared with those of background technical controls (Figure 3.4, Figure 
3.5).  
The taxonomic identities of prominent OTUs varied among maternal body sites (Figure 
4). Maternal proximal and distal intestinal samples had the most OTU-rich bacterial profiles. The 
maternal proximal intestine was characterized by Bacteroides, Desulfovibrio, Helicobacter, 
Lachnospira, unclassified Lachnospiraceae, Lactobacillus, and S24-7, while the maternal distal 
intestine had bacterial profiles consistently comprised of “Candidatus Arthromitus,” 





Figure 3.5. Principal Coordinates Analysis (PCoA) of maternal samples and controls 
illustrating variation in 16S rRNA gene profiles among A) maternal swab samples and 
Dacron swab controls, and B) maternal tissue samples and blank DNA extraction kit 




vaginal and cervical bacterial profiles were dominated by unclassified Pasteurellaceae; the 
vagina also consistently contained Helicobacter. Maternal lung bacterial profiles were typified 
by Lactobacillus and S24-7, while those of the maternal mouth were dominated by 
Streptococcus, Mannheimia, Lactobacillus, and unclassified Pasteurellaceae. Maternal skin, a  
low microbial biomass site (Figure 3.3A), and the peritoneum, a very low to nonexistent 
microbial biomass site (Figure 3.3A), had bacterial profiles that overlapped with those of 
background technical controls more so than did the profiles of higher microbial biomass sites 
(Figure 3.4A). Specifically, skin bacterial profiles consistently contained Bifidobacterium, 
Helicobacter, unclassified Pasteurellaceae, Ralstonia, S24-7, Staphylococcus, and Streptococcus. 
Ralstonia was the dominant OTU in the bacterial profiles of the maternal peritoneum, as well as 
in the profiles of the background technical controls (Figure 3.4). Indeed, the bacterial profiles of 
the maternal peritoneum were not distinguishable from those of background technical controls 
(Bray-Curtis similarity index; NPMANOVA, F = 0.974, p = 0.467) (Figure 3.5). 
Comprehensive consideration of individual placental and fetal tissues across microbiological 
inquiries 
Of the 165 total bacterial cultures of placentas from the 11 mice, only nine (5.5%) 
yielded even a single colony, and five of those nine positive cultures came from a single mouse; 
2) of the 165 total bacterial cultures of fetal intestinal tissues, only one (0.6%) was positive, 
yielding a single isolate of Staphylococcus hominis; 3) the bacterial loads of placental and fetal 
brain, lung, liver, and intestinal samples were not higher than those of DNA extraction kit 
controls; 4) only two (2.6%) placental or fetal tissue samples yielded a 16S rRNA gene library 
with at least 250 sequences and a Good's coverage value of 95%; 5) the 16S rRNA gene libraries 
of each maternal skin, mouth, vaginal, and proximal and distal intestinal sample met these 
criteria, as did at least 25% of maternal lung, cervical, and peritoneum samples; 6) similar to the 
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placental and fetal tissues samples, maternal heart, liver, and uterine samples did not yield 16S 
rRNA gene libraries with at least 250 sequences and a Good's coverage value of 95%; 7) overall, 
from all placental or fetal tissues, there was only a single bacterial isolate (Bacillus circulans, 
cultured from the fetal brain tissue of Mouse F) that was cultured from a placental or fetal tissue 
that had a bacterial load higher than that of background technical controls, and that was 
identified in the 16S rRNA gene surveys of at least one of that fetus’ maternal samples (Table 
3.1). 
V. Discussion 
As the era of microbiome discovery and research progresses out of its infancy, many gaps 
of knowledge still exist. The Human Microbiome Project [42] was the first concerted and 
collaborative effort to describe the healthy microbiota of humans, and while many environments 
have had their microbiota characterized, many animals have not received the same degree of 
attention in terms of their microbiota. While there are many reports of various microbial 
communities for a wide range of animals, they are rarely described to the degree seen in the 
HMP, and even rarer, for multiple body sites of a particular animal to be described. Various 
issues, such as a lack of standardized methodologies and tools for describing microbiota, are 
difficult to overcome given the current limitations of technology and the relatively early stage of 
the field. One seminal effort was made to describe a portion of the murine microbiota, that of the 
intestine [224]. Investigators utilized culture, metagenomics, and 16S rRNA gene sequencing to 
extensively characterize bacteria associated with the mouse intestine. Through culture, they 
identified a new family, ten genera, and four species, as characterized by 16S rRNA gene 
sequencing, and even found two species with high prevalence among multiple strains of mice 
from several animal facilities. The importance of a fully characterized and understood mouse 
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microbiota is undeniable given that the majority of animal-driven, human-translatable research 
relies on the mouse model. 
Despite this limited knowledge of the broader murine microbiome, several studies have 
focused on investigating the murine placenta and fetal intestine for evidence of a microbiota. For 
instance, Martinez et al. [214] performed bacterial culture, 16S rRNA gene qPCR, and 16S 
rRNA gene sequencing on the placenta and fetal intestines of 13 mice at day 17 of gestation 
(same gestational age was used in our study). No bacteria were recovered from culture surveys; 
however, they did find higher bacterial loads of the fetal intestine to be higher than those of the 
placentas via qPCR. The bacterial profiles of placenta and fetal intestines were found to be 
different from each other after removing any OTUs detected in the background technical control 
samples of the 16S rRNA gene surveys. While Martinez et al. found no evidence that murine 
fetuses are populated by microbial communities, they are exposed to bacterial DNA in utero. 
Although limited to molecular surveys, another study by Kuperman et al. [225] investigated 24 
murine placental samples at gestational day 19 and was unable to detect 16S rRNA gene 
amplicons after PCR, similar to the limited detection of 16S rRNA gene signals we found in our 
study [212]. 
In contrast, Younge et al. observed bacterial signals in the murine placenta and fetal 
intestines from mice at early, mid, and late gestations. Bacteria cultured predominantly from 
fetuses at mid-gestation and were most commonly Lactobacillus, Escherichia, Enterococcus, 
Bacteroides, and Bacillus. Additionally, bacteria were visualized in fetal intestines using 
fluorescent in situ hybridization (FISH) with a universal probe targeting the bacterial 16S rRNA 
gene. The possibility that the cultured and visualized bacteria originated from maternal tissues 
due to contamination during sampling is unlikely and was addressed in mechanistic studies 
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utilizing surgical techniques and inoculations with two different antibiotic-resistant strains of E. 
coli. Using 16S rRNA gene sequencing, the bacterial profiles of placenta and fetal intestines 
were similar to each other, while variation was observed when comparing early gestation 
samples to mid and late gestation samples.  Sourcetracker analyses indicated that the bacterial 
signals from early gestation fetal intestines were most likely originating from background 
technical controls or unknown sources, while mid and late gestation samples were attributed to 
the placenta or amniotic membrane. Younge et al. [213] concluded that fetal exposure to 
microbial communities is occurring, and that the exposure is likely coming from the placenta and 
extraplacental membranes in utero. 
Similar to the debate over a microbiota in the human placenta, there is contradictory 
evidence regarding a murine placental microbiota and in utero colonization. The data presented 
in this chapter are more consistent with the prior reports of Martinez et al. [214] and Kuperman 
et al. [225] and are contradictory to the evidence reported by Younge et al. [213] regarding in 
utero colonization. In our study, culture of bacteria from placental and fetal tissues was generally 
rare. Most of the bacterial isolates were identified as Staphylococcus hominis. The origin of these 
bacteria could be maternal sites, as Staphylococcus spp. were routinely cultured from maternal 
sites and Staphylococcus hominis specifically was identified in molecular surveys of the maternal 
skin. Alternatively, these bacteria could potentially be contaminants from laboratory personnel, 
given that two of the five bacterial isolates recovered from negative control plates in this study 
were also Staphylococcus hominis. The other bacteria (Bacillus, Corynebacterium, 
Paenibacillus, and Propionibacterium) cultured from placental and fetal samples were rarely, if 
ever, cultured from maternal samples or identified in the molecular surveys of maternal samples. 
Given that the only possible source of placental and fetal microbiota is microorganisms in the 
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maternal compartments, the latter finding suggests that these bacteria were likely contaminants. 
Furthermore, there was no consistent recovery in culture of specific microorganisms (aside from 
Staphylococcus hominis) from multiple placental and fetal tissues from the same fetus or in the 
same tissue types among fetuses from different litters. Notably, the taxonomic identities of 
bacteria cultured in the current study generally differed, with the exception of Staphylococcus, 
Bacillus, and Paenibacillus, from those initially reported by Younge et al. [213] in placental and 
fetal tissues. Therefore, across studies culture has not provided consistent evidence for a 
placental or fetal microbiota. 
 Furthermore, qPCR revealed that the bacterial loads of the placenta, fetal lung, liver, 
brain, and intestine did not exceed those of background technical controls, whereas samples from 
maternal sites, excluding the peritoneum, did exceed those of controls. In addition, there was no 
variation in bacterial load among placental and fetal tissues. These results are in contrast to those 
of Martinez et al. [214] in which the bacterial loads of the fetal intestine exceeded those of the 
placenta. To our knowledge, no other studies have directly compared the bacterial loads of the 
placenta and fetal intestine in mammals. However, the qPCR results in our study agree with prior 
qPCR investigations of human placental tissues – the bacterial loads of placentas are 
indistinguishable from those of background technical controls [128, 150, 167]. Hence, there 
remains disagreement among studies with respect to the extent of bacterial biomass in placental 
and fetal tissues. 
 Herein, the murine placenta and fetal tissues did not yield substantive 16S rRNA gene 
sequence libraries, while the maternal sites other than the uterus, heart, and liver consistently did 
so. These results are consistent with those of Kuperman et al. [225], in which 30 cycles of PCR 
did not yield discernible amplicons from murine placental tissue. Notably, in our study, triple 
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library preparations were performed and pooled for each sample, and still minimal amplicons 
were generated after 30 cycles of PCR. Martinez et al. [214] also used 30 cycles of PCR in their 
sequence library preparations and included samples in their analyses if they yielded at least 200 
quality-filtered sequences, reporting a distinct bacterial DNA signal in the placenta and fetal 
intestine. In this study, we only included samples in analyses if they yielded at least 250 quality-
filtered sequences with a Good’s coverage value of at least 95%. If we had used the criterion of 
200 sequences, independent of any consideration of Good’s coverage, only one additional fetal 
sample would have been included in analyses. Younge et al. [213] generated substantive 
sequence libraries for placental and fetal intestine samples; however, their library preparation 
protocol was based on that of the Earth Microbiome Project (i.e. 35 cycles of PCR). The 
discrepancies among murine studies may therefore be due to underlying differences in the 
sequence library protocols used. Nevertheless, as with culture and qPCR approaches, we did not 
find consistent evidence of a bacterial signal in placental and fetal tissues using DNA 
sequencing. 
 Notably, in this study, there was only one case in which a bacterial isolate (i.e. Bacillus 
circulans) from a placental or fetal sample (i.e. fetal brain) had a bacterial load exceeding that of 
all background technical controls, and in which the bacterium was also identified in molecular 
surveys of at least one corresponding maternal sample (i.e. maternal skin). Therefore, in this one 
case, there may have been hematogenous transfer from a distant maternal site to the fetus. 
However, overall, there was not consistent evidence of resident bacterial communities in the 
murine placenta or the fetus.  
 Although the context of this chapter has shifted from humans to mice, it is important to 
highlight that our work and the works of others [213, 214, 225] are challenging paradigms of 
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sterility. That being stated, the value of finding consistent and reproducible evidence cannot be 
neglected, nor can the caveats of working with low microbial biomass tissues. Our study 
emphasizes the importance of including appropriate background technical controls, as well as 
positive and negative tissue controls, in all microbiological approaches from culture to 
sequencing when reevaluating paradigms of sterility. Ultimately, while several studies, including 
our own, have included multiple methodologies of microbiologic inquiry, no studies have thus 
far met all the criteria put forth in Theis et al. [150] for establishing the presence of a resident 
microbiota. One major oversight in the work thus far has been the lack of inclusion of a germ-
free mice cohort compared to a wild type cohort, which presents an opportunity to investigate in 
utero exposure and colonization that is uniquely available to animal studies and should be 





CHAPTER 4: A URINARY MICROBIOTA IN PREGNANCY: CULTIVATION- AND 
MOLECULAR-BASED COMPARISON OF FOLEY CATHETERIZED URINE, CLEAN 
CATCH URINE, AND VAGINAL SWABS FROM THE SAME WOMEN 
Note: Ali Alhousseini, a former PhD student in the Department of Physiology and the Theis 
laboratory at Wayne State University contributed equally to this chapter. I am responsible for all 
analyses, generation of tables and figures, writing of the Abstract, Methods, and Results, and 
revision of the Introduction and Discussion. Dr. Alhousseini collected all the clinical samples, 
participated in the processing of these samples, and originally wrote the Introduction and 
Discussion sections. A prior version of this study was included in his dissertation thesis as well. 
I. Abstract 
Urine and the bladder have historically been considered sterile, especially in the context 
of clinical assessment. Recent work has been capitalizing on enhanced culture techniques and 
next-generation molecular sequencing surveys to re-assess the sterility of urine. Indeed, the 
scientific community has been shifting towards accepting that the bladder does contain 
microorganisms in healthy individuals, yet further investigation is warranted, as demonstrated in 
Chapters 2 and 3 of this dissertation. My focus these past five years has been on paradigms of 
sterility in perinatal medicine, and studies on the urine of pregnant women have been limited 
thus far. This is surprising given that pregnant women are at an increased risk of urinary tract 
infections (UTIs) and UTIs can lead to pregnancy complications. Because of these 
vulnerabilities, investigating the bladders and urine of pregnant women is critical in evaluating 
shifting paradigms of urine sterility. 
To better understand the existence and potential role of a bladder microbiota during 
pregnancy, we must first establish suitable approaches to its study and characterize which 
bacteria inhabit the bladder. To do so, we characterized the urinary microbiota of 25 pregnant 
women (delivering after 35 weeks gestation) by comparing the bacterial profiles of paired 
catheter urine, clean catch urine, and vaginal swabs using cultivation and molecular 
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microbiological survey methods. For culture, three bacterial taxa were detected in at least 20% of 
all urine samples (Lactobacillus species, coagulase negative Staphylococcus species, and 
Ureaplasma urealyticum), and all three taxa were detected less frequently in Foley catheter urine 
than in CC urine. Ureaplasma urealyticum was the most frequently recovered bacteria in Foley 
catheter urine (13/25 women). 16S rRNA gene surveys showed that the microbial profiles of 
Foley catheter urine and vaginal swabs differed in composition and structure, but that the profiles 
of clean catch urine and vaginal swabs were similar. For all three sample types, bacterial profiles 
were abundant in Lactobacillus and Gardnerella species, but there was variation in lower 
abundance taxa among these three sample types, especially with regards to Foley catheter urine, 
which is presumably most closely representative of a bladder microbial community, if one exists. 
 Overall, our data suggest that residential bacterial communities exist in the female 
bladder and urine during pregnancy, and that there is overlap between those communities and 
those in the vagina. Aside from Lactobacillus and Gardnerella species, which were frequently 
detected in molecular surveys of Foley catheter urine obtained directly from the bladder, there 
was high inter-individual variability of less abundant taxa. Several lower abundance taxa that 
were differentially more abundant in catheter urine than vaginal swabs in molecular 
microbiology surveys were Ureaplasma, Finegoldia, Anaerococcus, and Fenollaria species. Of 
these, Ureaplasma was detected by cultivation in a majority of women. The remaining bacteria 
are anaerobes, which would require targeted or enhanced culture methods for their detection. 
Future directions include validating these findings in a larger cohort and pursuing more robust 
cultivation methods that are efficient for capturing low abundance anaerobes in clinical samples, 
especially Gram-positive anaerobic cocci (including Finegoldia, Anaerococcus, Peptoniphilus, 
and Atopobium). Additionally, investigation of the bladder of women delivering preterm 
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(especially early preterm, < 32 weeks of gestation) is warranted for comparisons of bladder 
microbial communities to women delivering at term will allow us to assess influences of resident 
bacterial communities on perinatal health and pregnancy outcomes, which can ultimately be used 
to identify specific bacteria or bacterial communities whose presence or absence can serve as 
potential risk indicators for adverse pregnancy outcomes, especially spontaneous preterm birth. 
II. Introduction 
The bladder and urine have historically been regarded as sterile [115, 169]. However, this 
perception is being reconsidered [69, 114, 117, 118, 133, 226, 227]. Given appropriate 
cultivation conditions, based on atmospheric and metabolic requirements, microorganisms can be 
cultured from urine in healthy patients [64, 228]. Furthermore, capitalizing on contemporary 
advances in next-generation sequencing technologies, urinary microorganisms have been 
identified and characterized among asymptomatic non-pregnant women [69, 114, 117, 118, 133, 
226, 227], and, in a single study, among pregnant women [169]. Collectively, these studies have 
suggested that bacteria reside in the human bladder as commensals, and even potentially as 
mutualists [69]. For example, a current hypothesis is that microbes residing within the bladder 
and urine of healthy people competitively exclude potential pathogens and that dysbiosis of these 
resident microbial communities could lead to an overgrowth of opportunistic pathogens, 
resulting in urinary tract infections (UTIs), urinary urge incontinence, and other urinary tract 
disorders [63, 64, 67]. 
Despite recent work, the existence of a urinary microbiota has not yet been effectively 
investigated using contemporary molecular microbiology techniques in the context of pregnancy 
outcomes. Bacterial presence in the urinary tract has been considered pathologic and has been 
classified into asymptomatic bacteriuria (ASB), urinary tract infection, or pyelonephritis [137, 
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169, 229, 230]. Pregnant women are an important population in which to assess any potential 
influences of a urinary microbiota due to vulnerabilities associated with the urinary tract during 
pregnancy [162, 163, 231]. Specifically, women experience physiological and morphological 
changes during pregnancy, including ureteral dilation, decreased bladder tone, displacement and 
compression of the bladder, increased renal length, and decreased peristalsis. The consequences 
of these alterations can include urinary stasis, vesicoureteral reflux, and hydronephrosis [162, 
231], each of which contribute to conditions that are conducive to microbial growth [163], 
thereby increasing the risk of ascending UTIs. In fact, UTIs are the most common bacterial 
infection in women during pregnancy, occurring in up to 8% of pregnancies, with approximately 
5% of women experiencing at least one UTI event during a given pregnancy [232]. Urinary tract 
infections can lead to significant maternal and perinatal complications, including preterm birth, 
low birth weight, maternal sepsis, and disturbance of the immune system, including an increase 
in inflammation [157, 158, 233-243]. While women diagnosed with having asymptomatic 
bacteriuria (ASB) are at similar risk for adverse pregnancy outcomes as UTIs, the main 
difference between these two diagnoses, aside from symptom presentation, has been the 
magnitude of detectable bacteria in urine, or colony forming units (CFUs) from urine culture, 
which is still the clinical diagnostic standard along with urinalysis. Notably, asymptomatic 
bacteriuria has been reported in up to 10% of pregnancies [244-248], and, if left untreated, ASB 
can lead to symptomatic UTIs, including pyelonephritis in 30-40 % of the cases [249]. A recent 
Cochrane review therefore recommended treatment of ASB to reduce the incidence of 
pyelonephritis during pregnancy [244]. This is in line with typical clinical practice as a positive 
urine culture (> 10,000 colony forming units per ml) during pregnancy has traditionally elicited 
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antibiotic treatment and a repeat of culture within 1-2 months to confirm resolution of the 
infection [137]. 
An important consideration that needs to be addressed is that asymptomatic bacteriuria, 
and to a lesser extent UTIs, have historically hinged on the long-held belief that the upper 
urinary tract is sterile. While this now stands contradictory to multiple studies that have been 
published using enhanced culture and 16S rRNA gene sequencing surveys suggesting the 
existence of a urinary tract or bladder microbial community in healthy individuals, there are two 
important caveats inherent in characterizing urinary microbiota profiles. First, urine samples are 
susceptible to vulvovaginal contamination, so there is risk that characterized microbes were not 
actually residing in the bladder or the urine. Studies by Wolfe and colleagues [48, 115, 118] 
found many genera, although the most represented were Lactobacillus, Prevotella, 
Staphylococcus, Atopobium, Corynebacterium, and Gardnerella, which are all commonly 
associated with the vagina and human skin. Second, if there are indeed resident urinary microbial 
communities, they are present in very low abundances and thus, when characterizing them 
through next-generation sequencing, there is risk of amplifying and characterizing background 
bacterial DNA contamination from DNA extraction kits and PCR reagents [98, 99, 128, 149, 
189]. 16S rRNA gene sequences are ubiquitous in the environment and do not indicate viability 
of any surveyed bacteria. From our analysis of the current literature, we found that most of the 
publications investigating the urinary tract microbiota did not include appropriate technical 
controls to properly account for background DNA. Many of the less abundant genera detected in 
recent studies represent species that are not captured by routine cultures or have never been 
successfully cultured. It is also important to perform viability assays, such as expanded 
quantitative urine culture (EQUC) methods, to demonstrate viability of bacteria from these 
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samples because molecular surveys do not differentiate between ubiquitous environmental 16S 
rRNA gene sequences and those from living bacteria [115]. Additionally, some of the data 
provided in studies were low in sample size (e.g., n = 2), and conducted viability assays on only 
a subset of samples [117, 118]. Therefore, it is important for future work in this area to include 
larger sample sizes, more rigorous and extensive culture techniques, and ample background 
technical controls to draw a proper conclusion on the existence of microbial communities in the 
bladder. 
Our broad objective is to further investigate and resolve the ambiguities surrounding the 
presumed presence of urinary tract microbial communities among normal asymptomatic 
pregnant women, and to ultimately ascertain potential influences of these communities on 
women’s reproductive health. By investigating the presence of microbial communities in the 
bladder of pregnant women, follow-up studies can elucidate any associations that certain 
microbial species or community structures may have with pregnancy outcomes. Should we find 
that urine samples are not significantly different from technical controls, the medical community 
can reassess diagnostic criteria to address the asymptomatic presence of bacteria as an indicator 
of subclinical infection that can be addressed with prophylactic measures. Additionally, this 
result should reduce or stop the publication of studies alluding to urinary microbiota without 
including necessary technical controls. Conversely, if we find that there is a resident microbial 
community within the female urinary tract, it is critical that current paradigms of a sterile urinary 
tract be revised to accommodate these resident microbes and the corresponding microbiome. 
Additionally, given that infection in non-sterile sites may indicate disruption of microbial 
homeostasis, understanding of the underlying microbial community is critical for addressing and 
preventing urinary tract infections. This would also render the term bacteriuria obsolete and 
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require new approaches for handling the updated context of urinary tract disorders. In particular, 
women’s reproductive health serves to benefit most by this paradigm shift through better risk 
indicators through screening of these communities. If we find distinct community types 
associated with particular disease states or increased risks for obstetric or gynecologic 
complications, preventative measures can be taken to either alter the community or replace it 
with probiotics, antibiotics, or a combination of the two (i.e. synbiotics).  
The specific and principal objective of this study was to determine if there is a viable 
microbiota in the bladder and urine during pregnancy and, if so, to characterize it. Secondary 
objectives were to: 1) assess similarity of culture and next-generation sequencing 
characterizations of urinary microbial profiles; 2) assess the microbial load of urine sampled 
using catheter and clean catch collection methods via quantitative real-time PCR; 3) compare the 
composition and structure of the microbial profiles of urine from pregnant women obtained using 
catheter and clean catch collection approaches with those of background technical controls; and 
4) contrast the microbial profiles of the urine of pregnant women obtained through these two 
collection approaches with those of the vagina to assess potential vulvovaginal contamination. 
These objectives were achieved by collecting 3 sample types, catheter urine, clean catch urine, 
and vaginal swabs, from pregnant women and characterizing their urine and vaginal microbiota 
profiles through both culture and next-generation sequencing surveys. To accomplish our 
objectives, our study was divided into two components. In Study Component 1, we evaluate 
whether the urine of pregnant women has bacterial loads and bacterial profiles distinct from 
those of technical controls, as assessed by quantitative real-time PCR and 16S rRNA gene 
sequencing. Additionally, we determine what is an appropriate volume of urine to use for 
effective surveys of potential bladder microbial communities. In Study Component 2, after 
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establishing that urine samples are distinct from technical controls and identifying an appropriate 
urine volume for assessing microbial communities, we compare urine collection methods to 
assess the most informative and accurate method for detecting and characterizing 
microorganisms in the bladder, while controlling for vulvovaginal and background DNA 
contamination. Finally, we detail the evidence of a bladder microbiota in this cohort and identify 
the bacteria that are likely members of the bladder microbiota during pregnancy. 
III. Methods and Materials 
Clinical specimens 
Urine and vaginal swab samples were obtained at the Perinatology Research Branch, an 
intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, National Institutes of Health, U.S. Department of Health and Human Services, 
Wayne State University (Detroit, MI), and the Detroit Medical Center (Detroit, MI). The 
collection and use of human materials for research purposes were approved by the Institutional 
Review Boards of the National Institute of Child Health and Human Development and Wayne 
State University. All participating women provided written informed consent prior to sample 
collection. 
Study design 
This was a cross-sectional study in which the urinary and vaginal microbiota were 
examined in 25 women admitted for delivery after 35 weeks gestation. There were two 
components to the study. First, the bacterial loads and bacterial profiles of urine samples 
collected using Foley catheter and clean catch sampling methods were compared in a subset of 
women ( n = 8 ). These comparisons were made across a range of urine volumes (1 ml, 1.8 ml, 
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5.4 ml, 10 ml, and 25 ml).Second, the bacterial loads and bacterial profiles of 5.4 ml of Foley 
catheter urine, clean catch urine, and vaginal swabs were compared across all women and were 
contrasted with those of background contamination controls. 
Inclusion and exclusion criteria 
Inclusion criteria: 1) delivery after 35 weeks of gestation, and 2) intact membranes at the time of 
collection of vaginal swabs and clean catch urine samples. Exclusion criteria: 1) any maternal or 
fetal condition that requires termination of pregnancy; 2) known major fetal anomaly or fetal 
demise; 3) active vaginal bleeding; 4) serious medical illness (e.g. renal insufficiency, congestive 
heart disease, chronic respiratory insufficiency, etc.); 5) asthma requiring systemic steroids; 6) 
patient requiring anti-platelet or non-steroidal anti-inflammatory drugs; 7) active hepatitis; and 8) 
signs or symptoms of urinary tract infection, asymptomatic bacteriuria, and pyelonephritis at the 
time of sampling.  
A urinary tract infection (UTI) is bacterial growth of more than 10,000 colonies of a 
single bacterial type per milliliter (CFU/ml) of urine coincident with one of the following 
symptoms: hematuria, dysuria frequency, urgency or suprapubic pressure [229, 230]. However, 
because others have recommended a much lower threshold of 100 CFU/ml for diagnosing 
symptomatic UTIs [250], we applied the latter definition. Asymptomatic bacteriuria (ASB) is the 
presence of 100,000 CFU/ml without any associated symptoms [137, 229, 230]. Pyelonephritis is 
infection of the kidneys and the presence of systemic signs or symptoms such as fever, nausea 
and vomiting, chills or flank pain [137, 229, 230]. Again, no woman in this study had a urinary 
tract infection, asymptomatic bacteriuria, or pyelonephritis. 
In the first component of the study, which assessed bacterial load and profiles of urine 
samples at multiple volumes compared to background contamination, no subject had received 
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antibiotics in the last week. In the second component of the study, evaluating differences in 
bacterial load and profiles of Foley catheter urine and clean catch urine and vaginal swabs, no 
subject had received antibiotics in the last month. 
Sample collection 
On admission, each woman provided a mid-stream clean catch urine specimen (CC). A 
speculum exam was performed, and a sample of vaginal fluid was collected from the posterior 
vaginal fornix under direct visualization by an obstetrician using a FLOQSwab (Copan 
Diagnostics, Murrieta, CA, USA). During labor or prior to a cesarean delivery, a sterile Foley 
catheter was inserted, and a second urine specimen was collected (Foley catheter was placed 8.36 
± 1.93 (mean ± SE) hours after the clean catch sample was collected). Urine (excluding the 
aliquot for culture, see below) and vaginal swabs were frozen at -80°C within one hour of 
collection. 
Bacterial culture of urine 
A 2 ml aliquot of urine was sent for bacterial culture. Aliquots of urine were delivered to 
the University Laboratories Microbiology Core in the Detroit Medical Center, wherein they were 
processed and cultured under aerobic and anaerobic conditions that day. A genital mycoplasma 
assay (Mycofast US; Logan, UT) was also conducted for each urine sample [251]. Incubation for 
aerobic, anaerobic and Mycoplasma/Ureaplasma cultures was performed at 35°C. Aerobic plates 
were TSA 5% SB (Trypticase Soy Agar w/5% Sheep's Blood), Columbia CNA SB, MacConkey 
and MTM II (Modified Thayer Martin). Anaerobic plates used were Brucella OxyPRAS Plus, 
KVL/BBE Biplate (Brucella Laked Blood Agar with Kanamycin and Vancomycin/Bacteroides 
Bile Esculin Agar) and CDC ANA BLD (CDC Anaerobic Blood Agar). Aerobic cultures were 
grown in an incubator with 8% CO2, anaerobic cultures were grown in a plastic anaerobic culture 
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chamber in a non-CO2 incubator, and the Mycoplasma/Ureaplasma cultures were grown in an 
oxic environment without CO2 supplementation. In each case, one drop of urine, equivalent to 
approximately 0.05 ml, was used. Urine samples were incubated for 48 hours. The taxonomies of 
resultant isolates were characterized using Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF) within the University Laboratories Microbiology Core 
[252]. 
Genomic DNA extractions 
Preparation of urine samples for DNA extraction: For 1, 1.8, and 5.4 ml sample volumes, DNA 
extractions were performed as follows: Urine samples were originally stored at -80°C in either 2 
ml cryovials or in 15 ml centrifuge tubes. Samples were thawed at room temperature and 
thoroughly vortexed before aliquoting into 1.8 ml mini-centrifuge tubes (one tube for 1 and 1.8 
ml sample volumes, and three tubes for the 5.4 ml sample volume). Samples were spun in a 
mini-centrifuge in a 4oC cold room for 30 minutes at 17,000 g. After centrifugation, each sample 
had the majority of supernatant removed. For the 1 ml sample, approximately 750 µl of 
supernatant was carefully removed with a 1 ml pipette tip, avoiding the pellet, thereby leaving 
about 250 µl of the supernatant and the pellet for DNA extraction. For the 1.8 ml sample, 775 µl 
was removed twice, again being careful to avoid disturbing the pellet, leaving about 250 µl of the 
supernatant and the pellet for DNA extraction. For the three 1.8 ml tubes constituting the 5.4 ml 
sample, 860 µl was removed twice from each tube, carefully avoiding the pellet, leaving 80 µl of 
supernatant and the pellet in each tube for DNA extraction. The initial step of the DNA 
extraction protocol requires adding 500 µl of the kit’s PowerBead Solution to the sample; the 
PowerBead Solution was added directly to these 1.8 ml tubes. The tubes were then thoroughly 
mixed through vortexing and by pipetting the solution up and down to ensure that the pellet was 
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dislodged into solution and would be transferred to the bead tube in the next extraction step. For 
the 5.4 ml sample, 500 µl of PowerBead Solution was added to the first 1.8 ml tube, the tube was 
then mixed, transferred to the second tube, mixed, transferred to the third tube, and mixed again 
before being transferred to the PowerBead Tube in the next extraction step. 
For DNA extractions performed on 10 and 25 ml samples: Urine samples were originally 
stored at -80°C in either 2 ml cryovials or in 15 ml centrifuge tubes. Samples were thawed at 
room temperature and thoroughly vortexed before transferring 10 or 25 ml into 50 ml centrifuge 
tubes. These samples were spun at 4oC at 17,000g for 30 minutes. After centrifugation, 
supernatant was removed without disturbing the pellet. The initial step of the DNA extraction 
protocol requires adding 500 µl of PowerBead Solution to the sample, so the PowerBead 
Solution was added directly to these 50mL tubes. These tubes were then thoroughly mixed 
through vortexing and pipetting the sample up and down to ensure that the pellet was dislodged 
into solution and would be transferred to the bead tube for the following step in the extraction 
protocol.  
Extraction protocol: Genomic DNA was extracted from urine and vaginal swab samples using 
QIAGEN DNeasy PowerLyzer PowerSoil Kits according to the manufacturer’s protocol with the 
following modifications: 1) instead of adding 750 μl of PowerBead Solution to each sample, 500 
μl of PowerBead Solution and 200 μl of phenol/chloroform:isoamyl alcohol were added and the 
sample was incubated in the PowerBead Tubes at room temperature for 10 minutes, 2) steps that 
entail adding Solutions C2 and C3 were combined into one step; 1 μl of RNase A enzyme was 
also added, 3) instead of adding 1200 μl of Solution C4, 650 μl of C4 and 650 μl of 100% 
ethanol were added, 4) the dry-spin after Solution C5 was extended from 1 to 2 minutes, 5) 
Solution C6 was heated to 60°C prior to elution of DNA, and 6) 60 μl instead of 100 μl of 
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Solution C6 were added to the Spin Column and incubated for 5 minutes before final 
centrifugation. Blank DNA extraction kits with no urine sample added (n = 12) were processed 
alongside urine samples. Purified DNA was stored at -20°C. 
Quantitative real-time PCR (qPCR) of 16S rRNA genes in samples 
Bacterial DNA abundance within samples was determined via quantitative real-time PCR 
(qPCR) amplification of the V1 – V2 region of the 16S rRNA gene according to a protocol 
described by Dickson et al [70] with minor modifications. These modifications included the use 
of a degenerative forward primer (27f-CM: 5’-AGA GTT TGA TCM TGG CTC AG-3’) and a 
degenerate probe containing locked nucleic acids (+) (BSR65/17: 5’-56FAM-TAA +YA+C ATG 
+CA+A GT+C GA-BHQ1-3’). All qPCR reactions were performed in triplicate (20 μl each), 
with each reaction containing 0.6 μM of 27f-CM primer, 0.6 μM of 357R primer (5’-CTG CTG 
CCT YCC GTA G-3’), 0.25 μM of BSR65/17 probe, 10.0 μl of 2X TaqMan Environmental 
Master Mix 2.0 (Life Technologies, Carlsbad, CA), and 4.0 μl purified DNA. Cycling conditions 
were as follows: 95°C for 10 min, and 45 cycles of 94°C for 30 s, 50°C for 30 s, and 72°C for 30 
s. Fluorescent readings were taken at the end of each cycle on an ABI 7500 Real-Time PCR 
System (Applied Biosystems, Waltham, MA). Raw amplification data were normalized to the 
ROX passive reference dye and analyzed with Standard Curve 3.3.0-SR2-build15 (Thermo 
Fisher Cloud), using automatic threshold and baseline settings. Cycle of quantification (Cq) 
values, defined as the average number of cycles required for normalized fluorescence to 
exponentially increase, were calculated. DNA derived from Escherichia coli ATCC 25922 
containing seven 16S rRNA gene copies per genome (GenBank accession: CP009072) was 
quantified using a Qubit 3.0 fluorometer with a Qubit dsDNA HS Assay kit (Life Technologies, 
Carlsbad, CA) according to the manufacturer’s instructions and used for the generation of 
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standard curves. To estimate qPCR efficiency, a standard curve containing seven 10-fold serial 
dilutions (three replicates each) ranging from 1.99 X 107 to 1.99 X 101 copies was included in 
each run. Prior to analyzing qPCR data with the on-line platform Thermo Fisher Cloud (Standard 
Curve (SR) 3.3.0-SR2-build15), an external master standard curve was generated by performing 
a regression of the standard curve data from all six qPCR runs. The regression values for the 
master external standard curve were: slope = -3.4629, y-intercept = 40.122, R2 = 0.9798. 
16S rRNA gene sequencing 
16S rRNA gene sequencing was completed on an Illumina MiSeq (San Diego, CA) 
instrument at the University of Michigan’s Center for Microbial Systems (Ann Arbor, MI). The 
V4 region of the 16S gene was amplified using a modified PCR approach (95° for 2 min, 
followed by 32 cycles of 95° for 30 s, 55° for 30 s, and 72° for 30 s, with a final elongation step 
at 72° for 10 min). DNA template volumes were 5 μl for urine and blank DNA extraction kits, 
and 3 μl for vaginal swabs. The MiSeq sequencing protocol was performed using the dual 
indexing sequencing strategy developed by Schloss and colleagues [219, 253].  
16S rRNA gene sequence processing 
Sequence data were processed using Mothur software (v1.39.5) [41]. Specifically, paired 
reads were assembled, quality-filtered (no ambiguous base calls, homopolymers ≤ 8 bases long), 
and aligned to the SILVA 16S rDNA reference database (release 102) [221, 222]. Sequences in 
the final dataset had an average length of 253 bp. We performed a preclustering step (diffs = 2) 
to reduce potential influence of sequencing errors and removed chimeras identified by UCHIME 
[254]. For taxonomic classification, the SILVA reference database [222] was used with a 
confidence threshold of 80% [255]. Sequences from an unknown domain, Eukaryota, 
Chloroplasts, Mitochondria, or Archaea were removed. Operational taxonomic units (OTUs) 
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were defined using a 3% sequence dissimilarity cutoff. Good’s coverage values for all urine and 
vaginal samples exceeded 99%. 
Statistical analyses 
Bacterial culture: The rate of cultivation of bacterial phylotypes (as identified via MALDI-TOF, 
e.g. Lactobacilllus, coagulase negative Staphylococcus, Ureaplasma urealyticum) from urine 
was compared between Foley catheter and clean catch collection methods using generalized 
estimating equation models assuming a binomial distribution (i.e. detected or non-detected). 
Only bacterial phylotypes detected in at least 20% of the samples, regardless the method of 
collection, were tested. Significance of the odds ratios was assessed via Wald tests, implemented 
in the geepack package in R (v 3.4) [256]. The paired differences in the total numbers of 
bacterial phylotypes detected within the Foley catheter and clean catch urine samples among the 
women were assessed using a Poisson generalized estimating equation model. 
16S rRNA gene qPCR: To assess differences in 16S rDNA abundance between each urine 
volume and collection method and blank DNA extraction kit controls, differences in cycle of 
quantification (Cq) were evaluated via Mann-Whitney tests. To assess variation in 16S rDNA 
abundance among urine samples of different volumes from the same women, variation in Cq 
values was evaluated via repeated-measures analysis of variance (ANOVA) followed by Tukey’s 
tests for pair-wise comparisons or Friedman’s ANOVA followed by Wilcoxon matched pairs 
tests. In component 2, differences in 16S rDNA abundance between sample types were assessed 
using Friedman’s ANOVA followed by Wilcoxon matched pairs tests. Statistical analyses were 
performed using PAST software (v3.16) [202]. 
16S rRNA gene profile alpha and beta diversity: For Study Component 1, blank DNA extraction 
kit controls were sequenced twice and subsequently pooled bioinformatically. The controls with 
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Good’s coverage values exceeding 98% were retained for analysis [n = 5, additional controls 
were processed during DNA extractions for Study Component 2 and used as part of the LEfSe 
analysis (n = 7)]. Alpha diversity in Study Component 1 was analyzed after subsampling 
individual libraries to 447 sequences, which corresponds to the sequence number of the least 
represented background technical control sample. After subsampling, Good’s coverage remained 
above 95% for all but one sample (91%). 
Alpha diversity in Study Component 2 was analyzed after subsampling individual 
libraries to 2007 sequences, which corresponds to the number of sequences in the second least 
represented sample. A sample with 445 sequences was excluded from these analyses. In 
Component 2, after subsampling, Good’s coverage values for urine and vaginal samples 
remained greater than or equal to 98%. 
Alpha diversity was assessed using the Chao1 index as an indicator of richness and the 
Shannon and Inverse Simpson indices as indicators of heterogeneity (evenness). Differences in 
alpha diversity between urine and background technical control samples were evaluated through 
t-tests or Mann-Whitney tests. For comparisons among different urine volumes (Component 1: 1 
ml, 1.8 ml, 5.4 ml, 10 ml, 25 ml) or between sample types (Component 2: Foley catheter urine, 
clean catch urine, vaginal swabs) variation in alpha diversity was evaluated through repeated 
measures ANOVA followed by Tukey’s matched-pairs or their non-parametric equivalents. 
To evaluate differences in beta diversity of 16S rRNA gene profiles, Jaccard (i.e. 
composition) and Bray-Curtis (i.e. structure) similarity index values were calculated using OTU 
percent relative abundance data within samples and were visualized through Principal 
Coordinates Analyses (PCoA). Non-parametric MANOVA (NPMANOVA) tests were 
performed on Jaccard and Bray-Curtis similarity indices to assess differences between 
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background technical controls and different urine volumes (Component 1), and variation among 
catheter urine, clean catch urine, and vaginal samples (Component 2).  
Alpha diversity indices were generated in mothur (v1.39.5) and statistically evaluated in 
PAST (v3.16). Beta diversity indices and PCoA plots were generated using PAST software 
(v3.16). Non-parametric MANOVA [257-259] tests were performed in R (version 3.4.2) with 
adonis in the vegan package. The “strata” parameter in adonis was used to control for repeated-
measures. Heatmaps were generated via the Morpheus online tool [204].  
SourceTracker analysis: SourceTracker software [121] was used to identify what percentage of 
OTUs found in urine samples could be attributed to contamination from vaginal samples. For 
each urine collection method, SourceTracker analysis was done in triplicate with a rarefaction 
depth of 500 and the proportions from the three model runs were averaged to give the mean 
percentage of OTUs predicted to be from vaginal samples. Singletons and doubletons were 
removed from 16S rRNA gene datasets prior to these analyses. Wilcoxon paired tests of the 
averaged SourceTracker runs were evaluated in PAST (v3.16). 
LEfSe analysis: Linear discriminant analysis effect size, or LEfSe, was used to identify any 
OTUs that differed in relative abundance between each of the three biological sample types 
(Foley catheter urine, clean catch urine, vaginal swabs) and blank DNA extraction kits (n = 7). 
Singleton OTUs were removed from the datasets prior to analyses and the default settings for 





Study Component 1: Comparing the bacterial load and 16S rRNA gene profiles of different 
volumes of urine from the same women 
Patient characteristics 
Eight women were included in Component 1 of the study. The median and interquartile 
range for age, body mass index (BMI), gestational age at sampling, and neonatal birthweight 
were 27.5 (25.2-28.2) years, 31.6 (28.5-45.8) kg/m2, 39.7 (38.8-40.8) weeks, and 3,392 (3,256-
3,882) grams, respectively (Table 4.1). 
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine samples 
Quantitative real-time PCR demonstrated that the median cycle of quantification (Cq) 
values for each volume of urine were significantly lower than the median Cq values for blank 
DNA extraction kit controls, regardless whether the urine was collected via Foley catheter 
(Mann-Whitney; U = 0, p = 0.0058) or the mid-stream clean catch method (U = 0, p = 0.0081). 
The volume of urine processed had an effect on Cq value for Foley catheter (repeated measures 
ANOVA; F = 9.805, p < 0.0001) and clean catch (F = 28.01, p < 0.0001) urine samples. For both 
urine collection methods, a urine volume of 5.4 ml was the lowest volume to yield Cq values that 
did not significantly differ from 25 ml of urine (Tukey-adjusted comparisons; Figure 4.1), which 
was the highest volume of urine investigated in this study.  
16S rRNA gene profiles of urine samples 
Alpha Diversity: Bacterial profile richness (Chao1 index) and heterogeneity (Shannon and 
Inverse Simpson indices) did not differ between any volume of catheter or clean catch urine and 
blank DNA extraction kits after correcting for multiple comparisons (Table 4.2).  A global effect 
of sample volume on heterogeneity was observed for Foley catheter urine; however no pairwise 
comparisons were significant after correcting for multiple comparisons (Table 4.2). 
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Table 4.1. Descriptive and clinical characteristics of subjects for Study Components 1 and 
2. 
Study Component 1   
N = 8 Median IQRa 
Age (yrs) 27.5 25.2 – 28.2 
BMIb (kg/m2) 31.6 28.5 – 45.8 
GAc at sampling (wks) 39.7 38.8 – 40.8 
Birthweight (g) 3392 3256 – 3882 
   
Race   
African American 8 (100 %)  
Study Component 2   
N = 25 Median IQRa 
Age (yrs) 24.0 21.0 – 29.0 
BMIb (kg/m2) 31.7 26.3 – 35.8 
GAc at sampling (wks) 39.3 39.0 – 39.85 
Birthweight (g) 3165 2892.5 – 3615 
   
Race   
African American 22 (88.0 %)  
White 2 (8.0 %)  
Other 1 (4.0 %)  
a Interquartile range 
b Body Mass Index 




Figure 4.1. Quantitative real-time PCR (qPCR) of the 16S rRNA gene results from urine 
sample volumes of 1.0, 1.8, 5.4, 10, and 25 ml. Seven and six women contributed Foley 
catheter and clean catch urine samples, respectively. Both Foley catheter and clean catch urine 
collection methods yielded samples with microbial burdens exceeding those of blank DNA 
extraction kits (Foley catheter, N = 4, clean catch N = 5). Letters correspond to pairwise 
comparisons where p > 0.05, suggesting the microbial load in those volumes were not different 




Table 4.2. Comparisons of alpha diversity of Foley catheter urine and clean catch urine 
processed at 5 different volumes and blank controls. 
t-test or Mann-Whitney U test Chao1 Shannon Inverse Simpson 
Foley catheter v Blank controls t P t P t P 
1.0 ml 0.2860 0.7814 1.6081 0.1423 1.5260 0.1613 
1.8 ml 1.4256 0.1877 1.3154 0.2209 1.1052 0.2978 
5.4 ml 2.0131 0.0746 14* 0.9247 0.8111 0.4382 
10 ml 2.4313 0.0379 1.9453 0.0836 1.6474 0.1339 
25 ml 1.4779 0.1736 1.4726 0.1750 1.5136 0.1644 
Clean catch v Blank controls t P t P t P 
1.0 ml 0.4407 0.6688 2.1093 0.0611 1.7277 0.1147 
1.8 ml 0.0219 0.9830 2.2362 0.0493 1.7596 0.1090 
5.4 ml 0.7251 0.4850 2.3172 0.0430 1.8545 0.0934 
10 ml 0.2532 0.8053 2.5737 0.0277 2.0930 0.0628 
25 ml 0.0377 0.9707 2.8564 0.0171 2.1924 0.0531 
Repeated-measures ANOVA  
or Friedman’s ANOVA 
F P F P F P 
Foley catheter       
Volume 1.7700 0.1998 10.45** 0.0349 4.215 0.0233 
Pairwise comparisons    All > 0.01  All > 0.01 
Clean catch F P F P F P 
Volume 0.5478 0.7033 1.462 0.2600 1.911 0.1578 
Pairwise comparisons       




Beta Diversity: The composition (Jaccard index) and structure (Bray Curtis index) of the 
bacterial profiles of all five volumes of Foley catheter and clean catch urine samples differed 
from those of blank DNA extraction kit controls (Table 4.3, Table 4.4, Figure 4.2, Figure 4.3). 
Subject identity, not urine sample volume, principally influenced the composition and structure 
of urine bacterial profiles, regardless the method of collection (Table 4.3, Table 4.4, Figure 
4.3). 
Study Component 1 Outcome 
Given that a sample volume of 5.4 ml was the lowest volume of urine to yield Cq values 
that did not differ from those of 25 ml of urine, regardless collection method, a urine sample 
volume of 5.4 ml was used in Component 2 of the study. 
Study Component 2:  Evaluating differences in microbial burden and 16S rRNA gene 
profiles between Foley catheter and mid-stream clean catch urine in relation to those of 
vaginal swabs 
Patient characteristics 
Table 4.1 describes the demographic and clinical characteristics of the 25 women 
included in Component 2 of the study [the median and interquartile range for age were 24 (21-
29) years, for body mass index were 31.7 (26.3-35.8) kg/m2, for gestational age were 39.3 (39-
39.85) weeks, and for neonatal birthweight were 3,165 (2,892.5-3,615) grams]. Twenty-two 
women were African-American, two were Caucasian, and one was self-reported as Other. Seven 
women (28%) had a history of at least one lifetime UTI, and two (8%) experienced a UTI 





Table 4.3. Statistical analysis of bacterial community composition (Jaccard similarity 
index) for Foley catheter urine and clean catch urine processed at five different volumes 
and compared to blank controls. 
Jaccard NPMANOVA F R2 P 
Foley catheter v Blank controls  
1.0 ml 1.0893 0.0901 0.0056 
1.8 ml 1.1143 0.0920 0.0046 
5.4 ml 1.1300 0.0932 0.0019 
10 ml 1.2040 0.0912 0.0008 
25 ml 1.1190 0.0923 0.0086 
Clean catch v Blank controls 
1.0 ml 1.1223 0.0926 0.0026 
1.8 ml 1.1113 0.1000 0.0031 
5.4 ml 1.1021 0.0993 0.0041 
10 ml 1.0916 0.0903 0.0062 
25 ml 1.0863 0.0980 0.0095 
Foley catheter    
Subject (n = 4) 1.5412 0.2241 0.0001 
Volume 1.0023 0.1943 0.4393 
Clean catch    
Subject (n = 5) 1.7169 0.2555 0.0001 
Volume 1.0028 0.1492 0.4313 
Table 4.4. Statistical analysis of bacterial community structure (Bray-Curtis similarity 
index) for Foley catheter urine and clean catch urine processed at five different volumes 
and compared to blank controls. 
Bray-Curtis NPMANOVA F R2 P 
Foley catheter v Blank controls  
1.0 ml 2.7119 0.1978 0.0011 
1.8 ml 2.5168 0.1862 0.0011 
5.4 ml 2.4866 0.1844 0.0009 
10 ml 3.4612 0.2239 0.0008 
25 ml 2.4820 0.1841 0.0011 
Clean catch v Blank controls 
1.0 ml 2.2496 0.1698 0.0012 
1.8 ml 1.6062 0.1384 0.0321 
5.4 ml 1.6077 0.1385 0.0299 
10 ml 2.3175 0.1740 0.0020 
25 ml 1.6200 0.1394 0.0353 
Foley catheter    
Subject (n = 4)    12.5868 0.7004 0.0001 
Volume 1.0389 0.0771 0.4032 
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Clean catch    
Subject (n = 5) 27.4836 0.8427 0.0001 
Volume 1.1295 0.0346 0.3222 
 
 
Figure 4.2. Principal Coordinates Analysis (PCoA) plots: using A) Jaccard and B) Bray-
Curtis similarity indices illustrating that the composition and structure of the bacterial profiles of 
all urine samples, independent of sample volume or collection method, were distinct from those 
of DNA extraction kit controls. Subject identity, indicated by color, was the principal driver of 
urine bacterial profiles. 
 
Figure 4.3. Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average 
relative abundance) among urine samples from subjects, ordered by urine collection 
method and sample volume. Urine volume had little influence on bacterial profiles, while 
subject identity was the primary driver. The bacterial profiles of blank DNA extraction kits are 




Only three types of bacteria (Lactobacilllus species, coagulase negative Staphylococcus 
species, and Ureaplasma urealyticum) were cultured from at least 20% of all urine samples. 
Each was cultured less frequently from urine obtained through a Foley catheter than through 
mid-stream clean catch urine (Table 4.5; Figure 4.4). On average, urine collected with a Foley 
catheter yielded three less types of bacteria than paired urine samples collected through clean 
catch (Poisson generalized estimating equations model; p < 0.001). Ureaplasma urealyticum was 
the most frequently detected bacteria in Foley catheter urine (13/25 women). 
Quantitative real-time PCR (qPCR) of 16S rRNA gene abundance in urine and vaginal swab 
samples 
The bacterial load of clean catch urine exceeded that of catheter urine (Figure 4.5; 
Wilcoxon matched-pairs: W = 325, p < 0.0001). The relationship was the same for vaginal swabs 
and catheter urine (Figure 4.5; W = 321, p < 0.0001).  
16S rRNA gene profiles of paired catheter urine, clean catch urine, and vaginal swab samples 
Alpha Diversity: Catheter urine, clean catch urine, and vaginal swab samples did not vary in 
richness (Chao1 index; Friedman’s ANOVA: p > 0.05), but they did vary in heterogeneity based 
on Shannon (Chi2 = 7.28, p = 0.027) and Inverse Simpson (Chi2 = 7.44, p = 0.025) indices 
(Figure 4.6A & B). The bacterial profiles of Foley catheter and clean catch urine were more 
heterogeneous than those of vaginal swabs (Wilcoxon matched pairs with Bonferroni corrections 
applied: Foley catheter, Shannon index: W = 266, p = 0.0054, Inverse Simpson index: W = 257, 
p = 0.011; clean catch, Shannon index: W = 277, p = 0.0021, Inverse Simpson index: W = 253, p 




Table 4.5. Odds ratios of detecting bacterial phylotypes through culture in urine obtained 
from a Foley catheter compared to urine collected through the mid-stream clean catch 
method. 
Bacterial phylotype 




Lactobacilllus species 0.11 0.000 0.000 
Coagulase negative Staphylococcus species 0.03 0.000 0.000 
Ureaplasma urealyticum 0.34 0.007 0.007 
 
 
Figure 4.4. Urine bacterial cultivation results indicating differential recovery of bacterial 
phylotypes from catheter urine, clean catch urine, or both. Subject identity is indicated by 
color. In all but two occurrences, Staphylococcus species recovered were coagulase negative, the 
exception being S. aureus recovered in both urine samples of one patient and the clean catch 




Figure 4.5. Quantitative real-time PCR (qPCR) of the 16S rRNA gene results from Foley 
catheter urine, clean catch urine, and vaginal swabs. 25 women contributed paired Foley 
catheter urine, clean catch urine, and vaginal swab samples. Color represents subject identity, 




Figure 4.6. Jitter and Principal Coordinates Analysis (PCoA) plots illustrating alpha and 
beta diversities of Foley catheter urine, clean catch urine, and vaginal swabs collected from 
the same women. Panels A and B show differences in heterogeneity between sample types, with 
catheter urine having the greatest diversity for both indices. Panels C and D illustrate the 
composition and structure of the bacterial profiles of the three sample types. Several subjects are 
highlighted to illustrate the influence of individual identity on the bacterial profiles. Subject 




Beta Diversity: Overall, subject identity was the principal driver of the composition and structure 
of the bacterial profiles of Foley catheter urine, clean catch urine, and vaginal swabs (Table 4.6, 
Table 4.7, Figure 4.6C & D, Figure 4.7). Nevertheless, controlled for subject identity, the 
composition of the three sample types differed from one another (Table 4.6, Figure 4.6C). With 
respect to structure, the bacterial profiles of catheter urine differed from those of clean catch 
urine and vaginal swabs, but the profiles of clean catch urine did not differ from the profiles of 
their paired vaginal swabs (Table 4.7, Figure 4.6D). 
SourceTracker analyses: SourceTracker analysis found there was a greater contribution of OTUs 
explained by vaginal swabs in clean catch urine than in catheter urine (Figure 4.8; Wilcoxon 
paired test: W = 279, p < 0.001). 
Bacterial profiles in detail: The bacterial profiles of catheter urine, clean catch urine, and vaginal 
swabs were dominated by Lactobacillus and Gardnerella (Figure 4.7). BLAST analyses 
indicated that OTUs 1 and 2 were Lactobacillus iners and Gardnerella vaginalis, respectively.  
OTUs 3, 5, and 12 were each identified as multiple species of Lactobacillus. OTU 3 was 
identified as Lactobacillus crispatus (most likely [48, 68, 115, 118, 133, 169]), acidophilus, or 
gallinarum, OTU 5 was identified as Lactobacillus jensenii (most likely [48, 68, 115, 118, 133, 
169]) or fornicalis, and OTU 12 was identified as Lactobacillus gasseri (most likely [48, 68, 
115, 118, 133, 169]) or johnsonii. Thus, consistent with prior observations [50, 51, 68, 133, 227], 
the urogenital bacterial profiles of pregnant women were largely comprised of three community 
state types: 1) dominance by Lactobacillus crispatus; 2) dominance by Lactobacillus iners; or, 3) 
co-dominance by Lactobacillus iners and Gardnerella vaginalis. Both Lactobacillus and 
Gardnerella were rarely detected in the cultivation surveys of urine, suggesting their molecular 
signals may have been due to contamination, although both genera often require specialized 
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Table 4.6. Statistical analysis of bacterial community composition (Jaccard similarity 
index) for Foley catheter urine, clean catch urine, and vaginal swabs. 
Jaccard NPMANOVA F R2 P 
Foley Catheter v Clean Catch v Vaginal Swab  
Subject (n = 25)     1.02349     0.32957     0.0019 
Sample Type     0.98388     0.02640     0.7941 
Foley Catheter v Clean Catch  
Sample Type within subject     1.0515     0.02144     0.0022 
Clean Catch v Vaginal Swab  
Sample Type within subject     1.1345     0.02309     0.0014 
Foley Catheter v Vaginal Swab  
Sample Type within subject     1.1306     0.02301     0.0027 
Table 4.7. Statistical analysis of community structure (Bray-Curtis similarity index) for 
Foley catheter urine, clean catch urine, and vaginal swabs. 
Bray-Curtis NPMANOVA F R2 P 
Foley Catheter v Clean Catch v Vaginal Swab  
Subject (n = 25)     1.55064     0.42797     0.0002 
Sample Type     0.87084     0.02003     0.6228 
Foley Catheter v Clean Catch  
Sample Type within subject     0.88327     0.01807     0.0222 
Clean Catch v Vaginal Swab  
Sample Type within subject     0.92679     0.01894     0.4834 
Foley Catheter v Vaginal Swab  




Figure 4.7. Heatmap illustrating variation in the profiles of prominent OTUs (≥1% average 
relative abundance) among paired Foley catheter urine, clean catch urine, and vaginal 
swab samples from 25 pregnant subjects. The order was determined by hierarchical clustering 
of Bray-Curtis similarity indices of clean catch samples. Bars along the bottom horizontal axis 
mark the catheter sample of each patient. 
 
Figure 4.8. SourceTracker analysis comparing the percentage of OTUs explained by 





media even when recovering them from pure culture.  Besides Lactobacillus and Gardnerella, 
the bacterial profiles of catheter urine also variably contained a high relative abundance (at least 
one sample with >50% relative abundance) of 5 additional OTUs: an unclassified 
Mycoplasmataceae (OTU7), Escherichia (OTU 9), Buttiauxella (OTU 9), Streptococcus (OTU 
10), and Veillonella (OTU 13). Notably, 5 additional OTUs, not previously discussed, were 
detected in at least 12 catheter urine samples and had a relative abundance of ≥ 10% in at least 
one sample. These OTUs included an unclassified Coriobacteriaceae (OTU 11), Staphylococcus 
(OTU 17), Finegoldia (OTU 19), Ureaplasma (OTU 26), and Peptoniphilus (OTU 27). 
LEfSe analysis: Linear discriminant analysis effect size (LEfSe) analyses identified eight OTUs 
that were consistently more abundant in controls than any of the biological sample types, 
suggesting these OTUs are likely contaminants (Figure 4.9). These OTUs were identified as 
Escherichia (OTU 9), Staphylococcus (OTU 17), Pelomonas (OTU 53), Massilia (OTU 86), 
Haemophilus (OTU 90), Virgibacillus (OTU 102), Acinetobacter (OTU 107), Cloacibacterium 
(OTU 329). Analyses comparing catheter urine to vaginal swabs identified 17 OTUs more 
relatively abundant in catheter urine (Figure 4.10). While this analysis did not control for patient 
identity, four of these seventeen OTUs were also more relatively abundant in catheter urine than 
negative controls (Figure 4.10, highlighted in blue). These included Finegoldia (OTU 19), 
Ureaplasma (OTU 26), Anaerococcus (OTU 49), and an unclassified Clostridiales [OTU 43 
(BLAST query identified it as Fenollaria massiliensis)]. 
After identifying these four OTUs as potentially indicative as members of a bladder 
microbiota (i.e. more relatively abundant in catheter urine than in controls, and possibly more 
than vaginal samples as well), their abundances in catheter urine and vaginal swabs were 




Figure 4.9. Linear discriminant analysis Effect Size analyses identified several bacteria that 
were more relatively abundant in blank extraction kits. Analyses of 16S rRNA gene 
sequence datasets from DNA extraction compared to each sample type. OTUs highlighted in red 
were more relatively abundant in extractions kits than in all 3 biological samples suggesting 




Figure 4.10. Linear discriminant analysis Effect Size analyses identified several bacteria 
that were more relatively abundant in Foley catheter urine over vaginal samples, 
suggesting they are members of a urine and bladder microbiota. Analyses of sequence 
datasets from Foley catheter urine with DNA extraction kits, clean catch urine, and vaginal 
swabs. Highlighted in blue are taxa identified as being more relatively abundant in catheter urine 




than vaginal swabs with sequential Bonferroni corrections applied (Wilcoxon matched pairs: 
OTU 19, W = 152, p = 0.02; OTU 26, W = 134, p = 0.006; OTU 43, W = 69, p = 0.019; OTU 
49, W = 74, p = 0.046). Notably, vaginal swab samples did not have any OTUs that were more 
relatively abundant than they were in Foley catheter urine samples, which can be explained 
because the vaginal samples were less diverse overall – they were dominated by a few OTUs, 
accounting for over 90% of the average OTU abundance, and these OTUs were also identified in 
the urine samples (OTU 1 Lactobacillus, OTU 2 Gardnerella, OTU 3 Lactobacillus, OTU 4 
unclassified Lachnospiraceae, OTU 5 Lactobacillus, and OTU 16 Bifidobacterium). 
V. Discussion 
Principal findings of the study 
(1) Quantitative real-time PCR showed that the bacterial load of urine exceeded technical 
controls regardless of the urine collection method (Foley catheter or clean catch) or the volume 
of urine processed; (2) A urine volume of 5.4 ml was the lowest to yield a similar 16S rRNA 
gene load and profile as 25 ml of urine, which was the largest urine volume we investigated; (3) 
Via cultivation, three isolates were detected in at least 20% of all samples (Lactobacilllus 
species, Staphylococcus species coagulase negative, and Ureaplasma urealyticum) and all three 
were detected less frequently in catheter than clean catch urine; (4) An average of three less 
isolates were recovered from catheter urine clean catch urine; (5) Molecular sequencing 
techniques showed that the bacterial profiles of clean catch urine were more similar to vaginal 
swabs than catheter urine, suggesting a greater influence of vulvovaginal contamination on clean 
catch samples; (6) Lactobacillus iners, L. crispatus, and Gardnerella vaginalis were the most 
relatively abundant bacteria among all 3 sample types; (7) Ureaplasma (detected in culture and 
molecular surveys) and multiple Gram-positive species including elusive Gram-positive 
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anaerobic cocci (GPAC) such as Finegoldia and Anaerococcus were more relatively abundant in 
in catheter urine than clean catch urine or vaginal swabs. 
Overall, our study suggests that resident bacterial communities exist in the bladder and 
urine of pregnant women, and that while there is overlap with the vaginal microbiota, there are 
also distinct lower abundance taxa in the bladder. 
Urinary Tract Infections (UTIs) and Pregnancy 
Approximately 10% of women report having at least one episode of UTI in the previous 
12 months and the lifetime probability of a woman having at least one UTI event is around 60% 
[230, 260-262]. Among women with culture-confirmed UTIs, around 28% had recurrence within 
six months [230, 263]. The bacterium most responsible for UTIs is Escherichia coli, followed by 
Staphylococcus saprophyticus, Streptococcus agalactiae, and Klebsiella and Enterococcus 
species [158, 233, 244, 249]. The occurrence of a UTI during pregnancy is associated with 
significant odds ratios of 1.4 for low birth weight, 1.3 for preterm birth (< 37 weeks), 1.4 for 
maternal hypertension and preeclampsia, 1.6 for maternal anemia (hematocrit less than 30%), 
and 1.4 for chorioamnionitis [157, 158]. The risk of occurrence of these complications is higher 
among patients with pyelonephritis [158, 264]. Acute pyelonephritis occurs in 2% of pregnant 
women and recurs in 33% of them [134, 158]. 
In 2017, a European interdisciplinary group consisting of 17 representatives of 12 
medical societies was formed to update the diagnosis and management of uncomplicated UTIs in 
non-pregnant premenopausal women and concluded that the diagnosis of uncomplicated cystitis 
be based on clinical criteria evaluating the symptoms of the patient and the course of the disease 
[265]. They also recommended that no microbiological examination is needed in asymptomatic 
non-pregnant patients [265]. In pregnancy, asymptomatic bacteriuria is to be detected and treated 
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because of the potential serious complications, including pyelonephritis in 30-40 % of the cases 
[249]. The American college of Obstetricians and Gynecologists (ACOG) and other societies 
recommend urine culture as one of the routine tests to be obtained early in pregnancy [266, 267], 
with mid-stream clean catch being the most common collection approach. If mid-stream clean 
catch urine culture is performed, the detection of Escherichia coli is predictive of bacterial UTI 
while the detection of other bacteria such as enterococci and group B streptococci is not 
predictive [265]. Negative urine dipsticks and urine microscopy are useful to rule out the 
likelihood of presence of UTI in asymptomatic non-pregnant women [265]. Urine culture is 
useful if only one type of bacteria was cultivated [265]. 
Vulvovaginal contamination of urine samples 
Prior culture-based studies concluded that clean catch urine samples obtained from 
female patients have poor ability to detect UTI because of contamination from the skin and 
vaginal microbiota [268-270]. A study of 113 asymptomatic pregnant women showed a high 
level of contamination in clean catch samples [268]. Baerheim et al. [269] found that employing 
precautions such as cleaning the perineum or obtaining mid-stream samples led to similar 
contamination rates as obtaining samples without any precautions [269]. Lifshitz et al. [270] 
evaluated 242 symptomatic female patients divided into 3 groups 1) no cleaning, 2) perineal 
cleaning and midstream sampling, and 3) perineal cleaning, midstream sampling and vaginal 
tampon. Contamination rates in the three groups were all similar at approximately 30% [270]. 
In women undergoing cesarean deliveries, two randomized clinical trials showed an 
increase in the incidence of UTIs in the indwelling bladder catheterization group compared to the 
no catheterization group [271-273]. Mid-stream clean catch remains a more convenient approach 
for patients and health care staff; however, culture results of clean catch samples need careful 
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interpretation since around 30 percent of clean catch samples showed contamination in previous 
studies [268-270]. Our cultivation studies confirmed that Foley catheter samples yield less 
cultivars than clean catch samples and are less likely to be contaminated by vaginal microbiota 
than are clean catch samples. 
In the context of next-generation sequencing, it is important that: 1) vulvovaginal 
contamination be limited during urine sample collection; 2) collected urine specimens be 
promptly frozen to mitigate growth and replication of acquired contaminants; 3) a sufficient 
volume of urine is collected for effective DNA extraction; and 4) that background technical 
controls be included to account for potential DNA contamination.  
5.4 ml of urine is an appropriate volume for 16S rRNA sequencing 
Previous urine microbiota studies have utilized different sample volumes of urine for 16S 
rRNA gene analysis [69, 114, 117, 118, 226, 227]. Component 1 of our study showed that a 
volume of 5.4 ml represents an appropriate volume for molecular survey analysis. While a 
bacterial signal was obtained from all volumes (1, 1.8, 5.4, 10 and 25 ml), there were higher 
bacterial loads detected (lower Cq) in the 5.4, 10.0, and 25.0 ml groups compared to the 1.0 and 
1.8 ml groups. There was no statistical significance between 5.4 ml and either the 10.0 or 25.0 ml 
groups. These results show that 5.4 ml urine volume yields an appropriate quantity of DNA for 
16S rRNA gene sequencing and that the DNA yield would not substantively change with a 
greater volume of urine processed (at least up to 25 ml). Clean catch urine samples consistently 
had a greater bacterial load than catheter urine samples indicating that the biological source of 
the sample (clean catch versus Foley catheter) has a greater influence on bacterial load than the 
volume of the sample. 
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Both urine collection methods resulted in bacterial profiles that were significantly 
different than controls regardless of the urine volume processed. While urine samples primarily 
exhibited dominance of 2 to 3 OTUs, controls showed a more even spread between various 
OTUs including common contaminants such as Escherichia, Streptococcus and Staphylococcus. 
Our results suggest that a bladder microbiota exists during pregnancy 
For Study Component 2, while individual identity was the primary influence on 16S 
rRNA gene profiles, differences were found for both beta diversity indices (i.e. Jaccard and Bray 
Curtis) between the three sample types: catheter urine, clean catch urine, and vaginal swabs. 
Pairwise comparisons showed that the bacterial profiles of catheter urine were different than 
those of both clean catch urine and vaginal swabs in composition and structure, whereas the 
profiles of clean catch urine were different from vaginal swabs only in structure. This suggests 
that urine collected via the clean catch method has a bacterial profile more similar to that of the 
vagina due to proximity and increased likelihood of vulvovaginal contamination. In this way, 
clean catch urine likely represents a dynamic mix of members of the skin and vaginal microbial 
communities in addition to those of a resident bladder microbial community. Whilst urine 
collected via a catheter is still likely subject to some degree of vulvovaginal contamination, our 
data suggest a microbial community in the bladder is distinct in several lesser abundant 
microbes. 
LEfSe analyses identified seven OTUs that were more relatively abundant in Foley 
catheter urine than in blank extraction controls, and four of these OTUs were also more relatively 
abundant in catheter urine than in vaginal swab samples, suggesting that these OTUs may be 
representative of members of the bladder microbiota, at least in some women. While only 
Ureaplasma was recovered from cultivation surveys, Finegoldia and Anaerococcus species are 
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Gram-positive anaerobic cocci recalcitrant to culture, typically requiring long incubation times 
and complex growth requirements [274]. This may explain why they were not recovered in 
culture. Other groups investigating urine via molecular surveys have also identified Finegoldia 
and Anaerococcus species in non-pregnant females, in healthy cohorts as well as among women 
with non-UTI urinary disorders [48, 67, 116, 118, 153, 275]. The fourth OTU, while originally 
described as an unclassified Clostridiales, was a 100% sequence match to the newly identified 
genus and species Fenollaria massiliensis gen. nov., sp. nov [276, 277]. Its relatively recent 
discovery may explain why it was not detected by culture as most clinical microbiology 
laboratories are likely unfamiliar with this organism. This microorganism is discussed in more 
detail below. 
Ureaplasma species, like other members of the class Mollicutes, lack a cell wall, require 
specialized media, and can require long incubation times [248, 278]. Ureaplasma is well-
documented in its association with diseases of the urinary tract [48, 63, 64, 67, 278, 279] as well 
as adverse pregnancy outcomes, including preterm birth [49, 140, 280-283] and diseases of the 
neonate [284-287]. In fact, it is the most common microorganism found in the amniotic cavity 
[140, 288]. Despite its associations with disease, Ureaplasma is frequently detected by culture 
and molecular surveys in urine of asymptomatic women, pregnant [65, 137, 156, 169, 246, 248] 
and non-pregnant [48, 67, 68, 116], suggesting its potential role in a bladder microbiota. The 
various consequences associated with the presence of Ureaplasma in the bladder of pregnant 
women is likely multifactorial, of which adverse outcomes are likely associated with a 
combination of the individual’s own immune response [289], the composition and structure of 
the broader microbial community [69, 171], and the specific strain of Ureaplasma [290-293]. 
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Finegoldia has been associated with the genitourinary tract, gastrointestinal tract, and 
skin as a commensal but has also been isolated from and attributed to infections from wounds 
and various body sites making it an opportunistic pathogen. Difficulty in cultivation has been 
evident in clinical reports where accurate diagnoses were dependent on detection via PCR 
despite cultures yielding negative results [294-296].  
Anaerococcus species are also commensals of the skin, gastrointestinal tract, and oral 
cavity and members have been isolated from vaginal secretions and purulent wounds [274, 297, 
298]. Literature reports successful growth of Anaerococcus species on standard anaerobic plate 
types [299, 300] by some groups, while others indicate the addition of supplemental nutrients 
such as hemin and vitamin K [274, 299-302]. Reported incubation times have also varied from 2 
days up to 7 days [300, 302]. 
Fenollaria massiliensis is a newly discovered and understudied anaerobic rod recovered 
and characterized from osteoarticular, genital, and tissue samples, and is suggested to be a 
genital-associated microbe [276, 277]. The two studies describing this organism report growth on 
several enriched media types after 72 hours and on supplemented Brucella Blood Agar after 48 
hours under anaerobic conditions. 
Our study showed that catheter urine samples do yield a 16S rRNA gene signal beyond 
that evident in controls and suggest catheterization may be an appropriate sampling method for 
evaluating any microbial communities that may exist in the bladder. Also, our results suggest 
that the vaginal microbiota influences or contaminates clean catch urine to a larger degree than 
catheter urine, and that while some catheter samples are still influenced by vaginal microbes, a 
potentially unique signal may exist in some individuals. Our evidence suggests that underlying 
Lactobacillus and Gardnerella abundance in the urine of pregnant women, anaerobic organisms 
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like Finegoldia, Anaerococcus, and Peptoniphilus may be low abundant members of a bladder 
microbial community. However, to more confidently assert that the bladder contains microbiota 
in pregnancy, a suprapubic sampling approach would provide better insight. We suspect that the 
gold standard for investigating a potential bladder microbiota would be suprapubic aspiration of 
urine in concert with tissue sampling of the bladder epithelium. Culture should be performed to 
discriminate live bacteria from remnant DNA from dead bacteria. 
Strengths and limitations 
This is the first extensive study that attempts to characterize the urinary microbiota in 
pregnancy by comparing Foley catheter, clean catch, and vaginal samples from 25 women. In 
addition, this is the first study that compared different volumes of urine to determine the optimal 
volume for performing 16S rRNA gene surveys. Furthermore, this study utilized cultivation, 
qPCR, and sequencing approaches to study the existence and viability of microbiota in the 
bladder. The main limitation of the study is that our population mainly consists of one ethnic 
group (i.e. African American). It is possible that other ethnic groups may have a different bladder 
microbiota. Non-pregnant women were not included in this study, therefore differences and 
similarities between a healthy female bladder microbiota and a pregnant female bladder 
microbiota cannot be addressed. Additionally, is difficult to assess if and how much of the 
bacterial signal in catheter urine was due to vulvovaginal contamination, specifically regarding 
the top 3 most abundant taxa. More extensive culture methods may have allowed the lower 
abundance anaerobic organisms to be recovered.  
Conclusions 
Our study suggests that resident bacterial communities exist in the bladder and urine, and 
that there is overlap with the vaginal microbiota. While the most frequent microorganisms 
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recovered by Foley catheter samples were Ureaplasma, molecular surveys identified low 
abundance anaerobic bacteria in addition to Ureaplasma as potential members of a bladder 
microbiota. 
Future directions  
Future research should endeavor to evaluate the typical presence of a microbial 
community within the urinary tract of pregnant women by comparing and analyzing 16S rRNA 
gene sequence data from pregnant women delivering preterm (condition; defined as delivering ≤ 
37 weeks) and at term (biological control; defined as delivering > 37 weeks) and the appropriate 
technical controls. In doing so, we can assess influences of resident microbiota on perinatal 
health and pregnancy outcomes and identify bacteria or bacterial communities whose presence or 
absence can serve as potential risk indicators. Ultimately, being able categorize and describe 
bladder microbial communities and their associations with preterm birth should lead to potential 
targets, therapeutic interventions, and other methods for treating or modifying the bladder 




CHAPTER 5: GENERAL CONCLUSIONS 
Contemporary sequencing technologies have allowed for the examination, in some cases 
re-examination, and deep characterization of microorganisms in a multitude of environments, 
from the seemingly inhospitable (e.g., deep sea hydrothermal vents and Antarctic permafrost) to 
the clearly hospitable and heavily populated (e.g., sea water and the human gut).  The use of 16S 
rRNA gene and metagenomic sequencing has become so widespread that it would be difficult to 
enumerate the amount of exploratory studies that have relied on these technologies or to find an 
environment whose microbiota and/or microbiome has not yet been at least preliminarily 
characterized. Indeed, many have begun reexamining classic paradigms of sterility surrounding 
various anatomical sites of the human body. Researchers have been investigating environments 
of progressively lower microbial biomass to the point where these investigations have reached 
the limits of detection for these molecular surveys [98, 103, 104, 119]. Numerous studies have 
now been published that fail to address and/or account for the limitations of sequencing 
technologies and this has shaped the various controversies laid out in this document, especially 
with respect to the existence of a placental and/or bladder microbiome. 
In the context of the placenta, by pushing molecular techniques to their limits, premature 
conclusions have likely been drawn regarding the existence of a placental microbiome [44, 84, 
95, 110-113]. If widely accepted, these conclusions have the potential to influence how clinicians 
perceive the microbiology of the placenta and the intra-amniotic environment and to alter current 
understanding of microbial invasion of the amniotic cavity and its effect on pregnancy outcomes 
[129, 136, 140, 143, 217, 303-307]. Our investigations of low microbial biomass sites address 
and account for the limitations of current molecular technologies through the inclusion of 
multiple microbiologic methodologies and extensive background technical controls.  
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We first investigated the human placenta and found no evidence to support the existence 
of a placental microbiome. We then extended our investigations to a mouse model.  The value of 
a mouse model is that more than just the placenta can be sampled and interrogated for the 
existence of a microbiome – samples can be collected from the placenta, the fetus, and sites of 
the mother that are both typically colonized or presumed sterile. Again, we found no evidence of 
a placental microbiome, and further we found no evidence for in utero colonization of the fetus. 
Our results from our human and mouse model studies are largely congruent with the results of 
other recent studies [128, 167, 213, 225]: when appropriate measures are taken to address the 
caveats associated with investigations of low microbial biomass sites and the limitations of 
current technologies, there is no consistent evidence for a placental microbiome or in utero 
colonization of the fetus. 
Alternatively, our investigations of the potential existence of a bladder microbiome, 
which also addressed and accounted for the limitations of current molecular technologies through 
the inclusion of multiple microbiologic methodologies and extensive background technical 
controls, revealed that the bladder is not likely a sterile organ. By following a similar study 
design to our human placental work [150], we successfully cultured bacteria from the bladders of 
pregnant women and detected molecular signals in the bladders through qPCR and 16S rRNA 
gene surveys that exceeded those of background technical controls. Additionally, by accounting 
for the possible influence of vulvovaginal contamination on the microbial profiles of urine 
samples, we were able to identify low abundance bacteria that are likely members of a bladder 
microbiota during pregnancy. Ureaplasma (detected through both culture and molecular surveys) 
and multiple Gram-positive anaerobic cocci (detected in molecular surveys, e.g Finegoldia and 
Anaerococcus), despite being present in low abundances, were identified as distinct features of 
139 
 
catheterized urine over clean catch urine and vaginal swabs. Despite the negative impacts 
Ureaplasma can have on pregnancy outcome in some women, it is regularly detected in the 
bladder and vagina of women that are asymptomatic [48, 248, 275], suggesting that while under 
some circumstances it may cause disease, it may also be a common commensal member of the 
microbial communities of these body sites. Although prior studies characterizing a bladder 
microbiome have not emphasized Ureaplasma, it is present at only low relative abundances in 
molecular surveys and may therefore be overlooked and it requires specific growth media which 
are typically not included in cultivation efforts of urine [115, 118]. Our research presented here 
provides a unique opportunity for future studies investigating Ureaplasma in the context of the 
bladder microbiome, as well elucidating potential genetic differences that may contribute to its 
being a commensal or a pathogen. The Gram-positive anaerobic cocci detected in our study are 
often detected in the bladder microbiome studies of others [48, 115, 118, 227, 275]. However, 
they are infrequently recovered in culture [118]. This is likely due to their fastidious growth 
requirements and long incubation periods [248, 274, 294]. These Gram-positive anaerobic cocci 
also present a unique opportunity for future investigations of their potential contributions to a 
bladder microbiome. Ultimately, efforts to identify and characterize the specific bacteria that are 
most closely associated with the uro-epithelium, such as intracellular or biofilm-producing 
bacteria, are necessary for developing a complete understanding of the bladder 
microenvironment and its potential role in human health and disease.  
It is important to appreciate contemporary sequencing technologies for their facilitating 
our ability to characterize the microbial communities in all environments, including the human 
body. However, when seeking to overturn paradigms of sterility, we must employ multiple 
microbiologic methodologies and address and account for background DNA contamination. The 
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burden of proof for overturning longstanding paradigms of sterility is high; there must be clear 
and consistent evidence for the existence of a microbiome across multiple microbiologic 
methodologies and the signal of this microbiome must exceed that of controls and rise above the 
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Next-generation sequencing technologies, especially 16S rRNA gene and metagenomic 
sequencing have allowed investigations of low microbial biomass tissues of the human body. 
While these sequencing methodologies have provided large amounts of reliable data for higher 
microbial biomass sites, such as the mouth, intestine, and vagina, tissues of low microbial 
biomass sites are subject to specific caveats that were not appropriately considered in early 
investigations of these sites. Low microbial biomass sites of particular interest have included 
those of the reproductive and urinary systems. Utilization of DNA sequencing methodologies 
have allowed researchers to challenge existing paradigms of sterility around these sites that were 
historically considered sterile, including but not limited to the placenta, the endometrium, and the 
bladder. While a thorough and complete understanding of the microbial signals in urogenital 
compartments is necessary for the best patient care and treatment, premature conclusions that 
redefine historical paradigms can have harmful consequences on patient health, especially for 
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pregnant women with whom microorganisms have been associated with multiple adverse 
pregnancy outcomes. 
 In this dissertation, I present a lack of evidence for a placental microbiota in humans 
using multiple modes of microbiological inquiry. Through culture, quantitative real-time PCR 
(qPCR), 16S rRNA gene sequencing, and metagenomics we found no evidence of bacterial 
signals beyond those also present in background technical controls. This work with human 
subjects was subsequently complemented by work in mice, in which we investigated the 
bacterial signals in the murine placenta and fetus, as well as multiple murine tissue control sites; 
we again found no consistent evidence of a placental microbiota or in utero colonization through 
multiple microbiological methodologies. Conversely, investigations of the urine of pregnant 
women revealed evidence of a low abundance bladder microbiota. We found bacterial signals 
that clearly exceeded those of technical controls, suggesting that a shift in sterility paradigm for 
the upper urinary tract may be warranted. Specifically, through bacterial culture, qPCR, and 16S 
rRNA gene sequencing we found evidence of a bladder microbiota in pregnant women that 
showed strong variation among individuals and consisted of Ureaplasma urealyticum and Gram-
positive anaerobic cocci. A more thorough understanding of the bladder microbiota in pregnant 
women across gestation will allow healthcare professionals to address urinary and bladder 
symptoms in a way that alleviates or prevents pregnancy complications. 
 This body of work provides strategies for the thorough investigation of low microbial 
biomass sites and demonstrates the high degree of evidence necessary to overturn classic 




 As I am finishing my tenure as a graduate student, I can feel a deep-seeded excitement 
for what is to come. One of the hallmarks of my personality, even since I was a child, has been 
my inquisitive nature. There have been more times than I can count that I have felt the frustration 
of others from my relentless questioning, like a child asking “why does this thing do that”, with a 
follow-up, “but, why”, and another… and another. This was a time before the internet, when 
Googling something was not the answer to any random question a person might have. But 
believe me, my questions never stopped. They reached the Googling era, and my mom has used 
that line on me on more than a few occasions, “why don’t you Google it?”. My inquisitive nature 
is part of what brought be back to science. Having been raised by a young and quick-to-tenure 
Psychology professor and a nurse, who later also became a professor of nursing, I always felt an 
intrinsic pressure to be an intellectual of some sort. External pressures from my parents were 
average at most times; they were wonderfully supportive in any endeavors I chose to pursue, as 
long as I was doing something. 
 I was a lackluster high school student and endeavored on an unconventional and 
exaggerated route through college that eventually led me to explore psychology. I enjoyed it, but 
again I enjoy most things, but it wasn’t until my final semesters that I re-engaged with the 
biological sciences, rediscovering a passion that I experienced in middle school and only briefly 
in high school. I was able to channel some of this passion into tutoring other students after 
having graduated college. In addition to tutoring, I got a job as a medical laboratory technician at 
a local hospital, which allowed me to see the medical and industrial sides of my re-awakened 
passion. These experiences culminated into my decision to pursue graduate school, one I had 
always assumed I’d do, but we know what they say about assumptions. When I first came to 
Wayne State, I had never heard a thing about the microbiome. It was serendipitous that Dr. Theis 
was hired the same time that I started my first semester. And I honestly have never looked back. 
I am excited for the future, new directions in life and my professional career. I feel an ardent 
initiative to take what I have learned and completed as a graduate student and apply it to new 
avenues of research and most certainly many new questions. 
 
